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Abstract 
Author: Ian Sinha 
Thesis title: Outcomes in clinical trials in children with asthma 
The selection of outcomes is a critically important decision when designing 
randomised controlled trials (RCTs). Informed clinical decisions can only 
be based on the results of RCTs that have measured outcomes of 
importance to both clinicians and patients. It can be difficult to know 
which outcomes should be measured in RCTs. Some groups advocate core 
outcome sets, which are a minimum set of outcomes that should be 
measured, and reported, in all clinical trials in a given condition. These 
increase the likelihood that important outcomes are measured, reduce non-
uniformity between studies, and reduce the risk of outcome reporting bias. 
We systematically reviewed studies that determined which outcomes to 
measure in clinical trials in children, and found that such work had been 
conducted in only few conditions, and the quality of existing work was 
variable. Few studies used structured consensus techniques to reach 
agreement about which outcomes to measure in trials, and parents were 
seldom involved. No studies included children. One condition in which 
there were no robust recommendations about which outcomes to measure 
 II 
in RCTs was childhood asthma, which is a condition of considerable global 
importance. 
We subsequently aimed to assess whether the absence of a core outcome 
set for RCTs of children with asthma meant that certain outcome domains 
were measured less frequently than others, and whether there was non-
uniformity between studies in terms of outcomes selected. We conducted a 
systematic review of RCTs of children with asthma, published between 
January 1988 and December 2007, and found that the included studies 
focussed on short-term disease activity, but quality of life, functional 
status, and long-term outcomes were infrequently measured. Certain 
outcomes were measured and reported in various ways. We recommended 
that a core outcome set should be developed for childhood asthma, using 
structured consensus techniques, such as the Delphi process.  
In order to aid the development of such a core set, we first systematically 
reviewed studies that used the Delphi process to determine which 
outcomes to measure in clinical trials. We observed variations in the 
methodology used, identified potential sources of bias, and provided 
recommendations about how such studies could be conducted and reported.  
In order to develop a core outcome set for childhood asthma, we used a 
Delphi process to ascertain the views of 46 clinicians, and around 100 
parents and young people, about which outcomes are most important and 
 III 
relevant from their perspective, when making shared decisions about 
regular therapies which control asthma. The most important outcomes were 
symptoms, exacerbations, and quality of life. Although consensus still 
needs to be reached amongst other groups of individuals involved in 
clinical trials, we conclude that these outcomes should be measured, and 
reported, in all RCTs that aim to evaluate the effectiveness of regular 
therapies for children and young people with asthma.
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C h a p t e r  1  
Introduction 
 
1.1 Outcomes in clinical trials 
Interventions used in healthcare may have various beneficial and harmful 
effects. These are known, in clinical practice and research, as outcomes. 
Interventions in randomised controlled trials (RCTs) are evaluated in terms 
of the effect they have on pre-determined outcomes. It is critically 
important, therefore, that the right outcomes are measured in RCTs. 
 
Primary and secondary outcomes  
The primary outcome is an integral component of the research question. It 
should be explicitly stated and described, because it reflects the objective 
of the trial, and determines the sample size required (Moher et al 2001). 
There is usually only one primary outcome, which should relate to the 
research question. In some situations, more than one primary outcome can 
be measured, in order to assess treatments more comprehensively. This can 
be useful if it unclear which single primary outcome will best answer the 
research question. For example, in trials of patients with schizophrenia, one 
co-primary outcome can measure a patient’s cognitive ability, while the 
other assesses functional ability  (Green et al 2008). In other situations, one 
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co-primary outcome may measure the efficacy of an intervention, and the 
other its safety, such as in trials of therapies for children with familial 
hypercholesterolemia  (Tonstad et al 1996).  
Most trials also measure secondary outcomes, in order to evaluate other 
beneficial or harmful effects of treatments. These must be clearly stated 
and described in the study protocol and report  (International Conference 
on Harmonization 1999). They should be used judiciously, because the 
more that are measured in an RCT, the more likely it becomes that one will 
show a statistically significant result because of chance alone  (Pocock 
1997).  
 
Why RCTs must measure important outcomes in order to inform 
clinical decisions  
Justifying the use of a healthcare intervention depends on whether its 
beneficial effects are important, and sufficiently outweigh its risks. As 
RCTs are the most valid scientific method for evaluating these effects, their 
results are used to inform such decisions  (Guyatt, & Rennie 2002). In 
order for the results of RCTs to be useful, they should measure outcomes 
that are relevant to people involved in making clinical decisions about an 
individual patient, group, or population.  
For individual patients, clinicians should integrate the best available 
research evidence to determine which interventions are most helpful and 
safe (Sackett et al 1996). This evidence should be derived from well 
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designed, rigorously conducted RCTs, which will best inform practice if 
they have measured outcomes that patients and clinicians find important. 
To decide whether or not an outcome is important to patients, the following 
has been suggested  (Guyatt, & Meade 1997):  
“ Imagine suggesting to patients that the outcome in question, and no other, 
would change with treatment. If patients would be willing to undergo 
whatever risks and inconvenience are associated with the treatment, and 
willing to pay ...  the associated costs, then the outcome is important to 
them”. 
 
This definition is even more pertinent today, because the medical 
profession has observed a shift from the traditional ‘paternalistic’ 
relationship, in which clinicians decide what is best for patients, towards a 
situation in which they make shared decisions about management. This 
change was initiated on ethical grounds, as it was felt that patients had a 
right to be involved in decisions about their own health  (Charles et al 
1997; Frosch, & Kaplan 1999). Evidence now suggests that involving 
patients in management decisions also improves their satisfaction with their 
care, adherence to treatment, and overall health  (Joosten et al 2008; 
Hamann et al 2003). In order for patients to share in making informed 
decisions about an intervention, they should know whether it is likely to 
benefit them in the way that they would hope, and this relies on the 
measurement of outcomes, in RCTs, which they feel are important. 
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RCTs are also used to inform decisions about whether interventions are 
appropriate for populations of patients. In the UK, the National Institute for 
Health and Clinical Excellence (NICE) design clinical guidelines, and 
approve or reject funding for interventions, based on whether their benefits 
are worth their financial cost  (Claxton et al 2002; Drummond 2002). Drug 
regulatory authorities, such as the Food and Drug Administration (FDA), 
and European Medicines Agency (EMA), will grant a marketing 
authorisation for a product to be used in their area of jurisdiction if its 
benefits outweigh its risks. In order to enable these agencies to make such 
assessments accurately, RCTs should provide information about important 
beneficial and harmful treatment effects that are likely to affect the 
patient’s health or overall well-being. 
 
1.2 Outcome domains 
Outcome domains are frameworks, which can be used to classify broad 
aspects of the effects of interventions. It may not be clear which domains 
should be measured in an RCT, and several outcomes may be relevant to a 
single domain.  The ways in which clinicians and researchers consider the 
effects of illnesses have changed over time, and this has led to the 
evolution of certain important outcome domains that are measured in 
RCTs. 
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Outcomes reflecting disease processes: the biomedical model 
For much of the 20th Century, the effects of illnesses were considered in a 
biological and physical framework, now known as the biomedical model. 
The basis for this model originated in the 19th Century, when medical 
advances, notably in the field of pathology, enabled clinicians and 
researchers to consider illnesses in a more scientific manner  (Wade, & 
Halligan 2004). This is reflected by the outcomes measured in the earliest 
controlled clinical trials in the modern era, which were conducted by the 
Medical Research Council in the 1940s  (Chalmers, & Clarke 2004).  
In the first of these, patients suffering from common cold were randomised, 
by alternate allocation, to receive either Patulin or placebo solution for two 
days. After one, two, and seven days, they were assessed to see if their 
symptoms had resolved  (Medical Research Council 1944). The second 
trial evaluated whether treatment with Streptomycin and bed-rest for six 
months, when compared with six months of bed-rest alone, effectively 
treated pulmonary tuberculosis  (Medical Research Council 1948). 
Radiological findings, clinical condition, temperature, weight, 
sedimentation rate, and sputum culture, were compared in survivors after 
six months. The main analysis was based on radiological changes, as the 
authors suggest that this was “the single most important factor to consider”. 
Outcomes measuring biological effects of interventions remain important 
today. All four RCTs of medical treatments for pulmonary tuberculosis, 
published in 2009, measured clearance of bacteria from sputum, as the 
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primary outcome  (Conde et al 2009; Dorman et al 2009; Diacon et al 
2009; Bartacek et al 2009). 
 
The effects of illness on functional status: the biopsychosocial model 
The effects of interventions on a patient’s ability to perform normal daily 
functions has increasingly been recognised as an important domain in 
clinical trials  (Duncan et al 2000; Gandhi et al 2008).  
The earliest studies of the non-biological aspects of illness examined the 
levels of assistance required by elderly people  (New York Dept of Social 
Welfare 1937), and the functional ability of patients with heart disease  
(New York Heart Association 1939). The publication of a study of nitrogen 
mustard, as a palliative treatment for patients with cancer  (Karnofsky et al 
1948), is probably the earliest report of the evaluation of the effects of an 
intervention on functional status  (Prutkin, & Feinstein 2002).  
In the 1960s, psychologists and clinicians felt that the biomedical model 
did not reflect the complex relationship between biological, social and 
emotional aspects of illness, and this led to the development of the 
biopychosocial model of medicine. Also in the 1970s, the World Health 
Organization (WHO) recognised the need to change how they assessed the 
health of populations, because its member states, expected to routinely 
compile health statistics, reported only mortality rates from various 
diseases. The publication of the International Classification of 
Impairments, Disabilities and Handicaps  (WHO 1980) represented a 
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formal move to consider effects of disease not only in terms of anatomical 
and physiological abnormalities (“impairments”), but also the resulting 
restriction of activities (“disability”), and its consequences for an 
individual’s ability to function, in society, as they would like (“handicap”). 
A landmark study, which emphasised the importance of measuring 
functional status in clinical research, was The Health Insurance Experiment  
(Brook et al 1983). This large RCT, conducted between 1971 and 1982, 
compared medical insurance plans in the USA. Researchers found that, by 
measuring patients’ perceptions of their health and functional status, they 
generated useful information, which would not have been identified from 
traditional biological endpoints. The subsequent Medical Outcomes Study, 
which evaluated 20,000 patients’ own reports of their health and functional 
status, also recommended that the primary goal of treating chronic 
conditions should be to “maximise function in everyday life and to achieve 
the highest level of well-being”  (Tarlov et al 1989; Stewart et al 1989).  
 
The overall well being of patients: the psycho-sociological model 
The first use of the term “quality of life” (QoL) in the medical literature 
was in an article relating to patients receiving haemodialysis, in which the 
author comments that “for most, the quality of life was unacceptable”  
(Retan, & Lewis 1966). In the same year, an RCT, in which women with 
breast cancer were treated either with radical mastectomy, or more 
conservative surgery, was published. One secondary outcome was the 
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“quality of survival”, as measured by their feelings about their health and 
their treatment  (Eisenberg 1966). This was probably the first time 
emotional well-being was measured as an outcome in a clinical trial  
(Prutkin, & Feinstein 2002).  Until the 1980s, QoL slowly became a more 
prominent outcome in medical research. Medical researchers measured 
emotional well-being scales developed by psychologists, but physical and 
functional consequences of illness on QoL were infrequently studied in 
conjunction with these  (Prutkin, & Feinstein 2002).  
Two events in the 1980s catalysed the development of QoL as a clinical 
trial outcome  (Prutkin, & Feinstein 2002; Willke et al 2004). Firstly, the 
FDA announced that QoL should be measured as a “key efficacy 
parameter” in clinical trials of anticancer agents, which had traditionally 
focussed on length of survival. Furthermore, the FDA stated that if a 
therapy was shown to improve QoL, even if it did not have increase 
survival, it could still be granted a marketing license  (Temple 1995; 
Johnson, & Temple 1985). Secondly, the first RCT to measure QoL, as a 
primary outcome, was published  (Croog et al 1986). The effects of three 
antihypertensive agents on QoL were compared, using validated measures 
of satisfaction with life, physical state and social functioning. When 
patients who were randomised to receive one drug had significantly better 
QoL than those in other groups, the pharmaceutical industry realised that 
products could be marketed for their effects on QoL, as well as their 
physiological outcomes, and clinical researchers learnt that QoL could be 
measured, in a meaningful and valid way, in clinical trials. Since the 1980s, 
the number of RCTs measuring QoL has increased, but there are still 
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concerns that it is measured infrequently, using non-validated tools  
(Clarke, & Eiser 2004; Sanders et al 1998).  
 
1.3 Different types of outcomes 
As well as determining which domains to measure in trials, researchers 
must also decide on the most appropriate outcomes with which they should 
be measured. This can be difficult, because a variety of outcomes could be 
measured within each domain. As well as the importance of an outcome, 
trialists must consider whether it is relevant and acceptable for the patients 
included in the trial, responsive to the interventions being compared, and 
appropriate for the trial itself, in terms of the length of follow-up required, 
the financial cost, and whether validated methods are available for 
measuring it. The decision is made more complex by the various types of 
outcomes from which trialists can choose, which are described below.    
 
Clinical outcomes and surrogates 
A clinical outcome relates to how a patient feels, functions, or survives. A 
surrogate outcome is a laboratory measurement or physical sign that is used 
as a substitute for a clinical outcome  (Atkinson et al 2001; Temple 1995). 
A biomarker is a laboratory measurement that is used to predict a 
biological, pathogenic, or physiological outcome, rather than a clinical one  
(Lassere et al 2007). Trialists must decide which of these types of 
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outcomes is most appropriate for both the research question and the 
specific clinical trial.  
In late phase clinical trials, the primary outcome should reflect the effects 
of an intervention on an important clinical outcome. If the clinical outcome 
occurs a long time after the intervention is started, however, this may be 
difficult to achieve. Surrogate outcomes, which are affected by 
interventions earlier than clinical ones, can be used to predict these effects. 
This means that fewer patients need to be recruited, and less time is 
required, to conduct a clinical trial. As well as making clinical trials 
cheaper and easier to conduct, this can lead to faster approval of 
interventions by drug regulatory agencies. In certain clinical areas, in 
which effective therapies are lacking, such as oncology, there may be an 
urgency to make interventions available to patients quickly. In other areas, 
such as trials of anti-hypertensive agents for adults, the ultimate aim is to 
identify which treatments reduce the risk of mortality. In these situations, 
surrogate outcomes and biomarkers are used to accelerate the drug 
development process, as trials may need to be conducted for several 
decades to determine such effects.     
Despite these theoretical advantages, surrogate outcomes have been the 
subject of much debate since the mid-1990s. When they have been 
criticised, the main limitation has been that their correlation with the 
clinical outcome is inaccurate  (Holloway, & Dick 2002; Fleming, & 
DeMets 1996; D'Agostino 2000), or affected by confounding factors  
(Baker, & Kramer 2003). 
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Measured and reported outcomes 
Outcomes can be categorised by the kind of treatment effect they measure. 
Some are objective, biological outcomes, such as physiological measures 
of lung function in patients with asthma, or laboratory measures of 
glycosylated haemoglobin in patients with diabetes. Others, known as 
clinician reported outcomes, may be interpreted or observed by a medical 
caregiver. For example, a clinician could observe a patient (eg resolution of 
an infection), interpret an investigation (eg radiological results), or interpret 
information given by patients in order to complete a scale or score (eg the 
global physician response used in RCTs in juvenile arthritis  (Giannini et al 
1997)). Patient reported outcomes measure how a patient feels or functions, 
as described directly by the patient, without interpretation by a clinician or 
investigator. Commonly, these are measures of the patient’s view of their 
symptoms, functional status, or quality of life  (Willke et al 2004).  
Although laboratory and physiological measurements may be more 
objective, easier, and cheaper to measure, they usually provide a less 
comprehensive view of the effects of an illness than outcomes reported by 
clinicians or patients. Patient reported outcomes are also important because 
a patient’s view of how an intervention has affected their illness, or 
improved their life, may differ from their clinician’s opinion. 
 
 
 
 12 
Composite outcomes 
Composite outcomes comprise more than one endpoint, outcome or 
domain. One advantage of this approach is that composite outcomes may 
enable trialists to combine clinical events into a single primary outcome, 
and report the number of patients experiencing any one of these, so a 
smaller sample size is required for the trial. Another advantage is that a 
composite outcome may provide a more comprehensive evaluation of the 
treatment itself  (Montori et al 2005). This may be by combining separate 
events, such as serious complications of prematurity  (Anand et al 2004) or, 
as in the case of QoL, by capturing various continuous outcomes.  
Despite these advantages, composite primary outcomes can lead to 
misleading results, usually when the effects of the treatment on constituent 
components of the outcome differ. This may arise if the overall composite 
outcome improves, but the intervention does not affect the most important 
component, which is usually mortality. For this reason, each constituent 
component should be clinically meaningful  (Cannon 1997), and should be 
analysed and reported separately as a secondary outcome  (International 
Conference on Harmonization 1999; Freemantle et al 2003). 
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1.4 Standardising outcomes for clinical trials 
The selection and measurement of outcomes may vary across clinical trials 
in the same condition, and this can cause a variety of problems, which are 
discussed in this section.  
 
1.4.1 Problems with heterogeneous selection, measurement 
and reporting of outcomes 
A variety of domains and outcomes can be selected for clinical trials, and 
these can be measured, analysed, and reported in different ways. Three 
main problems can arise if the selection, measurement and reporting of 
outcomes is non-uniform across clinical trials. 
 
Important outcomes can be overlooked 
If trialists are not required to adhere to an accepted list of mandatory 
outcomes, it is likely that factors relating to the conduct of the trial, such as 
the sample size, will determine which outcomes are measured. The relative 
importance of outcomes then becomes a secondary consideration. As a 
result, outcomes that are favourable for researchers may be selected, but 
those that are important to patients or clinicians could be overlooked. 
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In a systematic review to evaluate the methodological quality of 199 RCTs 
in diabetes, published between 1987 and 2003, the authors categorised the 
primary and secondary outcomes as patient-important (defined as those 
expected to directly affect QoL), physiological measures that did not 
predict patient-important outcomes, and surrogate outcomes  (Montori et al 
2006). With regard to the primary outcomes, only 42/199 (21%) studies 
measured patient important outcomes, 118/199 (59%) measured 
physiological outcomes and 38/199 (19%) measured surrogate outcomes. 
The same group later evaluated outcomes in 436 ongoing trials in diabetes, 
and found that 78/436 (18%) measured patient important outcomes, 69/436 
(16%) measured physiological outcomes, and 268/436 (61%) measured 
surrogate outcomes  (Gandhi et al 2008).  
Another systematic review assessed the outcomes measured in 174 clinical 
trials of acute therapies for stroke, published between 1955 and 1995  
(Roberts, & Counsell 1998). Mortality was reported in 132/174 (76%), and 
outcomes reflecting physical impairment were reported in 133/174 (76%), 
but measures of disability were reported in 73/174 (42%) and measures of 
handicap or QoL in just 4/174 (2%). The author of another systematic 
review, of 51 RCTs of acute therapies for stroke, identified similar 
problems  (Duncan et al 2000).  
The authors of two of these systematic reviews recommended that a 
potential solution to these problems would be to develop core set of 
outcomes, incorporating outcomes of direct importance to patients, which 
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should be measured and reported in all clinical trials of diabetes  (Gandhi et 
al 2008) and acute stroke (Duncan 2000).  
 
Impaired meta-analysis 
When synthesising results of RCTs, in meta-analyses, problems arise if 
included studies measure different outcomes from each other. For example, 
in a Cochrane review of trials evaluating therapies for acute stroke, the 
primary outcome of the review was only reported in study reports of 9/22 
of the included studies  (Gubitz et al 2000). This represents a missed 
opportunity in the other 13 trials to contribute data to an important research 
question. 
Even if the same outcomes are selected, they may be measured and 
analysed in different ways, and this too can impair the ability to synthesise 
their results. One descriptive review, of 2000 trials of interventions for 
patients with schizophrenia, observed that 640 different scoring scales had 
been used  (Thornley, & Adams 1998). In a subsequent Cochrane review, 
the same authors recommended that “a concerted effort should be made to 
agree on which measures are the most useful. Studies within this review 
reported on so many scales that, even if results had not been poorly 
reported, they would have been difficult to synthesise in a clinically 
meaningful way”  (Adams et al 2007).  
A Cochrane review of probiotics for the prevention of antibiotic-associated 
diarrhoea in children included studies that varied considerably in the 
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definition of diarrhoea itself. As a result, one secondary outcome of the 
review included 4/10 studies, and the other included 3/10 (Johnston et al 
2007). For similar reasons, authors have recommended the development of 
core outcome sets in acute asthma  (Blitz et al 2005) and ulcerative colitis  
(Cooney et al 2007).  
 
Selective reporting of results 
In the absence of a set of core outcomes, which must be reported in all 
clinical trials in a given condition, trialists may decide to omit certain 
results from the final study report. The practice of selective reporting of a 
subset of the original recorded outcomes, based on the results, is called 
outcome reporting bias (ORB)  (Hutton, & Williamson 2000). 
A systematic review, of studies that examined ORB in published RCTs, 
found that statistically significant results are more likely to be fully 
reported than non-significant ones, and it appears to be common practice to 
change or omit the original primary outcome, or introduce a new one, as 
the study progresses  (Dwan et al 2008).  
Further problems from ORB arise when systematic reviewers attempt to 
meta-analyse the results of RCTs. When conducting Cochrane reviews, 
authors are now required to assess the risk of ORB in included studies. A 
recent study examined the impact that ORB might have on the analysis of 
the primary outcome in 283 Cochrane reviews, published in 2006 and 2007  
(Kirkham et al 2010).  One third of reviewers had suspected ORB in at 
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least one of the reports of studies included in the primary analysis of the 
review. Furthermore, of the meta-analyses in which the review primary 
outcome showed statistically significant result, 8/42 (19%) became non-
significant after adjustment for outcome reporting bias, and 11/42 (26%) 
would have significantly overestimated the treatment effect, by at least 
20%.  The authors recommended that core outcome sets could prevent 
selective reporting, and make it easier to assess the risk of ORB in trial 
reports, by informing the reader which outcomes should have been 
measured, and hence which results should be reported. 
 
1.4.2 Standardising outcomes in trials 
The problems associated with non-uniform measurement, selection, and 
reporting of outcomes can be prevented by standardising outcomes across 
clinical trials in a given condition. Two notable examples of groups that 
have attempted to achieve this are described below. 
 
WHO outcomes for cancer 
Probably the earliest initiative to standardise outcomes for trials was in 
oncology. The WHO recommended that the ability to compare results 
between trials would be improved if trialists measured and reported a 
minimum core set of outcomes. International meetings were held in 1977 
(Turin) and 1979 (Brussels), involving 36 clinicians and researchers, with 
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the aim of reaching consensus about which outcomes should be measured, 
and how they should be reported  (Miller et al 1981). The panel 
recommended that, as a minimum, trialists must report the measured 
response of the tumour and metastases (including whether these completely 
or partially resolved), duration of response to treatment, acute and long-
term adverse effects of therapy, and a measure of the patient’s emotional 
well-being. 
 
OMERACT 
Probably the most notable examples of work to develop core outcome sets 
have been conducted in rheumatology. In 1992, rheumatologists from 
Europe and North America observed that RCTs in rheumatoid arthritis 
varied in the selection and measurement of outcomes, largely dependant on 
which continent they were conducted in, and that this impaired comparison 
and meta-analysis of results. This led to a conference, in 1992, at which 
around 80 participants aimed to agree on the minimum outcomes that 
should be measured and reported in these trials  (Tugwell, & Boers 1993). 
The collaboration was known as OMERACT (Outcome Measures in 
Rheumatoid Arthritis Clinical Trials). Since the initial conference, 
OMERACT has held 10 conferences at which core outcome sets are 
designed for various conditions in rheumatology.  
The OMERACT core outcome sets are based on evidence about which 
outcomes are most appropriate. Interested individuals collate and 
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summarise existing literature about domains and outcomes, and then a 
wider group of clinicians and researchers reach consensus about which 
outcomes should be included in the core set, and how they should be 
measured. This consensus is reached using structured techniques, discussed 
in the next section, which are likely to improve the quality and validity of 
the recommendations.  
 
1.4.3 Methods for reaching consensus  
Ideally, guidelines and recommendations are based on evidence derived 
from rigorously conducted empirical studies. In situations where the best 
recommendations are uncertain, or such studies have not been conducted, 
decisions made by a group of people are likely to be more credible than 
those made by one individual, because they are based on a wider range of 
experience and knowledge  (Murphy et al 1998).  
The three main methods for reaching formal consensus in health research 
are open group discussions, Nominal Group Technique (NGT), and Delphi 
process. These are described below. 
 
Open group discussions 
There are three main variations of open group discussion. In the informal 
discussion group, interaction between participants is not structured  
(Murphy et al 1998). In the structured group, the discussion is steered, by a 
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facilitator, through a series of problem-solving steps  (Murphy et al 1998; 
Jarboe 1996). In the NIH consensus development conference, a group, of 
around ten participants, discusses relevant evidence, before voting to reach 
agreement on a particular topic  (Fink et al 1984; Murphy et al 1998).  
The aim of open group discussion is to stimulate debate amongst 
participants. Types of personalities within the group, however, can inhibit 
the group’s productivity, and compromise the credibility of the pooled 
judgement. These may include participants who dominate the decision 
making process, are unwilling to change their position once publicly taken, 
do not voice disagreement with people more senior than themselves, 
acquiesce for the sake of reaching consensus, or are reluctant to mention a 
new idea, in case they are criticised  (Linstone et al 1975; Thangaratinam, 
& Redman 2005).  
 
Nominal Group Technique (NGT) 
NGT is a method of structuring interaction within a group. It was first 
developed because unstructured face-to-face discussion methods can 
inhibit members from speaking freely, and groups may focus on one 
particular idea, at the expense of others, when discussing a problem  
(Murphy et al 1998; Delbecq, & Van de Ven 1971).   
In the NGT, a group of individuals, typically between 10 and 15 in number, 
discuss one clearly defined problem at a time, during a face-to-face 
meeting. First, each participant shares their opinion with the group. After 
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this, each participant votes, anonymously, and the group opinion is 
compiled. There should be a pre-determined definition of what constitutes 
consensus, disagreement, or uncertainty amongst the group  (Murphy et al 
1998).  
The advantage of NGT is that specific problems can be discussed, in order 
to generate ideas and share opinions, with each participant’s view 
incorporated equally in the vote. This means that the final group decision is 
less likely to be swayed by a vocal minority, or by people of seniority. The 
disadvantages are that only a small group can be involved in a single NGT, 
and they must all convene at the same place and time.  
 
Delphi technique 
The Delphi technique comprises a series of questionnaires, which are 
answered, anonymously, by a panel of participants. After each 
questionnaire, the group response is fed back to participants  (Dalkey, & 
Helmer 1963).  
With regard to the overall validity of the final consensus, this approach 
confers certain advantages over less structured methods of reaching 
consensus. Participants in a Delphi study do not interact directly with each 
other, so situations where the group is dominated by the views of certain 
individuals can be avoided. When participants consider whether to change 
their opinion, after the overall group response is fed back following each 
questionnaire, this decision is not affected by the perceived need to be seen 
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to agree with senior, overly vocal, or domineering individuals. As with 
NGT, every person’s opinion is reflected equally in the results.  
The Delphi method was originally designed by the RAND corporation 
between the 1940s and 1960s  (Dalkey, & Helmer 1963; Dalkey 1969). 
RAND is an American institute, formed in the aftermath of the Second 
World War, which facilitates research between government agencies, 
military forces, industries and universities  (Campbell 2004). The Delphi 
method was initially designed as a forecasting tool for predicting Russian 
military strategies between the 1940s and 1960s, because it was thought 
that predictions made by a group of people were more likely to be correct 
than those made by the same individuals working in isolation. In the 1960s, 
Delphi methodology was mainly used for predicting social and 
technological change  (Ament 1970), and after this the research areas for 
which it was used diversified  (Linstone et al 1975; Needham, & Loë 1990; 
Rieger 1986; Mullen 2003). 
In the mid 1970’s, the validity of the Delphi technique was widely 
scrutinised (Hill, & Fowles 1975; Coates 1975; Goldschmidt 1975; 
Sackman 1975). Critics suggested that the fundamental characteristics of 
the Delphi technique were flawed, because ‘expertise’ is an arbitrary 
concept, anonymity leads to lack of accountability, and hence poor quality 
answers, and participants are led towards conformity with the group, rather 
than consensus of true opinions. Another criticism was that people who 
used the Delphi technique as a research tool were not adhering to accepted 
principles of scientific investigation, and that approaches to aspects of the 
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methodology, especially population sampling techniques and psychometric 
validation of questionnaires, were inadequate. 
Despite this period of scrutiny the Delphi technique continued to be widely 
used. It has been adapted to work well via electronic media, and 
improvements in global communication have made it feasible to involve 
geographically distant participants, in larger numbers than are traditionally 
used in open group discussions and NGT. It is increasingly being used to 
reach consensus around topics in medicine, such as education  (Alahlafi, & 
Burge 2005), clinical guidelines  (Morita et al 2005), and prioritisation of 
research topics  (Kellum et al 2008). 
 
1.5 Difficulties with selecting and measuring 
outcomes in clinical trials in children 
Conducting clinical trials in children presents unique challenges  (Caldwell 
et al 2004; Smyth 2001), including difficulties in the selection and 
measurement of outcomes. These can occur for various reasons. 
One problem with the selection of outcomes for RCTs in children is that it 
may be influenced by the fact that it is often difficult to recruit patients. 
This is partly because the number of children suffering from chronic 
conditions is less than that in adults, so there is a smaller pool of patients 
from which to recruit  (Smyth 2001). Problems may also arise because of 
reluctance from parents and clinicians to enrol children in research studies  
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(Caldwell et al 2004). As a consequence of the smaller sample size 
available, trialists may have to select a primary outcome based on 
feasibility, rather than importance.  
One approach to the small numbers of children participating in clinical 
research is to include them in RCTs conducted primarily in adults, possibly 
analysing them as a subgroup. This approach may not be appropriate, 
however, for two main reasons. 
Firstly, the outcomes and domains that are relevant and important for 
adults may not be suitable for children. Furthermore, the measurement of 
certain outcomes, such as physiological tests, or those requiring invasive 
investigation, may not be tolerated, feasible, or acceptable in children. 
Conversely, certain outcomes may be unique to a paediatric population, 
and may not be measured in a study primarily focussed on adults. For 
example, attainment of developmental milestones is an outcome that is 
unique to babies, infants, and pre-school toddlers, and growth to an optimal 
adult height is an outcome of importance in many chronic conditions in 
childhood.  
Secondly, illnesses affect children and adults in different ways. This means 
that the same outcome domains may need to be measured in different 
ways. The factors affecting functional status, for example, will differ 
between adults and children, because their perceived roles in society and 
the family are different.  
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Even amongst children, there are several distinct age brackets, in which 
different outcomes for evaluating treatments may be relevant. Sepsis is one 
example of a condition in which the relevant outcomes may vary between 
age groups. In preterm neonates, infections are frequently fatal, and so 
mortality would be the most important outcome. In older children, 
mortality from sepsis is much less common, and so outcomes reflecting 
treatment effects such as need for intensive care, long-term complications, 
or QoL after survival, may be more relevant.  
Whether an outcome is selected for an RCT in children may depend on 
whether or not there are age-appropriate, validated tools with which to 
measure it. The length of follow-up required to evaluate important long-
term outcomes, manifest in later childhood or adulthood, may preclude 
their direct measurement. In these situations, surrogate outcomes are often 
measured in place of the long-term clinical outcome. These surrogate 
outcomes, however, may not have been robustly validated to assess 
whether they accurately predict the long-term clinical outcome. Similar 
problems, of whether or not outcomes and instruments have been validated 
for use in a paediatric population, may occur with patient reported outcome 
measures (PROMs).  
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1.6 Asthma in children 
Much of the work in this thesis relates to outcomes in clinical trials in 
children with asthma. Section 1.6.1 discusses the impact of childhood 
asthma, and Section 1.6.2 discusses why it can be difficult to know which 
outcomes to measure in RCTs of pharmacological interventions for 
children with this condition. 
 
1.6.1 The impact of childhood asthma 
Asthma is a complex, chronic disorder of the airways. Inflammation and 
structural damage lead to airway obstruction and hyper-responsiveness. 
These cause frequent symptoms of cough, wheeze and shortness of breath, 
which are episodically worsened, acutely, by a variety of common triggers  
(Murray et al 2000; Forfar et al 2003). Asthma is the commonest chronic 
condition of childhood, and its prevalence has been increasing since the 
1980s  (Akinbami, & Schoendorf 2002). The annual direct and indirect 
financial costs of asthma were estimated, in the US, to be 5.1 billion dollars 
in 1997.  
Symptoms of asthma are often frequent and troublesome. The cough, 
which is typically nocturnal, can disrupt sleep for the child and other 
family members. Shortness of breath and poor exercise tolerance affect the 
child’s ability to play sport, partake in normal activities, or adhere to as 
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healthy a lifestyle as they would like  (Murray et al 2000; Forfar et al 
2003). Exacerbations of asthma can be frightening and disruptive for child 
and family, and often necessitate hospital admission. Asthma affects QoL 
in children not just because of physical impairment, but also because of 
effects on emotional well-being  (Annett 2001; Juniper et al 1999; van den 
Bemt et al 2010). 
Chronic inflammation in the airways of children with asthma causes 
structural changes, known as airway remodelling, which can result in 
permanent damage. Although its long-term clinical implications are 
unknown, airway remodelling may precede life-long respiratory illness, as 
many children with asthma develop chronic respiratory problems in 
adulthood. Although there is no test for evaluating permanent structural 
lung damage in children, the degree of obstruction, at a particular point in 
time, can be measured using physiological markers, of which the two that 
are most commonly used in practice are Forced Expiratory Volume in one 
second (FEV1) and Peak Expiratory Flow Rate (PEFR). In order to 
measure FEV1, a child must exhale into a spirometry machine, via a 
mouthpiece, as fast as possible, for as long as they can. In order to measure 
PEFR, a child must exhale a short, sharp breath into a handheld device. 
Other pathophysiological effects of asthma can also be measured. Exhaled 
Nitric Oxide (ENO) is a marker of the degree of airway inflammation, and 
tests of bronchial hyper-responsiveness can give an indication of the 
sensitivity of a child’s airways. These tests are less frequently used in 
clinical practice, and tend to be measured in specialist centres.  
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Although mortality from asthma is rare in children, the International Study 
of Asthma and Allergies in Childhood (ISAAC), which is the largest 
epidemiological study of asthma to date, has found that the number of 
deaths attributable to childhood asthma, in several countries, increased 
between 1995 and 2002  (Anderson et al 2008). Worryingly, many children 
who die from asthma were previously considered to have mild or moderate 
illness  (Robertson et al 1992).   
 
1.6.2 Clinical trials of regular therapies for children with 
asthma 
Until the 19th Century, asthma was regarded as a symptom of other 
respiratory ailments, rather than an illness in itself. Until the middle of the 
20th Century, constriction of the airways was felt to be the underlying 
pathological feature of asthma, and treatments focussed on 
bronchodilation, with the aim of providing short-acting symptomatic relief.  
The major advance in the understanding of the pathogenesis of asthma 
came in the mid 20th Century, when it became increasingly recognised that 
the major underlying factor was inflammation. As a result of this, asthma 
came to be considered a chronic condition, with inflammation occurring 
even when a patient may be free of symptoms. This led to the development 
of treatments that could modulate the underlying disease process. 
Therapies for asthma can, therefore, be classified as relievers, which 
provide symptomatic relief, or preventers, which aim to control symptoms 
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and reduce the risk of exacerbations. This thesis relates to clinical trials of 
preventer therapies, rather than bronchodilators or other acute treatments 
for exacerbations. 
By far the most widely used and successful preventative therapy, in both 
adults and children with asthma, has been inhaled corticosteroids (ICS). 
Steroid medication was first used for asthma in the 1950s, in an oral 
preparation, and was investigated, in a placebo-controlled RCT in children, 
which concluded that it effectively controlled symptoms and improved 
PEFR (Kennedy 1956). The need for inhaled preparations of steroids was 
initially driven by concerns that long-term use of oral cortisone was 
associated with a high incidence of serious systemic side effects. The 
development of inhaled steroids was made possible by the invention of the 
metered dose inhaler, in the late 1950s. Early trials of of Beclomethasone 
Diproprionate (BDP), the first ICS to be developed, evaluated whether it 
could control symptoms and improve PEFR, and also whether it could 
enable a reduction in the dose of oral steroid required  (Godfrey, & König 
1974). At around the same time, cromolyn medications, which modulated 
the inflammatory process, were evaluated in RCTs that measured similar 
outcomes  (Smith, & Devey 1968). 
As other types of ICS were developed, and methods for delivering them 
were refined, they replaced oral steroids as the main regular therapy for 
children with asthma (Chu, & Drazen 2005). The landmark RCT of ICS, in 
the 1980s, aimed to evaluate whether they could reduce bronchial hyper-
responsiveness, which had been recognised as an important consequence of 
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airway inflammation  (Haahtela et al 1991). Studies in the 1990s 
demonstrated the substantial burden of exacerbations of asthma, in terms of 
economic cost  (Smith et al 1997), and damage caused to the airways  
(Barnes 1989). In the late 1990s, two landmark RCTs evaluating ICS in 
asthma, in children  (Childhood asthma management program research 
group 2000), and children and adults  (Pauwels et al 2003), demonstrated 
that they were effective at preventing exacerbations, as well as controlling 
symptoms and improving lung function.  
Since their introduction in the 1970s, ICS have been widely prescribed, 
often at high doses, for children with asthma, but concerns remained that 
this formulation of steroids could also be associated with systemic side 
effects, albeit less severe than in those children who had been using oral 
cortisone. This was a major driver for the development of alternatives for 
ICS, and adjunct therapies that could be used as steroid-sparing agents.  
Long-acting beta-agonists (LABA), which act primarily to reduce 
bronchoconstriction, and Leukotriene receptor antagonists (LTRA), which 
target specific aspects of the immune process, are the most widely used 
adjunct therapies in asthma. The main RCTs in children measured the 
effects of these drugs on lung function, symptoms, and short-term asthma 
control as primary outcomes (Bisgaard 2000; Russell et al 1995; Lazarus et 
al 2001; Lemanske Jr et al 2001). 
There are problems with the existing evidence for therapies for children 
with asthma. In some situations, such as with LTRA, the majority of the 
evidence used to guide treatment in children has been extrapolated from 
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trials in adults. Furthermore, when systematic reviewers attempt to 
synthesise the results of these trials, they are faced with problems of non-
uniform outcome measurement and reporting, which make this task 
difficult, if not impossible.  
Largely because of these problems, even though ICS, LTRA and LABA 
are established therapies, that are known to do more good than harm, many 
questions remain unanswered about the best way to treat children with 
asthma. There is debate about who should administer asthma care, which 
treatments should be considered in the first instance, which should be 
second-line or additional agents, which devices should be used to deliver 
inhaled therapy, whether behavioural management of asthma is effective, 
and whether alternative homeopathic medicines are safe and helpful  
(James Lind Alliance 2007). There are also newer therapies such as 
Omalizumab, which modulate the immune response in asthma, and protect 
against the damage it causes, and these will require evaluation in large 
scale, late phase RCTs.  
Two recent initiatives should increase the number and quality of such trials 
in children. Firstly, large paediatric research networks, such as the UK 
Medicines for Children Research Network (MCRN) have been set up 
across Europe. The problems with recruiting children into clinical trials, 
which were mentioned earlier, have necessitated the need for collaboration 
between centres, and initiatives such as the MCRN will facilitate the design 
and conduct of such studies across the UK. Secondly, there have been 
changes in the regulations on the licensing of medicines for children. These 
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were in response to the observation that many medications used commonly 
in children were unlicensed in children, because they had not been tested in 
the paediatric population  (Conroy et al 2000; Bücheler et al 2002; Smyth, 
& Edwards 2006). Reasons for this lack of RCTs in children include 
ethical and practical complexities of conducting clinical research in a 
paediatric population  (Smyth, & Weindling 1999), and the smaller 
financial gain that pharmaceutical companies receive from marketing 
medications in children, as compared with adults  (Cohen et al 2007).  
In the United States, in the late 1990s, the FDA Modernisation Act of 
1997, the Best Pharmaceutical for Children Act, and the Paediatric 
Research Equity Act provided marketing incentives for pharmaceutical 
companies if they conducted FDA-approved RCTs in children  (Hawcutt, 
& Smyth 2008). In 2007, The European Union (EU) Paediatric Regulation 
was passed, which offers extended periods of market patent for companies 
who conduct EMA-approved RCTs in children. Key to the European 
legislation is the Paediatric Investigation Plan (PIP), submitted by 
pharmaceutical companies to the EMA early in the drug development and 
evaluation process, that details the research and development that they will 
conduct to evaluate the efficacy and safety of a drug in children. 
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1.6.3 The need for research to identify the most appropriate 
outcomes for clinical trials in children with asthma 
In order to answer important research questions, researchers and clinicians 
must take advantage of the initiatives described above, and conduct large-
scale multi-centre RCTs in children with asthma. One of the factors that 
will determine the success of these trials is whether or not they measure the 
right outcomes. It can be difficult to know which outcomes are most 
important for evaluating treatments in childhood asthma. Some of the 
reasons for these problems were highlighted in Section 1.5.   
The effects of asthma are diverse, and without research to identify which of 
these are important in clinical practice, it is not clear which should be 
measured as outcomes in clinical trials. Outcomes can measure the effects 
that interventions have on asthma at the level of the airways, such as 
measures of lung function, bronchial hyper-responsiveness or 
inflammation. Another approach is to assess the effects of these biological 
effects on the clinical features of asthma, such as symptoms or 
exacerbations. Yet another approach could be to measure the effects that 
the clinical features have on a child’s life, or their family, such as outcomes 
that reflect functional status or QoL. Further difficulties arise due to the 
complex natural history of asthma, for example it is unclear whether it is 
sufficient to measure short-term outcomes, or whether it may be more 
appropriate to measure lasting, long-term outcomes.  
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Generating a comprehensive picture of whether a child’s asthma has 
improved after starting an intervention can also be difficult because of 
methodological issues relating to data collection. Lung function tests are 
difficult to measure in young children, and diaries may be too complicated 
for children to complete. There are a variety of tools for measuring 
outcomes, especially QoL, and some of these may not have been validated 
(van den Bemt et al 2010).    
When considering which outcomes to measure, trialists must also consider 
that physiological outcomes do not correlate well with more patient-centred 
outcomes, such as symptoms and QoL, and therefore may not give a 
comprehensive view of whether an intervention is helpful from the 
patient’s perspective  (Brand et al 1999). This may confuse the issue of 
which intervention may be best for a patient, because the relative efficacy 
of different asthma medications may depend on the outcomes that are 
examined. For example, in one crossover RCT in adults with asthma, 
fluticasone (an ICS) was superior to eformoterol (a LABA) for clinic lung 
function and bronchial hyper-responsiveness, eformoterol was more 
effective for reducing the need for night-time reliever inhalers, and the 
drugs were equivalent for symptoms, PEFR, need for daytime reliever, 
QoL and patient assessments of asthma control (Jenkins et al 2005). 
Without knowledge of which of these outcomes is the most important, it 
can be difficult to know which medication is most appropriate for the 
patient. This was highlighted as a particular cause for concern by clinical 
and research experts at an international meeting in 2008, in which the 
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priorities for the improvement of asthma management and research were 
discussed  (Holgate et al 2008). 
Given how crucial the selection of appropriate outcomes is for the success 
of clinical trials, research to identify which outcomes are most important 
can be useful for a variety of people. Trialists from academia and industry 
who design and conduct RCTs, clinicians, patients and parents, and 
systematic reviewers, who synthesise the results of similar trials, will all 
benefit from a core outcome set that includes important outcomes. The 
purpose of this thesis is to examine the methodology of identifying the 
most appropriate outcomes for clinical trials, and to determine which 
outcomes are important in childhood asthma. 
 
1.7 Structure of this thesis 
In Chapter 2, a systematic review of studies that determine which outcomes 
to measure in clinical trials in children is described. The purpose of this 
review was to identify specialties in which such work had been conducted, 
and to examine the methodology used.  
In Chapter 3, a systematic review of RCTs in childhood asthma, published 
between 1988 and 2008, is described. This work was conducted because, in 
the review in Chapter 2, we found no robust core outcome set for 
childhood asthma. We, therefore, wished to identify which outcomes were 
measured in RCTs in asthma, investigate whether any outcome domains 
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were under-represented, and determine whether there was non-uniformity 
between studies. The main recommendation from this review was that a 
core outcome set should be developed for RCTs in childhood asthma.  
In Chapter 4, a systematic review of studies that have used the Delphi 
technique, to design core outcome sets for clinical trials, is described. This 
review highlighted important considerations when designing and reporting 
such studies. 
In Chapter 5, a study to determine which outcomes are most important in 
childhood asthma is reported. The methodology for this study, which 
reflects the recommendations from the systematic review described in the 
previous chapter, comprised a Delphi study involving paediatricians and 
respiratory nurses in the UK, and parents of young people with asthma, to 
determine the most important outcomes to these groups.  
In Chapter 6, an outline of the possible future directions of our research is 
presented. 
 37 
C h a p t e r  2   
A systematic review of studies that aim to 
determine which outcomes to measure in 
clinical trials in children 
 
2.1 Background 
When designing a clinical trial, the choice of which outcomes to measure is 
crucial. The selection of inappropriate outcomes can lead to wasted 
resources or misleading information that overestimates, underestimates, or 
completely misses the potential benefits of an intervention. Examples of 
these problems are well documented  (Fleming, & DeMets 1996; 
Holloway, & Dick 2002).  
It can be difficult to know which outcomes should be measured in clinical 
trials, because illnesses can have several effects, which could each improve 
after starting an intervention, and could therefore be selected as outcomes. 
There may be a lack of methodological research to determine which of 
these are most appropriate for clinical trials in a given condition.  
In light of these complexities, some work has been conducted, notably in 
the field of rheumatology, to determine the outcomes that researchers and 
clinicians feel should be measured in clinical trials  (Tugwell et al 2007). A 
few studies, conducted in adults, have also aimed to identify the most 
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important outcomes from the perspective of patients and families  (Kirwan 
et al 2005; Mancuso et al 2002; Arnold et al 2008). Research such as this 
should improve the likelihood that important outcomes are measured in 
clinical trials. Standardising outcomes across trials also makes it easier to 
synthesise the results of otherwise similar studies, by ensuring that 
outcomes are measured and reported in a uniform manner, and reduces the 
risk of selective reporting.  
This chapter describes a systematic review of studies that address the 
question of which outcomes to measure in clinical trials in children, under 
16 years of age. We have restricted this review to studies identifying 
outcomes for clinical trials in children because there is increasing 
recognition that children are not merely ‘‘small adults,’’ and the 
methodology of conducting research in this age group should be tailored 
accordingly. The outcomes that are appropriate for clinical trials in children 
may also, justifiably, differ from those relevant to clinical trials in adults.  
We anticipated that one way of determining which outcomes to use, in 
addition to the consensus techniques described above, may be to ascertain 
the opinions of both children and their parents regarding outcomes that 
they think are important. This process poses unique challenges that may 
not be relevant when conducting similar research in adults with a particular 
condition, so we deemed it appropriate to specifically review studies 
pertaining to the selection of outcomes, or outcome domains, in clinical 
trials in children.  
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2.2 Aims  
1. To identify studies which have been conducted to determine which 
outcomes or domains to measured in clinical trials in children.                         
2. To identify the methodological techniques utilised in these studies.      
3. To assess the quality with which the studies were conducted and 
reported. 
 
2.3 Methods of the systematic review 
2.3.1 Inclusion and exclusion criteria 
Studies that developed or applied methodology for determining which 
outcome domains or outcomes should be measured in clinical trials in 
children younger than 16 years of age were eligible for inclusion, as were 
systematic reviews of these studies. 
 
The following studies were excluded from the review:  
1. Studies that did not specifically state that the outcomes were considered 
for use in a paediatric population.  
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2. Studies relating to instruments, tools, scales, scores, and definitions, 
which address how outcomes should be measured, rather than which 
outcomes to measure.  
3. Studies relating to clinical trials that assess interventions given to adults, 
by measuring outcomes in children, for example the selection of neonatal 
outcomes to assess care given to their mothers.  
 
2.3.2 Identification of relevant studies  
In order to optimise the chances of identifying all relevant studies, a variety 
of medical literature databases were searched. These are described below: 
 
The Cochrane Library  
http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME 
This collection of databases contains primary and secondary biomedical 
and methodological research. The search was conducted simultaneously in 
the Cochrane Database of Systematic Reviews, Cochrane Database of 
Abstracts of Reviews of Effects, Cochrane Database of Methodology 
Reviews, Cochrane Methodology Register and Cochrane Central Register 
of Controlled Trials.   
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Medline  
http://www.ncbi.nlm.nih.gov/pubmed/ 
This database contains citations and abstracts from over 5000 journals 
relating to medicine, biomedical sciences and allied health professions. 
Coverage is from 1966 onwards.  
 
Cumulative Index of Nursing and Allied Health Literature (CINAHL)  
http://www.cinahl.com/library/library.htm 
This database of around 3000 journals, books, dissertations, conference 
proceedings and websites, relates to research in nursing, biomedical 
sciences and the allied health professions. Coverage is from 1981 onwards.  
 
SCOPUS  
(http://www.scopus.com/) 
This platform is used to search a variety of databases. EMBASE is one 
such database, which contains over 700 journals relating to pharmacology 
and biomedical sciences. Searching both EMBASE and Medline increases 
the chances of identifying all available literature  (Wilkins et al 2005; 
Suarez-Almazor et al 2000).    
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2.3.3 Designing an appropriate search strategy 
The design of the search strategy was an iterative process, in which search 
terms were modified to include synonyms and variations identified in 
retrieved publications  (Higgins, & Green 2008). The process of designing 
the search strategies is described below (Jones, & Smyth 2004). The search 
strategies are shown in Appendix 1.  
Synonyms were listed for the four specific terms “outcomes”, 
“methodology”, “clinical trials” and “children”, which reflected the aim of 
the review. Synonyms within in each of these four word lists were 
combined using the Boolean operator OR, so if a study citation included 
any of these terms in its title, abstract, or indexing words (either keywords 
specified by the authors, or MeSH words nominated by Medline 
librarians), it would be identified. To narrow the search, the four lists of 
synonyms were combined using the Boolean operator AND, so that only 
those studies which included at least one term from each list would be 
identified.  
Truncation and wildcards were used to improve the sensitivity of the 
search. Truncation, denoted by an asterix, identifies different derivations of 
search terms. For example child* would identify child, children, childhood 
etc. Wildcard characters, denoted by a question mark, account for spelling 
variations. For example p?ediatic would identify the terms paediatric and 
pediatric.  
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2.3.4 Selecting studies for inclusion in the review 
Each identified abstract was screened to assess eligibility. To reduce the 
chance of missing relevant studies, this process was performed twice. Full 
texts of potentially relevant articles were assessed with regard to the pre-
defined eligibility criteria. 
To check this process, a second reviewer independently screened a 
database that comprised all the abstracts for which full text had been 
obtained, and a selection of those that had been rejected. A sample, rather 
than the complete set, was selected due to resource constraints.  
A list of identified studies was emailed to the Clinical Study Group (CSG) 
members of the MCRN, who were asked to suggest other potentially 
eligible studies, published or unpublished. The speciality-specific CSGs 
constitute a multidisciplinary group of experts with a strong interest in the 
planning of clinical trials. 
 
2.3.5 Data Extraction  
From each study, the following data were extracted by one reviewer (IS), 
and checked by the second reviewer: 
1. The condition for which the outcome domains or outcomes were 
considered 
2. A description of the method 
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3. People involved in selecting outcome domains or outcomes 
4. The outcome domains and outcomes that were selected 
5. The geographical setting of the study. This was ascertained either by 
reading the text or, where listed, the names and institutions of people 
involved in the collaborations  
 
2.3.6 Assessing the quality of included studies 
The methodological quality of the studies was assessed by IS, and checked 
by the second reviewer. Reporting quality was assessed in terms of whether 
the study methods were reproducible.  
No validated assessment tool for critically appraising consensus statements 
existed at the time of this review, so two experts, one with experience of 
qualitative research, and the other with experience of consensus statements, 
were asked to advise on this assessment. To assess the quality of systematic 
reviews, the Critical Appraisal Skills Programme Systematic Review 
Appraisal tool was used 
(http://www.phru.nhs.uk/Pages/PHD/resources.htm). 
 
2.3.7 Data Analysis 
Studies were described narratively, and results presented in textual format. 
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2.4 Results 
2.4.1 Study selection 
The process of identifying studies is summarised in Figure 1 (shown on the 
next page).  
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Figure 1 Flowchart of the review: identification of studies that aim to 
determine which outcomes to measure in clinical trials in children 
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The initial database search identified 8,889 potentially relevant abstracts, of 
which 8819 were excluded. Of 70 articles that were retrieved in full, 25 
were included in the full review. These described studies conducted by 13 
separate collaborative groups. In addition, the members of the MCRN 
CSGs suggested 13 other articles. One of these summarised the work of a 
collaboration that was identified by the literature search, but did not itself 
describe the methodology used in sufficient detail to warrant inclusion in 
the full review, so is added as an additional reference  (Giacoia et al 2006). 
The other 12 suggested studies were not deemed relevant.  
In total, therefore, 57 full-text articles were reviewed and subsequently 
excluded. Of these studies, 19 were excluded because the authors did not 
use methodology for selecting outcomes (e.g. a review article based on 
personal opinion), 18 related to how to measure outcomes, rather than 
which outcomes to measure, 10 made no mention of outcome selection, 6 
did not specifically state that the outcomes which were selected were 
relevant to children, and 4 described consensus statements relating to 
clinical practice rather than clinical trial design. The reasons for exclusion 
of each individual study are presented in Appendix 2. 
 
2.4.2 Agreement between reviewers 
The second reviewer was provided with a database of 100 abstracts. These 
included a randomly selected sample of 30 abstracts that had been excluded 
at the initial screening stage, and 70 for which full text had been retrieved.  
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The second reviewer agreed with the exclusion of all 30 abstracts that were 
rejected at the initial screening stage. Of the 70 abstracts for which full text 
had been obtained, the second reviewer agreed with 61, and disagreed with 
9. After discussion, it was agreed that all nine should be retrieved in full 
based on the abstract. Of these, eight were subsequently excluded, after 
reading the full text, and one was included. Following full text review there 
was complete agreement between reviewers about the 25 included and 45 
excluded abstracts. Subsequently, there was also complete agreement 
regarding the data extraction and methodological assessment of the studies. 
 
2.4.3 Description of included studies 
The 25 articles included in the full review represented the work of 13 
collaborative groups, which are listed in Table 1. A detailed summary of 
each study is included in Appendix 3.  
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Table 1 List of studies included in the review 
 
Footnotes and legend to Table 1: 
a Concerned the selection of outcomes for use in a specific clinical trial 
b Concerned the selection of outcomes which could be used in clinical trials of 
children with clinical features of an underlying condition 
c Collaboration working on behalf of the Neonatal Drug Development Initiative 
(NDDI) 
d IMACS = International Myositis Assessment and Clinical Studies Group  
e PRINTO = Paediatric Rheumatology International Trials Organisation 
 
 
 
 
 
 
 
 
 
 
 
Speciality Condition Authors  
Critical care Sepsis Goldstein 2005  
Dentistry Dental restoration DeRouen 2002 a 
Gastroenterology Crohn’s disease Griffiths 2005  
Transplant 
medicine 
GVHD Pavletic 2006  
Apnoea Finer 2006 b c 
Cardiac instability Short 2006 b c 
Pain Anand 2005, Anand 2006  b c 
Postoperative cardiac 
dysfunction 
Roth 2006   b c 
Neonatology c 
Seizures Clancy 2006   b c 
Neurology Infantile spasms Lux 2004, Osborne 2001  
(on behalf of West Delphi Group)  
Bipolar affective disorder Carlson 2003  Psychiatry 
Nonepileptic seizures  La France 2006 b 
Asthma Smith 1996  Respiratory 
medicine Cystic fibrosis  Ramsey 1994  
Idiopathic Inflammatory 
Myopathy 
Miller 2001, Rider 2002, 2003, 
2004  Oddis 2005 (on behalf of 
IMACS d) 
Systemic Lupus 
Erythematosis/ 
Dermatomyositis 
Ruperto 2003, Ruperto 2004, 
Ruperto 2006 (on behalf of 
PRINTO e)  
Rheumatology 
Rheumatoid arthritis Giannini 1997  
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Four groups  (Carlson et al 2003; Goldstein et al 2005; LaFrance et al 
2006; Lux, & Osborne 2004) and the five eligible studies within the 
Neonatal Drug Development Initiative (NDDI)  (Anand et al 2006; Clancy 
2006; Finer et al 2006; Roth et al 2006; Short et al 2006) considered 
outcomes while addressing wider clinical trial design issues.  
Six groups  (Griffiths et al 2005; Ramsey, & Boat 1994; Pavletic et al 
2006; Giannini et al 1997; Miller et al 2001; Ruperto et al 2003) aimed to 
reach consensus specifically around outcome selection and measurement. 
One group  (Smith et al 1996) aimed to ascertain the opinions of clinicians, 
about outcomes which could be measured in clinical trials in children with 
asthma, but did not aim to reach a consensus around this topic.  
One group  (DeRouen et al 2002) addressed the question of which 
outcomes to measure in a specific trial in paediatric dental restoration. No 
systematic reviews of these, or other relevant studies, were identified.  
Eight groups were based in the USA  (Carlson et al 2003; DeRouen et al 
2002; Goldstein et al 2005; Griffiths et al 2005; LaFrance et al 2006; 
Pavletic et al 2006; Ramsey, & Boat 1994; Giacoia et al 2006). One group 
was based in Europe, but included participants from several countries in 
Europe, North America, and Asia  (Lux, & Osborne 2004). One group was 
based in Australasia  (Smith et al 1996). The three rheumatology 
collaborations  (Giannini et al 1997; Miller et al 2001; Ruperto et al 2003) 
involved clinical researchers in the US and Europe. 
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2.4.4 Participants involved in the studies 
Clinicians 
All 13 groups included clinicians with expertise in treating the conditions 
for which outcomes were being selected.  
 
Research experts 
All groups included participants with experience of conducting clinical 
research in the condition for which outcomes were being selected. In 
addition to clinical research experts, some groups also included 
biostatisticians and epidemiologists. It is difficult to quantify exactly how 
many groups employed such personnel, because they may have been 
referred to as ‘‘research experts”.  
 
Patients or parents 
Three groups involved parents of children with medical conditions, but 
none involved children directly. One study  (Carlson et al 2003) involved 
“representatives of families with affected children” in discussions about 
outcomes for clinical trials of children with bipolar affective disorder. One 
study report  (Pavletic et al 2006) acknowledges “patients and patient and 
research advocacy groups”. The level of involvement of these patient 
representatives was not described in either article. One study report  (Miller 
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et al 2001) acknowledges funding and administrative support given by two 
named patient support group leaders.  
 
Representatives from the pharmaceutical industry and drug 
regulatory authorities 
Three groups included participants whose interest in clinical trials related 
to drug licensing and marketing. The Neonatal Drug Development 
Initiative (NDDI) is described as a collaboration between the FDA and 
“neonatal experts and colleagues, representing industry and academia”  
(Giacoia et al 2006). Carlson (2003) mentions the involvement, in a 
consensus statement about outcomes for clinical trials of children with 
bipolar disorder, of “pharmaceutical industry sponsors with an interest in 
mood stabilizer products, staff of the FDA and their counterparts from 
regulatory agencies in Canada and the European Union”.  Participants in a 
consensus conference to identify outcomes for clinical trials in Cystic 
Fibrosis included “representatives from both the Cystic Fibrosis 
Foundation and the U.S. Food and Drug Administration” (Ramsey, & Boat 
1994). 
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2.4.5 Methods used to select outcomes  
The following techniques were used to determine which outcomes should 
be measured in clinical trials in children with specific conditions.  
 
Delphi technique 
The Delphi technique (Dalkey 1969) is a method of reaching a consensus 
opinion, in which sequential questionnaires are answered, anonymously, by 
participants. After each questionnaire, the group response is fed back to 
participants. Three groups utilised this method as follows.  
The West Delphi group  (Lux, & Osborne 2004) used the Delphi technique 
to identify which outcomes should be measured in clinical trials of children 
suffering from infantile spasms. The process was conducted, by email, over 
six rounds. In the first round 133 invited participants, of whom 42 
responded, were asked multiple-choice questions covering various aspects 
of clinical trial design, including outcomes. In the second round, multiple-
choice questions were asked about these topics. At this stage participants 
were also invited to comment and provide their personal opinions 
regarding outcomes. In the third round, statements were formulated from 
earlier responses. Participants were invited to answer whether they agreed 
or disagreed with these statements. In the fourth round, these statements 
were modified and participants commented on their suitability and content. 
The final two rounds involved the formulation of the final consensus 
statement and study report.  
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The PRINTO group  (Ruperto et al 2003) used the Delphi technique, over 
two sequential questionnaire-based surveys, to identify which outcomes 
should be measured in clinical trials of children with SLE. In the first 
questionnaire they asked 267 participants to indicate up to 10 variables 
they judged as clinically important. In the second questionnaire, the 
facilitators listed those indicators that had been suggested by at least ten 
responders, and the participants ranked, in order, their top ten choices. 
The IMACS group  (Miller et al 2001) used a Delphi technique to develop 
a core set of outcome domains and outcomes for use in clinical trials in 
children with inflammatory myopathy. The actual process itself is not 
described in detail in the article, but authors stated that the group consisted 
of “more than 100” members.  
 
Nominal group technique 
Nominal Group Technique (NGT) involves structured face-to-face 
discussion, followed by a vote on the options presented. Two groups 
utilised this technique.  
The PRINTO group  (Ruperto et al 2003) used NGT to select outcomes 
from those identified by the Delphi technique described earlier. The NGT 
exercise had five objectives, which were tackled by a group of 40 
participants: (1) to classify the proposed outcomes into ‘‘domains’’; (2) to 
classify the outcomes into “concepts of disease activity”; (3) to select the 
outcome domains that should be measured in clinical trials; (4) to select the 
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outcomes that should be used to measure these domains; and (5) to discuss 
specific design issues of the prospective validation phase of the study.  
Giannini et al (1997) used NGT to select, from a set of potential outcomes, 
a preliminary core set of six. The process used is not described in further 
detail in the study. The initial list of potential outcomes had been identified 
by sending a questionnaire to a 16-member advisory council.  
 
Semistructured discussion 
Eight groups, including the studies within the NDDI collaboration, came to 
consensus by discussion at meetings or workshops  (Goldstein et al 2005; 
DeRouen et al 2002; Griffiths et al 2005; Pavletic et al 2006; Carlson et al 
2003; LaFrance et al 2006; Ramsey, & Boat 1994; Anand et al 2006; 
Clancy 2006; Finer et al 2006; Roth et al 2006; Short et al 2006).  
 
Questionnaires 
Smith et al (1996) sent questionnaires to 39 health care professionals and 
researchers with expertise in asthma to ask which outcomes they would use 
for a variety of clinical, research, and public health scenarios, including 
questions about which outcome they would use in clinical trials of acute 
and preventative asthma medication. Three other groups  (Giannini et al 
1997; Lux, & Osborne 2004; Ruperto et al 2003) used questionnaires as 
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part of the process of ascertaining the opinions of experts, mainly in the 
preliminary phases of the consensus process.  
 
2.4.6 Outcomes and domains that were selected 
Authors of the included studies either categorised outcomes into disease-
specific domains, or presented a list of uncategorised outcomes. Having 
listed the outcomes selected in each study, we categorised them into the 
following six domains, which were felt to be applicable to all paediatric 
conditions: disease activity; complications of the disease; adverse effects of 
therapy; functional status; social outcomes, family outcomes and QoL; 
health resource utilisation. The outcomes selected by each group are shown 
in Appendix 4, categorised by these domains. 
 
2.4.7 Assessment of the quality of studies 
Reporting of methodology 
Of the four collaborations who used structured consensus formulation 
techniques, namely one or both of NGT or Delphi Technique, three 
described the process of reaching consensus clearly in the study report  
(Giannini et al 1997; Lux, & Osborne 2004; Ruperto et al 2003). Each of 
the eight collaborations who came to a consensus after structured 
discussion, but without using Delphi technique or NGT, described the 
discussions in some detail, but the actual process of how consensus was 
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reached was generally not reported. The methodology used in the study 
that used a single questionnaire based survey  (Smith et al 1996) was 
described in sufficient detail to be able to repeat the study. All groups 
described the background of their participants. Only two, however, 
described in detail the process by which it was decided which particular 
individuals would be involved  (Lux, & Osborne 2004; Smith et al 1996).  
The reporting quality of the methodology used in the individual studies is 
summarised in Table 2.  
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Table 2 Quality of reporting in studies that aim to determine which 
outcomes to measure in clinical trials in children 
Description of the participants  Study Process of reaching consensus 
described in detail? 
Expertise of 
participants 
described? 
Selection 
of 
individuals 
described?  
Anand          
2005, 2006 
Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Carlson 2003 Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Clancy 2006 Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
De Rouen 
2002 
Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Finer 2006 Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Giannini 1997 Process of coming to consensus is 
clearly described 
Yes No 
Goldstein 
2005 
Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Griffiths 2005 Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
La France 
2006 
Discussion points are described. 
Actual process of reaching consensus 
is not described 
Yes No 
Lux 2004   
Osborne 2001 
Process of coming to consensus is 
clearly described 
Yes Yes 
Miller 2001, 
Rider 2002, 
2003, 2004; 
Oddis 2005 
Techniques used for coming to 
consensus are described. The actual 
process of coming to consensus is not 
described in detail. 
Yes No 
Pavletic 2006 Discussion points are described. 
Actual process of reaching consensus 
is not described 
Yes No 
Ramsey 1994 Discussion points are described. 
Actual process of reaching consensus 
is not described 
Yes No 
Roth 2006  Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Ruperto          
2003, 2005, 
2006 
Process of coming to consensus is 
clearly described 
Yes No 
Short 2006 Discussion points are described. 
Actual process of reaching consensus 
is not described. 
Yes No 
Smith 1996 Process of ascertaining opinions from 
experts is described 
Yes Yes 
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Techniques Used to Validate Outcomes 
Two groups made some attempt to prospectively validate the outcomes 
they had selected. In one study  (Giannini et al 1997), the multicollinearity 
and redundancy of a core set of outcomes for use in clinical trials of 
children with rheumatoid arthritis was assessed in a group of children in a 
clinical practice, and using a database from a previous observational cohort 
study. The acceptability of the core set of outcomes to a wider group of 
clinicians was assessed by sending a questionnaire to an international 
selection of rheumatologists, seeking their reactions to the outcomes.  
The PRINTO group  (Ruperto et al 2003) prospectively validated the core 
set of outcomes they had produced for clinical trials of children with SLE. 
This was done by measuring the outcomes in patients in a clinical out 
patients setting who were being started on new modalities of treatment for 
their condition. In this way the authors aimed to replicate a clinical trial 
setting, and assess the feasibility, discriminative ability, validity, and 
internal consistency of the core set of outcomes.  
Both of these groups, and the IMACS group  (Miller et al 2001) also 
developed “definitions of improvement,” based on the degree of change 
within each outcome, which could be used as a dichotomous index in 
clinical trials to determine whether patients had benefited from the 
treatment they had received. This was done in all three studies by 
developing a set of “paper patient profiles,” and asking clinicians whether 
or not they thought the patient had improved. A set of potential definitions 
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of improvement was narrowed down to a final definition by using various 
consensus techniques. 
 
2.4.8 Additional studies identified after this systematic 
review was conducted 
We identified two studies that met the eligibility criteria for inclusion in 
this systematic review, but were published after its completion.  
 
PedIMMPACT  
The IMMPACT (Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials) collaboration has developed core outcome 
sets for use in clinical trials that assess treatments for patients with pain. 
One study conducted by this group relates to outcomes in clinical trials of 
children suffering from pain  (McGrath et al 2008). 
This study involved 26 participants, of whom 23 were based in North 
America, and 3 in Europe. These included representatives from the clinical 
research community, drug regulatory authorities, and the pharmaceutical 
industry. The group conducted a two-stage Delphi process in which 
important outcome domains, and possible outcomes within these domains, 
were suggested and scored by participants. The results of this Delphi 
process were discussed at a consensus meeting at which, after semi-
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structured discussion, the group reached consensus about a core set of 
outcomes.   
The core outcomes suggested for children with acute pain were pain 
intensity, global judgment of satisfaction with treatment, symptoms and 
adverse events, physical recovery, emotional response, and economic 
factors. The core outcomes suggested for children with chronic pain were 
pain intensity, global judgment of satisfaction with treatment, symptoms 
and adverse events, physical functioning, emotional functioning, role 
functioning, sleep, and economic outcomes. 
 
Asthma 
In July 2009, a report was published which described a consensus 
conference relating to outcomes in clinical trials of patients, aged 6 years 
and older, with asthma  (Reddel et al 2009). The aims of the consensus 
group were to define the outcomes that are most important for measuring 
asthma control, to determine the most appropriate way to measure these, 
and to define the term ‘exacerbation’.  
Seven working groups each discussed one of the following topics: 
exacerbations; diary data; physiological measures; composite scores; 
biomarkers; indirect measures; or quality-of-life questionnaires. The 
discussions were informed by literature reviews around each of the topics. 
After each working group had formulated some guidelines, these were 
circulated to the other groups for discussion and comments. One other 
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group, comprising two paediatricians with experience of clinical research, 
offered advice on each working group’s suggestions, from the perspective 
of clinical trials in children.  
Composition of the group “was intended to represent a broad spectrum of 
clinical expertise and clinical trial experience”, but the areas of expertise of 
the participants is not described in further detail. In total, 25 clinicians were 
involved, including the paediatricians. The FDA and EMA provided, 
between them, three representatives. Pharmaceutical companies were not 
involved in the discussions, but were invited to suggest “written 
submissions”, of which three were circulated to the group members. It is 
unclear what they suggested. No patients or families were involved in the 
study. Participants were from the USA, Europe, Australasia and South 
Africa.  
The core outcomes were divided into those relating to current clinical 
control, and those relating to future risk. Outcomes were classified as 
essential, desirable and optional.  
The ‘essential’ core outcomes relating to current control were: Symptom-
free days; Reliever use; Composite scores (eg Asthma Control 
Questionnaire); Exacerbations; Quality of life 
The ‘desirable’ outcomes relating to current control were: FEV1; daily 
symptoms, reliever use and lung function, as recorded in a patient diary; 
corticosteroid use and health care utilisation. 
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The ‘optional’ outcomes relating to current control were biomarkers, 
airway hyperresponsiveness, and post-bronchodilator FEV1 
The ‘essential’ core outcomes relating to future risk were: Composite 
scores (eg Asthma Control Questionnaire); Exacerbations; Post 
bronchodilator FEV1 (as a measure of lung decline); treatment side effects, 
and Pre-bronchodilator FEV1 (as a predictor of exacerbations) 
The ‘desirable’ outcomes relating to future risk were: daily symptoms, 
reliever use and lung function, as recorded in a patient diary; health care 
utilization (e.g., corticosteroid use, ER visits, hospitalizations); mortality 
due to asthma; Airway hyperresponsiveness (as a predictor of future risk); 
Biomarkers (as predictor of future risk) 
No ‘optional’ outcomes relating to future risk were suggested. 
 
2.5 Discussion 
We systematically reviewed the work of 13 groups who addressed the issue 
of selecting outcomes for use in paediatric clinical trials. In many 
paediatric specialties, such work has not been conducted. The quality of the 
studies, with regard to the methodology used, and the level of detail with 
which the methods were reported, was variable.  
We identified three methods used for reaching consensus, namely NGT, 
Delphi technique, and semi-structured discussion. Many groups used a 
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multidisciplinary approach to the problem of outcome selection, including 
researchers with experience of clinical trial design, statisticians, and 
clinicians. Some groups also involved representatives from industry or 
drug regulatory authorities, but the nature of their involvement is not 
evident from reading the reports.  
As the aim of clinical trials should be to determine whether patients 
experience important benefits from an intervention, it was notable that we 
did not identify any studies that had directly asked children what they 
considered to be the most relevant outcome domains or outcomes. In the 
United Kingdom steps are being taken to involve consumers in medical 
research. A major initiative is the James Lind Alliance (JLA) 
(http://www.lindalliance.org/), a collaboration that aims to ascertain from a 
variety of people involved in clinical research, and patients, what they 
think are the most pressing research priorities for various conditions. 
Determining appropriate outcomes for paediatric studies is another area in 
which children and families can be involved in clinical trial design.  
 
Robustness of the review 
Our review was conducted in a rigorous, systematic manner. Two 
reviewers adhered to strict eligibility criteria to determine which studies 
should be included. Although the sample of excluded papers checked by 
the second reviewer represented a small proportion of all the ineligible 
studies, we concluded that agreement between the reviewers was adequate. 
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We determined that a smaller proportion of excluded studies would be 
sufficient for quality assurance, as compared with other systematic reviews 
in which the results of clinical trials are synthesised. 
Although the 8,889 abstracts identified were screened twice, it may be 
possible that some relevant studies were missed. The types of studies that 
may not have been identified at this stage include clinical trials that did not 
describe in the abstract how the authors selected their outcomes, but 
subsequently in the full text may have mentioned the process used. It is 
also possible that some studies may have been missed by not searching the 
“grey” literature such as unpublished conference proceedings.  
There were recurring features of the methodology and reporting quality of 
the consensus statements that may have compromised the scientific validity 
of the studies we identified. Most studies that described formation of a 
consensus statement did not explain in sufficient detail two key aspects of 
the process, namely the method used to select participants, and the process 
by which consensus was reached. Insufficient information was given to 
determine the level of involvement of certain groups involved in the 
research, particularly industry representatives, drug regulatory authority 
representatives, and parents of affected children. 
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Implications for clinical trials  
If implemented, the studies we identified could improve the standardised 
measurement, of important outcomes, in clinical trials. Uniform selection 
of outcomes would make interpretation of results and comparison across 
trials simpler, hence making meta-analyses easier and more powerful  
(Clarke 2007). Disease-specific, universally agreed core sets of outcomes, 
that should be measured and reported in all clinical trials of a specific 
condition, regardless of statistical significance, have also been advocated as 
a solution to the common problem of ORB  (Williamson et al 2005; 
Giannini et al 1997; Kirkham et al 2010).  
 
Implications for drug regulatory authorities 
As discussed in Chapter 1, there is a need for high quality paediatric 
clinical trials, and the development of Paediatric Investigation Plans (PIPs) 
is one of the changes in drug regulation in Europe that should facilitate this 
goal. The PIP, which is submitted to the EMA, is a detailed outline of 
research that would be needed to investigate the potential benefits and 
harms of medications for use in children. If a drug company were to be 
involved in the writing and implementation of a PIP, they would be eligible 
for marketing rewards in the form of prolonged patent protection and 
market exclusivity. When a PIP is submitted, the endpoints selected for the 
trial must be clearly stated and their appropriateness described 
(http://www.emea.europa.eu/htms/human/paediatrics/pips.htm).  
 67 
The studies we have identified should be of use to people designing a PIP, 
and it is possible that the types of studies we have identified may become 
more common as drug companies seek to take advantage of the benefits of 
conducting high-quality clinical trials in children. The new standards for 
conducting clinical trials of investigational medicinal products set by the 
EMA aim to improve the quality of paediatric research. In order to obtain a 
license for a drug, it must be investigated according to these guidelines 
(http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm). 
In July 2007, of the 13 paediatric conditions identified in this review, the 
EMA Web site included guidelines for one (juvenile idiopathic arthritis) 
and a concept paper discussing the need for guidelines for another (cystic 
fibrosis).  
 
2.6 Summary 
We have reviewed 13 studies that address the process of selecting 
outcomes for clinical trials in children. This work should make it easier to 
determine which outcomes to measure in clinical trials. Although it is 
commendable that there are existing collaborations in several clinical areas, 
future work in this area may be improved by involving children and 
parents. The studies identified by this review will go some way to 
improving the quality of paediatric research, but further research is justified 
and needed. 
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One of the clinical areas in which we found no core outcome sets, designed 
using structured consensus technique, is childhood asthma. One possible 
implication of this may be that trials conducted in children with asthma 
may select and measure outcomes in a non-uniform manner. Another 
possible implication may be that, even if trialists are measuring the same 
outcomes, certain important effects of treatments are being overlooked and 
under-represented.  The purpose of the review described in Chapter 3 is to 
identify whether these problems are evident in clinical trials of regular 
therapies for children with asthma.  
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C h a p t e r  3   
A systematic review to identify which 
outcomes are measured in randomised 
controlled trials in children with asthma 
 
3.1 Background 
Asthma in children is a major global health problem  (Bateman et al 2008). 
It is an important cause of morbidity, mortality, and economic cost  
(Masoli et al 2004), it is the commonest chronic condition in industrialised 
countries  (Beasley 1998), its prevalence is increasing  (O'Connell 2004), 
and in many children it is a progressive condition that continues into 
adulthood  (Martinez 2002). 
Several outcomes are relevant when evaluating the efficacy and safety of 
treatments in asthma, and it may be difficult for researchers to know which 
of these should be measured in clinical trials. One of the studies included in 
the systematic review in Chapter 2 related to outcomes for RCTs in 
children with asthma  (Smith et al 1996). As this study consulted only a 
limited group of paediatric experts, did not ask about all relevant domains, 
did not use structured consensus techniques, and did not involve children 
with asthma, or their parents, it does not provide a robust basis for 
recommendations about which domains and outcomes are most appropriate 
for RCTs of children with asthma. One other study, published after the 
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systematic review was completed  (Reddel et al 2009) used a more 
structured approach to reaching consensus about which outcomes to 
measure in clinical trials, but is too recent to have been implemented yet. 
The absence of a core outcome set, designed using structured consensus 
techniques, may have led to non-uniformity between studies, and may also 
mean that certain outcome domains have been overlooked. The systematic 
review described in this chapter evaluates which outcomes and domains are 
measured in clinical trials in asthma, to assess whether such problems are 
prevalent.  
 
3.2 Aims 
1) To assess which outcomes had been measured in clinical trials of ICS, as 
regular therapy for children with asthma, between 1988 and 2007, in order 
to determine whether all domains were represented, and whether there was 
consistent selection of outcomes within these domains.  
2) To determine whether the selection of outcome domains has changed 
over this period 
3) To determine whether domains measured in RCTs that exclusively 
involve children differ from those in studies involving both children and 
adults 
4) To determine whether domains measured in publically funded trials 
differed from those in trials funded by the pharmaceutical industry. 
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3.3 Methods of the review 
3.3.1 Inclusion and exclusion criteria 
In order to ensure that a group of similar studies was examined, this review 
included only RCTs with parallel group design that assessed ICS as a 
therapy to prevent symptoms or long-term effects of asthma in children. 
RCTs that only involved children younger than 18 years of age, and also 
studies that included children and adults, were eligible.  
Crossover trials were excluded, because they are generally of acute 
interventions, the length of treatment in these studies is typically shorter, 
and the outcomes they measure may differ from those measured in parallel 
trials  (Pocock 1983). In order to only include RCTs assessing long-term 
preventative therapy for asthma, studies with a treatment phase of less than 
one month were excluded. The review was restricted to studies published 
between January 1988 and December 2007. 
 
3.3.2 Identification of studies 
We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL). This database comprises citations to reports of clinical trials, 
from Medline, EMBASE, and other sources, such as registries and journals 
that are not indexed in Medline. Because of the wide range of sources that 
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are covered by CENTRAL, it is regarded as the most comprehensive 
database of RCTs  (Higgins, & Green 2008).  
 
3.3.3 Search strategy 
The process of designing and refining a search strategy is described in 
section 2.3.3. As the eligible studies were randomised controlled trials that 
assessed ICS as a therapy for children with asthma, the word lists that were 
generated included synonyms for the terms “children”, “inhaled 
corticosteroids” and “asthma”. The terms within each of these lists were 
combined using the Boolean operator OR, and then the word lists were 
combined using the operator AND. The full search strategy is included in 
Appendix 5. 
 
3.3.4 Data extraction and quality assessment 
From each report, the following data were extracted by one reviewer (IS): 
1. All outcomes reported 
2. If stated, the designated primary outcome, and whether this was 
described in sufficient detail, including the methods used to measure it, by 
whom, and when it was measured and analysed. 
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3. Other study features: year of publication; interventions compared; ages 
of children included; length of study treatment; single- or multi-centre; 
source of funding. The source of funding was identified either directly 
from a statement in the study report or, if this was not present, by 
contacting the authors using email.   
4.  Whether interventions were adequately masked. This was examined 
because the extent to which interventions were masked may affect the 
choice of outcomes, and whether they were measured objectively or 
subjectively. The adequacy of masking was categorised as follows. 
Adequately masked:  
Authors either clearly describe or imply, in the methods, how the allocated 
treatment was masked to the patient and family, medical caregiver, and 
trial personnel involved in measuring outcomes. 
Inadequately masked: 
Authors specifically state that the identity of the allocated treatment arm 
was not masked to at least one of the following: patient and family, 
medical caregiver, or relevant trial personnel involved in measuring 
outcomes. 
Unclear: 
It was unclear from study methods whether masking was adequate or not. 
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3.3.5 Data analysis and presentation 
For each study, the data were tabulated, and each outcome was grouped 
into one of the following six outcome domains, some of which were further 
divided into subdomains where appropriate: disease activity, physical 
consequence of disease, functional status, social outcomes and quality of 
life, side effects of therapy and health resource utilisation. These domains 
had been identified in the systematic review described in Chapter 2. 
To assess how the selection of outcomes has changed over time, the period 
1988 to 2007 was divided into sixteen separate epochs, each lasting five 
years. In each epoch, the proportion of studies measuring each outcome 
domain was calculated, and the results presented as a moving window. 
This was only done using studies that had exclusively involved children. 
 
3.4 Results 
3.4.1 Results of the search 
The search yielded 1668 potentially eligible reports. Of these, 1256 were 
excluded by reading the abstract. The remaining 412 were retrieved in full, 
and 203/412 were subsequently excluded. In total, 209 eligible reports, of 
159 RCTs, were included in the review. The review flowchart is shown in 
Figure 2.  
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Figure 2 Flowchart of the review: identification of RCTs, assessing 
ICS in children with asthma, published between January 1988 and 
December 2007 
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3.4.2 Description of included studies 
Of the 159 studies included in this review, 115 exclusively included 
children, and 44 included children and adults. Within the group of studies 
that included only children, 25/115 (21%) included children younger than 
four years of age. In the studies of adults and children, 42/44 (95%) 
included children aged between 12 and 18 years of age, but not younger 
than 12, and 2/44 (5%) included children between 5 and 18 years of age, 
but not younger than 5 years. 
Of the 159 studies, 83 (52%) included a comparison between ICS groups 
(either different doses, modes of delivery, or types of ICS, eg budesonide 
vs beclomethasone), 63 (40%) included a comparison with placebo, and 54 
(34%) included a comparison with another drug. 
Masking of interventions was deemed adequate in 121/159 studies (76%), 
inadequate in 33/159 (21%), and unclear in 5/159 (3%). Of the 33 studies 
that were classed as inadequately masked, 18 compared ICS with another 
drug, 8 compared ICS administered by different devices, 3 compared one 
ICS to another, 3 compared ICS administered using different dosing 
schedules, and 1 compared ICS with no treatment. Subjective outcomes 
that could have been affected by the lack of blinding were measured in 
29/33 of these studies (29/33 measured symptoms, 8/33 measured quality 
of life, and 6/33 measured functional status). 
The characteristics of included studies are summarised in Table 3. 
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Table 3 Characteristics of included studies 
Study 
characteristic 
Category Number (%) of 
RCTs that 
included only 
children (n=115) 
Number (%) of 
RCTs which 
included children 
and adults  
(n=44) 
January 1988 to  
December 1992 
10 (9) 1 (2) 
January 1993 to  
December 1997 
19 (17) 5 (11) 
January 1998 to  
December 2002 
48 (42) 22 (50) 
Date of 
publication 
January 2003 to  
December 2007 
38 (32) 16 (37) 
1 to 3 months 30 (26) 5 (11) 
3 to <6 months 46 (40) 30 (69) 
6 to <12 months 13 (11) 4 (9) 
12 months or longer 24 (21) 5 (11) 
Length of 
treatment 
period 
Unclear 2 (2) 0 
<4 years only 17 (15) 0 
<4 and 4 to <12 years 7 (6) 0 
<4 and 4 to<12 and 12 to 
18 years  
1 (1) 0 
4 to <12 years only  36 (31) 0 
4 to <12 years and 12 to 
18 years 
53 (46) 2 (5) 
Age groups 
of children 
included 
12 to 18 years only 1 (1) 42 (95) 
Multicentre 75 (65) 42 (95) 
Single centre 39  (34) 2 (5) 
Number of 
centres 
Unclear 1 (1) 0 
Industry 85 (74) 42 (95) Source of 
funding Public funding bodies 30 (26) 2 (5) 
ICS vs Other drug  26 (23) 12 (27) 
ICS vs placebo 25 (22) 4 (9) 
ICS 1 vs ICS 2 a 14 (12) 3 (7) 
ICS vs same ICS (other 
device) 
12 (10) 2 (5) 
ICS vs same ICS (other 
dose) 
9 (8) 3 (7) 
ICS vs no treatment 1 (1) 0 
ICS 1 vs ICS 2 vs 
Placebo a 
16 (14) 10 (23) 
ICS 1 vs ICS 2 vs Other 
drug a 
7 (6) 1 (2) 
ICS vs Other drug vs 
placebo 
4 (3) 4 (9) 
ICS1 vs ICS 1 (other 
dose and device) 
1 (1) 0 
Comparisons 
ICS 1 vs ICS 1 (other 
dose) vs ICS 2 
0 5 (11) 
Footnote:  a: ICS 1 vs ICS 2 refers to comparison of two different classes of ICS  
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3.4.3 Outcome domains measured in the studies 
Disease activity was measured in 157/159 (99%) studies, adverse effects of 
therapy in 135/159 (85%), functional status in 25/159 (16%), quality of life 
in 21/159 (13%), and health resource utilisation in 17/159 (11%).  
No studies measured the effects of ICS on long-term physical 
consequences of asthma, although two studies measured post-
bronchodilator FEV1, as a percentage of the predicted value, to assess 
‘lung growth’. In one of these studies, children, aged between 5 and 12 
years, were randomised to receive inhaled budesonide, nedocromil sodium, 
or placebo, for a period of four to six years, and FEV1was measured as the 
primary outcome  (Szefler et al 2000). In the other study, patients aged 
between 5 and 66 years were randomised to treatment with inhaled 
budesonide or placebo for three years, and FEV1 was measured as a 
secondary outcome  (Pauwels et al 2003).  
Similar outcome domains were represented in the 115 studies that included 
only children and the 44 that included children and adults. 
 
3.4.4 Outcomes that were measured within the domains 
Subdomains and outcomes varied across the studies. There was a wide 
variety of outcomes within individual domains. This was greatest for the 
disease activity domain, which was divided into five subdomains (clinical 
measures, physiological tests of lung function, global measures, bronchial 
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responsiveness to a challenge agent or exercise and markers of 
inflammation). The frequency with which domains, subdomains and 
outcomes were selected, in 115 studies that exclusively involved children, 
is shown in Table 4. 
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Table 4 Frequency with which outcomes were reported in the 115 
RCTs which involved only children 
Domain Subdomain 1 Subdomain 2 Outcome Number (%) of 
studies in which 
measured 
(primary or 
secondary 
outcome) n=115 
Number (%) 
of studies in 
which 
measured 
(primary 
outcome) 
n=84  a  
   114 (99) 74 (88) 
Symptom severity 90 (77) 10 (12) 
Symptom frequency 55 (47) 5 (6) 
Symptoms 
Use of rescue 
therapy 
90 (77) 2 (2) 
Exacerbation 
frequency  
35 (30) 4 (5) 
Clinical 
measures  
n=109 
Exacerbations  
Time to exacerbation 10 (9) 0 
FEV1 80 (70) 16 (19) 
FVC 31 (26) 0 
Mid expiratory flow 23 (20) 0 
FEV1:FVC 6  (5) 0 
Spirometry  
FEV1 reversibility 9 (8) 0 
PEFR 85 (73) 26 (31) 
Diurnal variability 13 (11) 0 
PEFR  
Day-to-day 
variability 
5 (4) 0 
Lung volume  Plethysmographic 4 (3) 0 
Lung function 
tests  n=103 
Airway flow  Resistance/conducta
nce 
5 (4) 2 (2) 
Physician-rated 8 (7) 1 (1) 
Parent/patient – rated 14 (12) 0 
‘Treatment failure’ 13 (11) 0 
Global 
measure of 
control n=29 
 
‘Treatment success’ 3 (3) 0 
Methacholine-
induced  
26 (22) 6 (7) Bronchial 
responsiveness 
to a challenge 
agent n=29 
Induced BHR  
Exercise-induced  7 (6) 0 
Exhaled nitric oxide 5 (4) 1 (1) 
Leukotriene b/ 
interleukin c 
4 (3) 1 (1) 
Disease 
activity 
Markers of 
inflammation 
n=20 
 
Eosinophils d/IgE e 18 (15) 0 
Physical 
consequence 
of disease 
   0 0 
 15 (13) 1 (1) HRU   
Unscheduled HRU 15 (13) 1 (1) 
 20 (17) 0 
Effect of asthma on 
ADL 
10 (9) 0 
Functional 
status 
  
School attendance 15 (13) 0 
 19 (17) 0 
Child’s QoL 9 (8) 0 
Caregiver QoL 5 (4) 0 
QoL/ family 
outcomes 
  
Caregiver functional 
status 
 
 
 
 
 
 
 
 
 
8 (7) 0 
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cont Subdomain 1 Subdomain 2 Outcome Number (%) of 
studies in which 
measured 
(primary or 
secondary 
outcome) n=115 
Number (%) 
of studies in 
which 
measured 
(primary 
outcome) 
n=84  a  
   96 (83) 14 (16) 
Patient/parent- 
reported 
80 (70) 1 (1) 
Routine laboratory 
AE  
32 (27) 0 
Orophayryngeal 
infection 
28 (24) 0 
Routinely 
monitored AE 
n=82 
 
Ophthalmological 
events 
7 (6) 0 
Urine/serum cortisol 52 (44) 0 H-P-A axis 
n=52 
  
ACTH stimulation 17 (15) 1 (1) 
Growth 41 (35) 9 (11) Growth n=41  
Lower leg growth  1 (1) 1(1) 
Markers of bone 
turnover 
11 (9) 0 
Adverse 
Effects of 
therapy 
Effects of ICS 
on bone n=15 
 
Measures of bone 
density 
8 (7) 2 (2) 
 
Abbreviations used in Table 4:  
ACTH= adrenocorticotropic hormone; ADL=Activities of Daily Living; AE= adverse 
events; BHR= bronchial hyperresponsiveness; FEV1= forced expiratory flow in one 
second; FVC= forced vital capacity; H-P-A=Hypothalamic-pituitary-adrenal; HRU= 
health resource utilisation; ICS= inhaled corticosteroids; IgE= Immunoglobulin E; PEFR= 
peak expiratory flow rate; QoL= Quality of life 
 
Footnotes to Table 4: 
a : Of 84 studies that specified primary outcomes, 5 specified co-primary outcomes, and 
hence the total number of primary outcomes measured is 89. 
b : Leukotriene LTC4 in serum and nasal secretions and leukotriene LTE4 in urine 
c : Interleukins in serum and sputum 
d : Eosinophils in serum and sputum, and Eosinophil Cationic Protein in serum and urine 
e : IgE in serum 
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3.4.5 Primary outcomes 
It was possible to determine the primary outcome in 84/115 (73%) of the 
studies that included only children. In 64/84, the primary outcome was 
clearly stated by the authors, and in 20/84 it was inferred from the outcome 
used to calculate the sample size. Five studies each selected two co-
primary outcomes.  
Of the 84 studies that specified a primary outcome, 74 (88%) selected 
primary outcomes that measured disease activity. A total of 17 different 
primary outcomes were selected, of which physiological measures of 
airway obstruction, mainly PEFR (26 studies) and FEV1 (16 studies), were 
the most frequent. None of the primary outcomes addressed the functional 
status or quality of life domains.  
In RCTs that included children and adults, it was possible to determine the 
primary outcome in 39/44 (89%) studies. In 34 of these, the primary 
outcome was clearly stated by the authors, and in the remaining 5 it was 
inferred from the outcome used to calculate the required sample size. In 
38/39 (97%) of studies, the primary outcome was a measure of disease 
activity. The most frequently measured primary outcome was FEV1 (28 
studies). 
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3.4.6 Outcomes measured in studies funded by the 
pharmaceutical industry 
The frequency with which most domains were measured was similar 
between the 127 studies sponsored by the pharmaceutical industry and the 
32 publicly funded studies. The main difference was that adverse effects of 
therapy were reported in a higher proportion of studies sponsored by the 
pharmaceutical industry (118/127, 93%) compared to studies funded from 
other sources (17/32, 53%). 
 
3.4.7 Trends over time in the selection of outcome domains  
The trend over the period January 1988 to December 2007 in the selection 
of outcome domains in RCTs that only included children is shown in 
Figure 3. Disease activity and adverse effects of therapy have consistently 
remained frequently measured outcome domains. Since the 1992–1996 
epoch the proportion of studies measuring functional status, for example by 
assessing school absence due to asthma, has decreased from 40% to 10%, 
and those measuring quality of life have increased from 10% to 25%. 
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Figure 3 Trends in the measurement of outcome domains between 
1988 and 2007 
 
 
Legend for Figure 3: The figure shows trends in the measurement of 
outcome domains in clinical trials of inhaled corticosteroid for children 
with asthma published between 1988 and 2008. Data are presented as a 
moving window. Each point along the horizontal axis represents the 
midpoint of a five year epoch. In each epoch the proportion of studies 
measuring each individual domain is shown. 
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3.5 Discussion 
We found that RCTs in children with asthma almost always assess the 
effects of therapies on short-term disease activity, but not the effects on 
long-term progression of disease. Quality of life and functional status are 
measured infrequently. While there were certain similarities between 
studies, particularly in the selection of primary outcomes that measure 
disease activity, the selection and measurement of outcomes showed wide 
variability. 
The pharmaceutical industry funded 80% of the RCTS we identified, and 
so it is not surprising that outcomes in the disease activity domain have 
been measured, as primary or secondary outcomes, as this reflects the 
requirements of the FDA  (FDA 1994; FDA 2007) and EMA  (EMA 1993; 
EMA 2002; EMA 2004; EMA 2007). These authorities recommend, for 
the purpose of drug licensing and marketing authorisation, that clinical 
trials of preventative therapies for children with asthma should measure, as 
primary outcomes, physiological tests of pulmonary function, and clinical 
measures such as symptom scores. Other measures of short-term disease 
activity, such as use of rescue medication, rate of exacerbations, and 
bronchial hyper-responsiveness are suggested as important outcomes. QoL 
and exercise tolerance are mentioned as additional outcomes that may 
provide useful information, but are not explicitly recommended. 
Given that the aim of an RCT is to evaluate the safety and efficacy of 
interventions, and provide some assessment of whether it does more good 
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than harm, it is disappointing to note that QoL and family outcomes ere 
only measured in 20% of RCTs in the last five years worth of studies 
included in the review, and that measures of functional status, such as 
school attendance, are reported in less than 10%. We identified no clinical 
trials in which the primary outcome measured these domains. In studies 
that have investigated which outcomes are clinically relevant to patients 
with other chronic conditions, such as long-term pain  (Dworkin et al 
2005), fibromyalgia  (Mease et al 2008), and rheumatoid arthritis  (Hewlett 
et al 2005), measures of functional status and quality of life were identified 
as being of great importance, and it is likely that this is also the case in 
children with asthma. Functional status overlaps with quality of life and 
disease activity. However, we feel that measures of functional status are 
important, distinct, markers of how asthma affects children. In clinical 
trials in adults with chronic illnesses, absence from work is an important 
outcome, and we feel that an appropriate childhood equivalent would 
include measures of school attendance and other activities of daily living. 
It is particularly important in trials of children to assess the impact of 
treatments in the long term. Very few studies have attempted to study the 
impact of ICS on modifying or affecting the physical consequences of 
asthma. Two studies, the Childhood Asthma Management Program 
(Childhood asthma management program research group 2000), and the 
Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START)  
(Pauwels et al 2003), indicated that they wished to investigate this effect. 
Both measured primary outcomes that we considered related to disease 
activity, although the CAMP study stated that their primary outcome 
 87 
(FEV1, %predicted) was a measure of ‘lung growth’. Although it is 
commendable that these trialists attempted to assess long-term benefits of 
ICS, investigators acknowledge the difficulties in assessing the impact of 
disease, or therapy, on ‘lung growth’ in children with asthma. It is unlikely 
that, in a clinical trial, a single measure will provide the best primary 
outcome, and more methodological research is needed to identify whether 
longitudinal outcomes, such as serial measurement of lung function, would 
be a more appropriate way of assessing lung growth. Although 24 of the 
studies that exclusively included children had a treatment period lasting 
longer than one year, only three measured outcomes after the end of the 
treatment period  (Szefler et al 2000; Visser et al 2004; Merkus et al 2004). 
The other 21 studies represent missed opportunities to investigate the long 
term effects of ICS on progression of asthma in children, and this question 
should be addressed in future clinical trials. 
The long-term safety of treatments for asthma has recently been identified 
as being of particular importance to patients and clinicians  (James Lind 
Alliance 2007). Although 83% of studies that we identified, that only 
included children, assessed the safety of ICS, the quality with which long-
term systemic side effects of ICS were measured was variable. Of the 24 
studies that lasted longer than a year, 21 measured effects on growth. None 
of the studies measured the final adult height attained, despite the fact that 
this is of most interest to children and parents. Only 14 studies measured 
the effect of ICS, when administered for longer than one year, on 
hypothalamo-pituitary-adrenal function, despite the serious and potentially 
fatal consequences of this adverse reaction  (Paton et al 2006). We suggest 
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that serious systemic side effects should be monitored in all clinical trials 
of ICS in children with asthma, so that both the benefits and risks of these 
drugs can be appropriately evaluated. 
As well as the fact that measurement of long-term efficacy and safety 
outcomes is not a requirement of drug regulatory authorities, there are 
other reasons why they may not have been measured in the studies we 
identified. Diagnostic and technical problems associated with measurement 
of lung growth, financial cost, and problems with patient attrition, also 
hinder the conduct of long-term studies in children with asthma. 
Agreement that long-term outcomes are important, amongst clinicians, 
patients, and researchers, could promote the conduct of such studies. There 
is also a need for research to identify the most appropriate long-term 
outcomes, and the ways in which they should be measured. 
 
Robustness of the review 
This review represents a thorough analysis of RCTs spanning twenty years, 
and this enabled us to thoroughly evaluate the outcome domains that were 
measured, and whether this changed over time. Even though we have 
reviewed RCTs assessing one aspect of the treatment of childhood asthma, 
it is likely that our findings would be similar if we were to conduct a 
similar review of, for example, clinical trials of LTRA or LABA. The 
studies we identified are comparable in terms of the population they 
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include and the interventions that they compare, and so we feel that our 
finding of heterogeneity of outcome selection between studies is valid.  
We have reviewed outcomes that have been reported rather than those 
which were actually measured. ORB in published RCT reports is common  
(Chan, & Altman 2005; Dwan et al 2008), and in order to have evaluated 
exactly which outcomes had been measured it may have been more 
accurate to assess trial protocols. Although ORB may lead to an 
underestimation of the frequency with which some outcomes were actually 
measured, it is unlikely that it would affect heterogeneity between studies. 
We chose to identify RCTs using the Cochrane Database of Controlled 
Trials because this database includes publications that are not held in 
Medline, and everything held within it has been categorised as being a 
controlled trial. In order to search for eligible RCTs even more thoroughly, 
if time constraints were not an issue, we could also have searched Medline. 
The main reason for doing this is that Cochrane databases are updated 
quarterly, whereas Medline is updated weekly  (Glanville et al 2006). It is 
unlikely, however, that many studies were missed by not searching 
Medline.  
 
3.6 Summary 
We have shown that outcomes in RCTs in children with asthma are 
focussed on short-term disease activity, and other domains are largely 
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overlooked. Studies are not uniform with regard to the selection, 
measurement, and reporting of outcomes. This can make it difficult to 
design, interpret, and meta-analyse clinical trials. One solution is a core set 
of outcomes that should be measured and reported, as a minimum, in all 
clinical trials of a specific condition. Core sets were first designed by the 
OMERACT group, which utilises structured consensus techniques, 
including the Delphi technique, amongst a diverse group of stakeholders 
and consumers. Our findings would suggest that a similar initiative in 
childhood asthma, with separate consideration of pre-school and older 
children, would make an important contribution to improving clinical 
research in this very prevalent, chronic disease. In Chapter 2, we showed 
that such a core set had not already been developed.  
In order to develop this core outcome set, it is important to review, in 
detail, other studies which have used structured consensus techniques to 
determine which outcomes to measure in clinical trials. In Chapter 2 we 
identified that the Delphi technique was the most widely used structured 
method for reaching consensus, whereas NGT could only be used amongst 
a smaller panel, and so, by itself, was not used as the only technique for 
developing a core outcome set. A systematic review of studies, which have 
used the Delphi technique to identify which outcomes to measure in 
clinical trials, in adults or children, is described in Chapter 4. 
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C h a p t e r  4  
A systematic review of studies that have used 
the Delphi process as a method for 
determining which outcomes to measure in 
clinical trials 
 
4.1 Background 
The standardisation of outcomes for clinical trials has been proposed as a 
solution to the problems of inappropriate and non-uniform outcome selection  
(Miller et al 2001; Clarke 2007) and reporting bias  (Giannini et al 1997; 
Williamson et al 2005; Kirkham et al 2010). The most notable work relating 
to outcome standardisation has been conducted by the OMERACT 
collaboration, which advocates the use of core outcome sets, designed using 
consensus techniques, which are measured and reported in clinical trials in 
rheumatology  (Tugwell et al 2007). However, such initiatives are 
uncommon. In some specialties, such as paediatrics, the number of conditions 
covered is low and the quality of existing studies variable.  
One method for reaching consensus around which outcomes to measure is the 
Delphi technique, which comprises sequential questionnaires, answered 
anonymously, by a panel of participants, who each have relevant expertise. 
After each questionnaire, the group response is fed back to participants  
(Dalkey, & Helmer 1963). With regard to the overall validity of the final 
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consensus, this approach has advantages over open discussions. Participants 
in a Delphi study do not interact directly with each other, so situations where 
the group is dominated by the views of certain individuals can be avoided. 
When participants consider whether to change their opinion or stick to their 
original answers, after seeing the group response, this decision is not affected 
by the desire to be seen to agree with senior, overly vocal, or domineering 
individuals. Improvements in global communication have made it feasible to 
use the Delphi technique to involve geographically distant participants, in 
larger numbers than are traditionally used in studies employing face-to-face 
discussion, and so it is also increasingly being used to reach consensus 
around other topics in medicine, such as education  (Alahlafi, & Burge 2005), 
clinical guidelines  (Morita et al 2005), and prioritisation of research topics  
(Kellum et al 2008). 
There is little guidance for researchers who wish to use the Delphi technique, 
even though aspects of its methodology can be interpreted in a variety of 
ways. Most published work has provided guidance based on authors’ 
experiences, rather than empirical research or theoretical justification for the 
methodological decisions made. One systematic review describes a variety of 
consensus techniques in the context of designing clinical guidelines  (Murphy 
et al 1998). The authors highlighted important methodological decisions that 
may affect the overall quality of the final consensus, including the types of 
participants involved, the questions they are asked, the information they 
receive to inform their answers, the manner of the interaction between them, 
and the way in which consensus is agreed.  
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To our knowledge, there is no guidance about how to conduct or report 
studies that use the Delphi technique to determine which outcomes or 
domains to measure in clinical trials or systematic reviews. The work 
described in this chapter is a systematic review of studies that have used the 
Delphi technique for this purpose. 
 
4.2 Aims 
1) To identify variations in the methods and reporting of studies that use the 
Delphi technique to determine which outcomes, or domains, to measure in 
clinical trials or systematic reviews.  
2) To discuss recommendations relating to the design and reporting of future 
studies, based on the findings of our review, for people who wish to use the 
Delphi technique for this purpose. 
 
4.3 Methods  
4.3.1 Inclusion and exclusion criteria 
Studies were eligible for inclusion if they used the Delphi technique to 
determine which outcomes or domains to measure in clinical trials or 
systematic reviews. We included both studies in which the final consensus 
was determined using the Delphi technique, and also studies that used the 
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Delphi technique to identify the opinion of a group of participants, but not in 
order to reach a final consensus about which outcomes to measure. This latter 
category includes studies in which the results of the Delphi technique were 
used to inform participants in subsequent meetings to agree which outcomes 
or domains to measure in clinical trials or systematic reviews. 
We felt it was appropriate to combine studies relating to outcomes with those 
relating to outcome domains, because we expected the methods used in both 
these types of studies to be sufficiently similar. 
Studies that did not specifically state that the outcomes selected could be used 
in clinical trials or systematic reviews were excluded. For example, studies 
identifying outcomes to evaluate the quality of care given by healthcare 
providers, or to guide the management of individual patients in clinical 
practice, were not included, unless the authors stated that participants 
considered their use in clinical research.  
 
4.3.2 Identification of studies, and the search strategy 
Medline was searched in January 2010 (from 1950 to January 2010). The 
process of designing a search strategy is described in Section 2.3.3. The 
following search strategy was used in this review:  
“((outcome$ OR endpoint$ OR end point$ OR variable$ OR domain$) AND 
(Delphi OR Delphi method OR Delphi technique$ OR sequential 
questionnaire$)).mp.”. 
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4.3.3 Data extraction 
The following methodological aspects were identified from each study report:  
1. Who was involved in the Delphi process, in terms of the number of 
clinicians, patients and other participants, and their geographical location  
2. The types of questions participants were asked  
3. Whether the study was completely anonymised (participants’ identities and 
answers were hidden from the group) or quasi-anonymised (identities of 
participants were disclosed to the group, but individual answers were not)  
4. Whether non-responders in earlier rounds were included or excluded from 
subsequent rounds 
5. The definition of consensus used by the authors. 
We contacted the corresponding author by email to obtain information that 
was not available or clear in the study report.   
 
4.3.4 Assessment of reporting quality 
We assessed in the study report whether the following methodological 
aspects were described:  
1. The number of participants invited to each round 
2. The types of participants involved, and the number of each type 
96 
 
3. How participants were initially identified as being eligible for the study  
4. The medium used to conduct the Delphi study (eg postal, email, internet) 
5. What information participants received before the first round 
6. How outcomes included in the first round of questions were identified (ie 
were they identified before the study, or did participants suggest outcomes 
that should be considered by the group) 
7. Whether the study was completely anonymised or quasi-anonymised 
8. What questions were asked in each round 
9. What feedback was provided to participants after each round  
10. How the authors determined, for each outcome, whether consensus had 
been reached as to whether it should be measured.  
If any of these were not described to the level of detail that would permit 
another researcher to reproduce the methodology, we classed the reporting of 
the methodological aspect as unclear. We also identified whether the authors 
explained these methodological choices.  
With regard to the reporting of results, we assessed whether the authors had 
described the following: 
1. The number of respondents to each round 
2. The proportion of participants who completed every round  
97 
 
3. The results for each outcome in each round 
4. A measure of group response and distribution for each outcome in the final 
round 
5. A list of all outcomes that the group decided should be measured in clinical 
research studies.    
 
4.3.4 Data analysis and presentation of results  
For synthesis of data the studies were described narratively. Consistent with 
the nature of the data, the results are presented in textual format. 
 
4.4 Results 
4.4.1 Identification of studies 
Of twenty studies for which the full text study report was retrieved, five were 
excluded because they aimed to identify outcomes for use in clinical practice, 
and the authors did not state whether the participants considered their use in 
clinical research studies  (Brunner et al 2008; Jones et al 2000; van Hulst et al 
2009; Weigl et al 2004; Radtke et al 2009). Fifteen studies were included in 
the review. The review flowchart is shown in Figure 4.  
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Figure 4 Flowchart of the review: Identification of studies that used the 
Delphi process to determine which outcomes or domains to measure in 
clinical trials or systematic reviews 
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Eight of the included studies developed core outcome sets for 
rheumatological conditions, of which five were conducted by the OMERACT 
group (relating to gout  (Taylor et al 2008), fibromyalgia  (Mease et al 2008), 
psoriatic arthropathy  (Taylor 2005), and systemic sclerosis  (Khanna et al 
2008), and associated pulmonary hypertension  (Distler et al 2008)) and three 
were conducted by other collaborations (relating to idiopathic inflammatory 
myopathy  (Miller et al 2001), juvenile systemic lupus erythematosis  
(Ruperto et al 2003), and ankylosing spondylitis  (Zochling et al 2008)).  
Others developed core outcome sets for pain in children  (McGrath et al 
2008), degenerative ataxia  (Serrano-Aguilar et al 2009), gastro oesophageal 
reflux disease  (Dent et al 2008), infantile spasms  (Lux, & Osborne 2004), 
maternity care  (Devane et al 2007), multiple sclerosis  (Khan, & Pallant 
2007), and thyroid eye disease  (Douglas et al 2009). The methods and results 
of one study were described across two publications, of which the one that 
describes the study most comprehensively  (Miller et al 2001) is included in 
this review, and the other is referenced as an additional article  (Oddis 2005). 
One study was conducted in two distinct stages, both of which were reported 
in separate publications. The most recent publication describes both stages of 
the study  (Mease et al 2008), and is included in this review, while the earlier 
publication is referenced as an additional article  (Mease et al 2005).     
Eight studies used the Delphi technique as the main method of reaching 
consensus about which outcomes to measure in clinical research studies. Four 
of these related to outcomes in rheumatological conditions (of which three 
were conducted by the OMERACT collaboration  (Distler et al 2008; Khanna 
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et al 2008; Taylor et al 2008) and one by another group  (Zochling et al 
2008)), two related to neurological conditions  (Khan, & Pallant 2007; Lux, 
& Osborne 2004), one related to gastroenterology  (Dent et al 2008) and one 
to maternity care  (Devane et al 2007). The remaining seven studies used the 
results of a Delphi process either to inform people involved in subsequent 
consensus studies  (Miller et al 2001; Douglas et al 2009; McGrath et al 
2008; Mease et al 2008; Ruperto et al 2003; Taylor 2005), or to help design a 
specific systematic review  (Serrano-Aguilar et al 2009).  
 
4.4.2 Reporting quality 
The reporting quality of the studies is summarised in Table 5. 
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Table 5 Summary of the reporting quality of the studies which used the 
Delphi technique to determine which outcomes or domains to measure 
in clinical trials or systematic reviews 
 Studies in which 
clearly reported 
Studies in 
which not 
clearly 
reported 
N/A 
Size and composition of the panel    
Number of participants 15 0 0 
Types of participants (eg clinicians, patients) 15 0 0 
Proportion of each type of participant 15 0 0 
How participants were identified/sampled 14 1 0 
Methodology of the Delphi process    
Administration of questionnaires (eg postal) 15 0 0 
How items were generated for first questionnaire 14 1 0 
What was asked in each round 15 0 0 
Information provided to participants before the 
first round 
6 9 0 
How the overall group response was fed back to 
participants 
8 7 0 
Level of anonymity (total or quasi-anonymity) 4 11 0 
A priori definition of ‘consensus’ about whether 
an outcome should be measured) 
7 1 7 a  
Were non-responders invited to subsequent 
rounds 
10 0 5 b 
Results    
Number of respondents to each round 14 1 0 
Number who completed every round 11 4 0 
Results for each outcome in each round 0 15 0 
  Group response for 
  each outcome (final round) 
8 7 0 
Distribution of response for each outcome in the 
final round 
7 8 0 
List of all outcomes that participants agreed 
should be measured 
8  0 7a 
 
Footnotes to Table 5:  
a: Reaching a final consensus was not the aim of the Delphi process, so a definition 
of consensus was not given 
b : All participants responded to each round so no discussion was made regarding 
non-responders 
102 
 
Reporting of methods 
The types of participants involved, and the size and composition of the group, 
were adequately described in all studies. All but one study described the way 
in which, at the start of the Delphi process, an initial list of outcomes was 
identified, for consideration by the panel. All studies described the questions 
that were asked, during the rounds of the Delphi process, to determine which 
of these should be measured in clinical trials. All studies described, when 
applicable, the pre-determined definition of ‘consensus’ about whether an 
outcome should be measured in clinical trials.  
Important methodological aspects that were generally less well reported were 
the information provided to participants at the start of the Delphi process 
(clearly reported in 6/15 studies), the information that was fed back to 
participants after each round (clearly reported in 8/15 studies), and the level 
of anonymity in the study (clearly reported in 4/15 studies).  
 
Reporting of results 
An assessment of response rate could be made in 14/15 studies, which 
reported, for each round, the number of invited participants who responded. It 
was possible to make an assessment of attrition rates in 11/15 studies, which 
reported the proportion of first round respondents who also completed the 
final round. Of these, six studies reported the proportion of participants who 
completed every round in the Delphi process, from start to finish.  
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Although all studies provided a list of outcomes that participants felt should 
be measured in clinical research studies, only eight reports presented a 
measure of the group opinion for each outcome listed in the final round, and 
seven of these also reported the distribution of scores for each item. No study 
reported the results, in each round, for every outcome that was considered by 
the group.  
 
Explanation for methods adopted in the study report, or discussion of 
the impact of methodological decisions on the final results 
The composition of the groups was discussed in ten studies, but only six 
discussed the implications of the size of their group on the external validity of 
their results. Two studies discussed why they chose to either identify 
outcomes in a certain way at the start of the Delphi process, or to let 
participants determine the initial list of outcomes. Five studies explained the 
methods used to determine which of these initial outcomes should be 
measured in clinical trials. Five studies discussed why they defined consensus 
in a certain way. Two studies discussed the implications of presenting results 
to participants in a certain way. 
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4.4.3 Methodological variation between the studies 
Composition of the group 
The group size varied from 13  (Dent et al 2008) to 222  (Ruperto et al 2003). 
Generally, studies conducted through clinical or research networks involved 
more participants.  
Clinicians were included in all but one study, which only involved patients  
(Serrano-Aguilar et al 2009). Eight studies were conducted through clinical 
trial networks  (Miller et al 2001; Khanna et al 2008; Lux, & Osborne 2004; 
Mease et al 2008; Ruperto et al 2003; Taylor 2005; Taylor et al 2008; 
Zochling et al 2008), four only involved clinicians who had published 
research in the relevant field  (Dent et al 2008; Distler et al 2008; Lux, & 
Osborne 2004; McGrath et al 2008), and three involved both clinicians and 
researchers  (Devane et al 2007; Douglas et al 2009; Khan, & Pallant 2007).   
Four groups involved patients or families  (Devane et al 2007; Serrano-
Aguilar et al 2009; Zochling et al 2008; Mease et al 2005). Some groups 
involved other types of participants, including health service managers  
(Devane et al 2007), pharmaceutical industry employees  (McGrath et al 
2008; Taylor et al 2008), and drug regulatory agency representatives  
(McGrath et al 2008).  
Five studies involved different types of participants, of which four used a 
single panel comprising a mix of the groups  (Devane et al 2007; McGrath et 
al 2008; Taylor et al 2008; Zochling et al 2008). In the other study, relating to 
a core set of outcomes for fibromyalgia, clinicians and patients completed 
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two separate Delphi studies, which were used to inform discussions at a 
subsequent consensus meeting  (Mease et al 2008; Zochling et al 2008).    
The size and composition of the groups is described in Table 6.  
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Table 6 Size and composition of the groups involved in Delphi 
processes to determine which outcomes to measure in clinical trials 
Study Method by 
which 
sample of 
identified 
Response 
to Round 
1 
(number) 
Number 
(%) who 
were health 
care 
providers 
Number 
(%) who 
were 
patients 
Other 
people 
involved 
in the 
study 
Research 
experience 
of the panel 
Number of 
countries 
represented 
(Continents) 
Dent  People 
known to 
facilitator 
13 12 (92) 0 Clinical 
trial 
methodolo-
gist n=1 
(8) 
1 member 
(non-
clinician) 
was ‘an 
expert in 
RCT 
methods’;  
9 (North 
America, 
Europe, Asia, 
Australasia) 
Devane  Health 
professional 
network; 
patient 
groups 
218 147 (68) 24 (11) Health 
service 
managers 
n=14(6); 
epidemiolo
-gists 
n=9(4); 
‘other’ 24 
(11) a 
78/218 
(36%) self- 
identified as 
researcher 
13 (North 
America, 
South 
America, 
Europe, Asia, 
Australasia, 
Africa) 
Distler  Clinical trial 
network 
69 69 (100) 0 0 All had 
published 
clinical 
research 
Unclear 
(North 
America, 
Europe, 
Australasia, 
Asia) 
Douglas  Health 
professional 
network 
84 84 (100) 0  Unclear 14 (North 
America, 
Europe, 
Australasia, 
Asia) 
Khan Local 
professional 
23 23 (100) 0 0 Unclear  1 (Australia) 
Khanna Clinical trial 
network 
62 62 (100) 0 0 All were 
members of 
a clinical 
trial 
network.  
Unclear 
(North 
America, 
South 
America, 
Europe, 
Asia) 
Lux  Published 
researchers 
31 31 (100) 0 0 All 
participants 
had 
presented/ 
published 
clinical 
research 
15 (North 
America, 
South 
America, 
Europe, 
Asia) 
Mease  Clinical trial 
network; 
Local 
patients 
96 23 (24) b 73 (76) 0 All 
clinicians 
were 
members of 
a clinical 
trial 
network.  
1 (North 
America) Nb 
consensus 
meeting at 
OMERACT, 
after the 
clinician 
Delphi, was 
multinational 
McGrath  People 
known to 
facilitator 
26 17 (65) 0 FDA/NIH 
n=5 (19); 
industry 
n=4 (16) 
All doctors 
were 
researchers  
4 (North 
America, 
Europe) 
Miller  Clinical trial 
network 
70 70 (100) 0 0 All were 
investigator
s in a 
clinical trial 
network 
14 (North 
America, 
south 
America, 
Europe, 
Asia) 
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Study Method by 
which 
sample of 
identified 
Response 
to Round 
1 
(number) 
Number 
(%) who 
were health 
care 
providers 
Number 
(%) who 
were 
patients 
Other 
people 
involved 
in the 
study 
Research 
experience 
of the panel 
Number of 
countries 
represented 
(Continents) 
Ruperto  Clinical trial 
network 
222 222 (100) 0 0 All were 
members of 
clinical trial 
networks.  
46 (North 
America, 
South 
America, 
Europe, Asia, 
Australasia, 
Africa) 
Serrano  Identified 
by patient 
groups 
53 0 53 (100) 0 All 
participants 
were 
patients 
1 (Europe) 
Taylor 
2005 
Clinical trial 
network 
32 32 (100) 0 0 Most were 
members of 
a clinical 
trial 
network  
10 (North 
America, 
Europe, 
Australasia, 
Africa) 
Taylor 
2008  
Clinical trial 
network 
33 30 (91) 0 Industry 
n=3 (9) 
Most 
participants 
were 
members of 
OMERACT 
11 (North 
America, 
South 
America, 
Europe, Asia, 
Australasia) 
Zochling  Clinical trial 
network 
55 53 (96) 2 (4) 0 All were 
members of 
a clinical 
trial 
network 
Unclear 
(unclear) 
Footnotes to Table 6: 
a: anaesthetists, social scientists and lactation specialists (numbers of each group unknown) 
b: 23 clinicians completed all 3 rounds. Unclear how many completed first round 
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Anonymity  
In thirteen studies conducted by email, post or internet, seven were conducted 
completely anonymously (participants were not aware who the other 
members of the group were, and individuals’ answers were not shared with 
the group)  (Devane et al 2007; Distler et al 2008; Lux, & Osborne 2004; 
McGrath et al 2008; Ruperto et al 2003; Serrano-Aguilar et al 2009; Taylor et 
al 2008), and in the others complete anonymity is presumed (it is unclear 
whether participants knew the identities of other individuals). In the two 
studies in which the Delphi process was conducted at face-to-face meetings, 
voting was anonymous in one  (Dent et al 2008) but not the other  (Khan, & 
Pallant 2007).  
In nine studies, participants met before  (Miller et al 2001; Taylor et al 2008), 
during  (Dent et al 2008; Khan, & Pallant 2007), after  (Douglas et al 2009; 
McGrath et al 2008; Ruperto et al 2003; Zochling et al 2008), or before and 
after  (Mease et al 2008) the Delphi process.  
The level of anonymity in each study is summarised in Table 7. 
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Table 7 Level of anonymity in the studies, and whether participants 
met at any point 
Study Number 
of 
rounds 
How Delphi 
was conducted 
Did 
participants 
meet 
Did 
participants 
know the 
identity of 
other group 
members? 
Did 
participants 
know the 
answers 
provided by 
other 
individuals in 
the group? 
Level of 
anonymity 
Dent  3 Meeting Yes a Yes No Quasi 
Devane  3 Internet No Unclear Unclear Complete 
Distler  3 Internet No b  No No Complete 
Douglas  3 Email Yes c Unclear No Complete 
Khan  3 Meeting Yes a Yes Yes Not  
Khanna  3 Email No b Unclear Unclear Unclear 
Lux  6 Email No No No Complete 
Mease 2008   Unclear Yes d Unclear No Presumed 
McGrath  2 Email Yes c No No Complete 
Miller  2 Email Yes e Unclear No Presumed 
Ruperto  2 Postal Yes c Unclear Unclear Complete 
Serrano  3 Email No No No Complete 
Taylor 2005  3 Email No Unclear Unclear Unclear 
Taylor 2008  3 Internet Yes e No No Complete 
Zochling  3 Email Yes f Unclear Unclear Unclear 
 
Footnotes to Table 7:  
a: at least part of the Delphi process was conducted at a meeting 
b: steering group met but did not participate in the Delphi process 
c: Results of Delphi process were used to inform participants at a subsequent 
consensus meeting 
d: Delphi was preceded by focus groups which did not constitute part of the 
Delphi process itself 
e: Delphi was preceded by meetings which did not constitute part of the 
Delphi process itself 
f: The results of the Delphi process were presented at a conference, involving 
participants, and the list of core outcomes was refined
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Structure of the Delphi process 
The general format involved identification of potential outcomes, followed 
by determination of those that were felt to be most important or appropriate 
for clinical trials. 
 
Identification of potential outcomes 
In four studies, participants suggested outcomes, at the start of the Delphi 
process, without prompting or guidance from the facilitators  (Douglas et al 
2009; McGrath et al 2008; Ruperto et al 2003; Serrano-Aguilar et al 2009). 
In two studies, participants suggested outcomes within a framework of 
domains, suggested by a steering group  (Khanna et al 2008), or based on 
international recommendations  (Khan, & Pallant 2007). 
In four studies, outcomes were proposed by a steering committee  (Distler 
et al 2008), or by facilitators who, by reviewing the literature, identified 
outcomes used in previous studies  (Lux, & Osborne 2004; Taylor et al 
2008; Zochling et al 2008). In three studies, outcomes measured in clinical 
trials were discussed at international meetings, and a list of potentially 
eligible outcomes for the Delphi surveys were identified  (Miller et al 
2001; Dent et al 2008; Taylor et al 2008). In one study, outcomes were 
identified from both a systematic review of clinical trials and by asking 
participants to suggest two ‘new’ outcomes that were not listed  (Devane et 
al 2007). In another, clinicians considered outcomes suggested by a 
steering group, and patients considered outcomes identified in focus groups 
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(which were conducted amongst patients, prior to the survey)  (Mease et al 
2008).  
 
Determining the importance of potential outcomes 
Participants either scored the importance of each outcome  (Devane et al 
2007; Distler et al 2008; Douglas et al 2009; Khanna et al 2008; Serrano-
Aguilar et al 2009; Taylor et al 2008), voted for or against its measurement 
in clinical trials  (Miller et al 2001; Dent et al 2008; Khan, & Pallant 2007; 
Lux, & Osborne 2004; Zochling et al 2008), distributed a set number of 
points amongst outcomes, according to importance  (Mease et al 2008; 
Taylor 2005), or ranked outcomes in order of importance  (McGrath et al 
2008; Ruperto et al 2003). In two studies, participants were asked to justify 
their answers  (Khan, & Pallant 2007; Lux, & Osborne 2004). 
 
Feedback of the results to participants after each round 
Nine groups fed back either the average score for each outcome  (Devane 
et al 2007; Distler et al 2008; Douglas et al 2009; Mease et al 2008; 
Serrano-Aguilar et al 2009; Taylor 2005; Taylor et al 2008), or the 
percentage of people voting for its inclusion in the core set  (Khan, & 
Pallant 2007). In four studies, facilitators analysed data and presented a 
new list of outcomes, without presenting a measure of group opinion to 
participants Khanna 2008; Lux 2004; Mcgrath 2008; Ruperto 2003). In two 
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studies it was unclear what measure of group response was fed back to 
participants  (Miller et al 2001; Zochling et al 2008).   
 
How consensus was reached about which outcomes to measure  
Eight studies used the Delphi technique as the main method of reaching 
consensus about which outcomes to measure, of which six recommended 
outcomes which received a pre-determined score  (Khanna et al 2008; 
Taylor et al 2008), or a pre-determined proportion of participants felt it 
should be included in a core set  (Dent et al 2008; Khan, & Pallant 2007; 
Lux, & Osborne 2004; Zochling et al 2008). These scores and proportions 
varied between the six studies. In another study  (Devane et al 2007), an 
outcome was included in the core set if its score was higher than the mean 
score of all outcomes and at least 70% of participants scored it 4/5 on a 
Likert-type scale. In one study, a steering group determined the final core 
set of outcomes  (Distler et al 2008).  
Seven studies did not use the Delphi process itself to reach consensus about 
which outcomes to measure. Six of these used the results of the Delphi to 
inform people participating in subsequent consensus studies that aimed to 
design core outcome sets. Two of these studies  (Douglas et al 2009; 
Ruperto et al 2003) used the Delphi process as a way of filtering out 
outcomes felt to be less important, and these were not considered at the 
subsequent consensus meeting. In the other four studies  (Miller et al 2001; 
McGrath et al 2008; Mease et al 2008; Taylor 2005), each outcome 
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considered in the Delphi process was carried forward to the subsequent 
consensus meeting, regardless of its score. The aim of one study was to 
inform the design of a systematic review  (Serrano-Aguilar et al 2009), and 
all the outcomes that were considered are ranked in order of importance, 
but the final decision about whether they should be measured in the review 
is not described.  
The decisions about which of the outcomes that were initially suggested 
should be measured in clinical research studies are summarised in Table 8. 
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Table 8 How consensus was reached about which outcomes to measure in clinical trials 
Study Was Delphi the final method for 
reaching consensus, or was it 
followed by another consensus 
process 
Definition of consensus Initial number of 
outcomes/ domains  
Number of outcomes/ 
 domains recommended 
Dent  Delphi was used to write consensus 
document about RCT design  
Consensus was reached if at least 75% of participants 
agreed with a statement that an outcome should be 
measured 
n/a a n/a a 
Devane  Delphi was final method for reaching 
consensus 
After each round, only outcomes whose mean score was 
higher than the mean score of all outcomes, and at least 
70% of participants scored it 4/5 on a Likert-type scale, 
were carried forward. After the final round, outcomes 
which met this criteria were included in the core set 
263 outcomes 48 outcomes 
Distler  Delphi was final method for reaching 
consensus 
The core set was selected by a steering group, after the 
final round of the Delphi. This was done using cluster 
analysis, in which outcome domains suggested by the 
group as being most important were classed as feasible 
or not  
17 domains 7 domains 
Douglas  Delphi process was followed by a 
meeting at which NGT was used to 
determine the final core set 
After the first and second rounds, outcomes with a 
median score of 3/9 or less on a Likert-type scale were 
removed. After the final round, only outcomes with a 
median score of at least 6/9 on a Likert-type scale were 
considered in a subsequent consensus meeting. At this 
meeting, 80% of participants had to agree for an 
outcome to be included in the core set. 
220 outcomes 40 outcomes 
Khan  Delphi was final method for reaching 
consensus 
After Round 1, outcomes voted for by < 50% of 
participants were removed. After the final round, 
outcomes voted for by > 50% of participants included in 
core set 
144 outcomes 30 outcomes 
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 Was Delphi the final method for 
reaching consensus, or was it 
followed by another consensus 
process 
Definition of consensus Initial number of 
outcomes/ domains  
Number of outcomes/ 
domains recommended 
Khanna  Delphi was final method for reaching 
consensus 
After the first two rounds, a 9 person steering committee 
filtered out outcomes they felt were not appropriate. 
After the second round of the Delphi process, this 
steering committee considered each outcome, and chose 
whether it should still be considered. Outcomes rejected 
by at least 33% of participants were removed. In Round 
3, all participants considered each outcome and scored, 
on a scale of 1-9, whether it should be included in the 
core set (9=should be included). Outcomes with a 
median score of at least 7 were included in the core set 
212 outcomes 31 outcomes 
Lux  Delphi was used to write consensus 
document about trial design 
(including statements about 
outcomes) 
There was no pre-defined level of consensus about 
statements relating to which outcomes should be 
measured. Instead, the participants agreed on the overall 
recommendations at the end of the Delphi process. 
n/a b n/a b 
Mease  Results of Delphi process were used 
to help participants at subsequent 
meetings  decide which outcome 
domains to measure 
There were no pre-defined cut-off scores for domains to 
be considered, at the consensus meeting involving 
clinicians and researchers, for inclusion in the core set. 
The participants at that meeting suggested that outcome 
domains which at least 50% of participants felt to be 
important should be considered ‘key’ domains for 
clinical trials. The top 15 domains considered in the 
separate patient Delphi process were listed  
40 domains presented 
to clinicians. 104 
domains presented to 
patients 
8 ‘key’ domains and 5 
‘important’ domains from 
clinicians. ‘Top 15’ domains 
from patients 
McGrath Results of Delphi process were used 
to help participants at subsequent 
meetings decide which outcomes to 
measure 
There were no pre-defined cut-off scores for domains to 
be considered at the consensus meeting. At this meeting, 
participants agreed on the overall recommendations at 
the end of the Delphi process. 
Unclear for acute 
pain. 6 domains for 
chronic pain 
6 domains for acute pain. 8 
domains for chronic pain 
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 Was Delphi the final method for 
reaching consensus, or was it 
followed by other consensus process 
Definition of consensus Initial number of 
outcomes/ domains  
Number of outcomes/ 
domains recommended 
Miller  Results of Delphi process were used 
to help participants at subsequent 
meetings decide which outcomes to 
measure 
There were no pre-defined cut-off scores for outcomes 
to be considered, at the consensus meeting, for inclusion 
in the core set. At this meeting, if at least 70% of 
participants felt an outcome should be measured in 
clinical research studies, it was included in final core set  
unclear 5 domains, 7 outcomes 
Ruperto  Delphi process was followed by a 
meeting at which NGT was used to 
determine the final core set 
Only outcomes suggested by at least 10 participants in 
Round 1 were carried forward to Round 2. There were 
no pre-defined cut-off scores for outcomes to be 
considered, at the consensus meeting, for inclusion in 
the core set. At this meeting, if at least 70% of 
participants felt an outcome should be measured in 
clinical research studies, it was included in final core set 
Unclear how many 
outcomes initially 
suggested. 41 
outcomes for SLE and 
37 for JDM were 
considered in Round 
2 
SLE: 8 domains, 11 outcomes. 
JDM: 11 domains, 15 outcomes 
Serrano  Delphi was used to rank the 
importance of outcomes 
Outcomes were ranked in order of importance after 
participants scored each from 1-10.    
11 outcomes 11 outcomes 
Taylor 
2005  
Aim of Delphi was not to identify a 
core set of outcomes, but to inform 
future consensus meetings  
There was no pre-defined level of consensus about 
which domains should be measured. The authors did 
split the domains into ‘higher’ and ‘lower’ scoring 
26 domains (spanning 
all situations) 
6 domains for rehabilitation 
trials, 7 domains for trials of  
disease controlling drugs, 5 
domains for trials of disease 
modifying drugs 
Taylor 
2008  
Delphi was final method for reaching 
consensus 
Outcomes were scored out of 7 as follows: 1-3=should 
definitely include in core set, 4=uncertain, 7-9=should 
definitely not include. In Round 2, all outcomes from 
Round 1 were presented again. In Round 3, only 
outcomes for which there was disagreement (ie bimodal 
response) or a median score of 4. After Round 3, 
outcomes with a median score of 1-3, and for which 
there was no disagreement, were included in the core set  
7 domains for acute 
gout, 15 domains for 
chronic gout 
6 domains for acute gout, 10 
domains for chronic gout 
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 Was Delphi the final method for 
reaching consensus, or was it 
followed by another consensus 
process 
Definition of consensus Initial number of 
outcomes/ domains  
Number of outcomes/ 
domains recommended 
Zochling  Delphi was final method for reaching 
consensus d 
In the first two rounds, outcomes were removed if less 
than 80% of participants voted for its inclusion in the 
core set. In the final round, outcomes voted by at least 
50% of participants were included in the core set 
7 domains  7 domains  
Abbreviations used in Table 8: JDM= Juvenile dermatomyositis; NGT= Nominal Group Technique; SLE=systemic lupus erythematosis 
 
 
 
Footnotes to Table 8:  
a: The aim of the study was to provide a list of statements about specific outcomes in trials of certain therapies. For example, “the primary outcome 
measure of a reflux chest pain syndrome trial should be a clinically meaningful reduction of chest pain”.  
b: The aim of the study was not to develop a core outcome set, but mainly to identify the most appropriate primary outcome, and to provide some 
guidance about the measurement and reporting of important secondary outcomes 
c: The primary aim of this study was to develop a list of core domains (called ‘elements’) that should be included in an international registry of 
patients with Ankylosing Spondylitis. 2/7 domains relate to demographic data and biologic-specific data, rather than outcomes of treatment. The 
remaining 5 domains relate to outcomes of treatment (clinical parameters, physical function, disease activity, imaging and Quality of Life)  
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Attrition of participants 
In four studies, no participants who completed the first round subsequently 
dropped out of the study  (Dent et al 2008; Khan, & Pallant 2007; McGrath 
et al 2008; Serrano-Aguilar et al 2009), and in one study the only 
participants who dropped out completed all but the final round of the study  
(Taylor 2005). In the remaining ten studies, some participants dropped out 
of the Delphi process before the final round. In five of these,  (Distler et al 
2008; Lux, & Osborne 2004; Mease et al 2008; Ruperto et al 2003; 
Zochling et al 2008) each participant was invited to every round, even if 
they did not complete previous questionnaires. In three studies  (Devane et 
al 2007; Khanna et al 2008; Taylor et al 2008) participants who did not 
respond to any given round were excluded from the remainder of the study. 
In two studies, additional participants were invited as the Delphi 
progressed  (Miller et al 2001; Douglas et al 2009).  
 
4.5 Discussion 
Across studies using the Delphi technique to identify which outcomes to 
measure in clinical research studies, the methodology differs considerably, 
and the quality of reporting of key aspects is variable. Researchers 
dominate participation in such studies, and patients and families are seldom 
involved. 
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Composition of the groups 
Informed clinical decisions can only be based on the results of trials that 
have measured outcomes of importance to both clinicians and patients. 
Initiatives to identify which outcomes to measure in clinical trials, 
however, focus on the opinions of researchers. This means that outcomes 
included in existing core sets may be selected to serve the needs of 
researchers in academia or industry, rather than according to how important 
they are to patients. 
Outcomes important to clinicians or researchers may differ from those used 
by patients. In one study, in which patients were involved in the design of a 
systematic review, they highlighted certain outcomes as particularly 
important, but these had not been measured in any of the included trials  
(Serrano-Aguilar et al 2009). Research conducted within the OMERACT 
group also suggests that clinicians and researchers may not realise that 
certain outcomes are very important for patients  (Mease et al 2008). The 
perspective of patients is now routinely incorporated into the work 
conducted by OMERACT  (Kirwan et al 2009).    
The opinions of different groups can be analysed either together or 
separately. The use of multiple panels, each comprising a different group  
(Mease et al 2008), acknowledges that there may be differences in opinion. 
If different groups with potentially conflicting views are included in a 
single panel, they may not be equally represented in the final consensus. 
This can happen either because the panel includes more participants from a 
certain group, so the final consensus is numerically dominated by their 
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responses  (Devane et al 2007), or because participants tailor their answers 
to agree with a group which they perceive to be more authoritative  
(Serrano-Aguilar et al 2009).  
In studies that use a single panel, comprising a mixture of participants, 
authors should report a measure of the distribution of scores for each 
outcome considered in the final round. This is because cut-off scores, used 
in most studies, do not describe how strongly the minority feel, and so an 
apparent consensus could actually be masking major disagreement within 
the group  (Goodman 1987). 
   
Avoiding bias introduced by researchers and facilitators  
So that researchers do not impose their views on participants, and thus 
introduce bias into the study, participants are traditionally asked open 
questions in the first round of a Delphi process. In the context of 
identifying which outcomes to measure in clinical research studies, this 
would translate into the practice of participants suggesting potential 
outcomes that they feel should be considered in the Delphi process, and 
would not be prompted or guided by facilitators, steering committees, or 
reviews of the literature. Most studies we identified did not take this 
approach. It is possible that provision of a list of outcomes to participants 
for initial consideration may overstate the importance of outcomes that are 
favourable to the researchers, rather than those which may be of more 
importance to clinicians and patients. It is known that outcomes measured 
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in previous clinical trials do not always reflect those deemed most 
appropriate by all stakeholders  (Gandhi et al 2008; Duncan et al 2000).  
 
Avoiding bias occurring because of participant attrition 
People with minority opinions may be more likely to drop out of studies 
that use the Delphi process, so attrition as rounds progress can lead to 
overestimation of the degree of consensus in the final results. Strategies to 
prevent attrition bias are to only invite people who respond to a pre-Delphi 
invitation to participate in the first round  (Ruperto et al 2003) or to list, in 
the final publication, only those participants who either completed the 
entire Delphi process or agreed the final consensus statement  (Lux, & 
Osborne 2004). 
   
Suggested aspects of the methodology and results that should be 
reported 
When the Delphi technique is used for identifying which outcomes to 
measure in clinical research, authors should describe important 
methodological aspects of the process in the study report. This will help 
enable appraisal of the study, which may affect whether or not the 
recommendations are implemented.  
Criticisms of the Delphi technique are that ‘expertise’ of the panel is 
arbitrarily defined, and the validity of the final consensus is questionable, 
122 
 
because individual participants are not accountable for their responses, and 
they may be led towards conformity with the group, rather than consensus 
of true opinions  (Sackman 1975). It has also been suggested that people 
who drop out of studies that use the Delphi technique are more likely to 
hold opinions which differ from the majority view, and so the degree of 
consensus reached in the final round may be overestimated  (Bardecki 
1984).  
To allow the reader to assess whether the composition of the panel was 
appropriate, authors should report the number and types of participants 
involved in the study, and how they were identified.  
To enable assessment of the Delphi process itself, they should report how 
potential outcomes were identified at the start of the study, and the process 
of determining which of these should be measured in clinical trials. Such 
details must include the types of questions asked, and how authors decided 
whether consensus had been reached amongst the group members.  
To enable assessment of the risk of bias from attrition of participants, 
authors should report whether or not non-responders were invited to 
continue in the study or whether they were excluded. They should also 
report the number of people who dropped out in each round.  
As a minimum, the results should describe the group opinion for each 
outcome that was included in the final round. They should describe a 
measure of the group response (eg average score) and distribution (eg 
interquartile range). 
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Finally, given the variations between studies, it would be helpful if authors 
explained the rationale behind their methodological choices, or discussed 
the effects these may have on the results.      
 
Robustness of this review 
Half of the studies we identified related to rheumatological conditions. 
Similarities in the methods used in these studies may have skewed our 
findings towards those proposed by the OMERACT group. However, we 
did identify differences between the studies, in terms of methodological 
decisions and reporting quality. 
 
Future areas of methodological research 
Given variations in methodology between studies, we feel there is a need 
for research to determine how best to develop core outcome sets. An 
agenda for this research could be designed through the COMET initiative 
(Core Outcome Measures for Effectiveness Trials), which is an 
international network of individuals and organisations with interest or 
experience of the development, application and promotion of core outcome 
sets (http://www.liv.ac.uk/nwhtmr/comet/comet.htm). One such area of 
ongoing research and discussion relates to whether core outcome sets 
designed for clinical practice, such as those developed in the five studies 
we excluded  (Brunner et al 2008; Jones et al 2000; van Hulst et al 2009; 
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Weigl et al 2004; Radtke et al 2009), should be the same as those designed 
for research. Another priority is research to identify the most effective 
ways to incorporate the views of different groups of participants, especially 
patients, in the design of core outcome sets.   
 
4.6 Summary 
Studies which use the Delphi process for the purpose of gaining consensus 
around a core outcome set for clinical trials are conducted to improve the 
quality and usefulness of clinical research, and in order for their 
recommendations to be implemented, they should be of sufficiently high 
quality. Where possible patients and clinicians should be involved in 
developing core outcome sets, and they should be directly asked, initially 
using open questioning techniques, which outcomes are of particular 
importance in routine clinical practice.  
Poor reporting of methodological decisions makes it difficult to appraise 
these studies. Researchers wishing to use the Delphi technique for this 
purpose should be aware of these issues when designing their study, and 
explain methodological decisions, in relation to the study aims, in the main 
publication. 
The need for a core outcome set or childhood asthma was identified and 
discussed in Chapter 3.  One important part of the process of developing 
such a core set is to identify which outcomes are most important and 
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relevant. A study, in which the Delphi process was utilised to identify these 
outcomes, is described in the next chapter. We used this systematic review, 
in which we identified methodological factors that should strengthen the 
validity of the Delphi technique, and others that put the process at risk of 
bias, to help design the study described in Chapter 5.
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C h a p t e r  5  
Identification of the most relevant outcomes 
for evaluating regular therapies for childhood 
asthma 
 
5.1 Background  
In order to inform clinical practice, late phase clinical trials should measure 
outcomes that are important and relevant to patients, clinicians, and 
policymakers. As we identified in Chapter 2, very little work has been 
conducted to identify which outcomes are important and relevant in 
childhood asthma. In one study, 14 clinicians and researchers indicated, by 
questionnaire, which outcomes they felt were most appropriate for a variety 
of clinical, public health and research settings related to asthma  (Smith et al 
1996).  
As shown in the systematic review in Chapter 3, outcomes in RCTs in 
children with asthma are focussed on short-term disease activity, but other 
domains are much less frequently measured. Furthermore, there is 
inconsistency between studies in the way that outcomes are measured and 
reported. For example, exacerbations are defined in several different ways, 
and a variety of scales are used to assess symptoms.  
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We recommended that one solution to these problems would be to agree a 
minimum set of core outcomes that should be measured, and reported, in all 
late phase RCTs in children with asthma. This core outcome set should be 
aligned to the assessments that are used, in clinical consultations, to decide 
whether a treatment regime is satisfactory, or whether it should be modified, 
and should include a few outcomes that are particularly important to patients, 
families, and clinicians.  
 
5.2 Aim 
To identify which outcomes are most important when evaluating regular 
therapies for childhood asthma, from the perspective of the following people: 
clinicians involved in the out-patient management of children with asthma; 
parents of children younger than 18 years, who have asthma; and young 
people with asthma, who are aged between 13 and 18 years. 
 
5.3 Methodological approach 
Identifying the outcomes used when making shared decisions in clinic 
consultations 
In previous attempts to develop core outcomes sets, participants have, 
generally, been asked to consider outcomes that were already measured in 
clinical trials. One problem that may arise from this approach is that some 
128 
 
important outcomes, if they are not routinely measured in clinical trials, may 
be overlooked. Conversely, this approach may perpetuate the inclusion in 
core sets of other outcomes, which may not be so relevant, on the basis that 
they have traditionally been measured in clinical trials.  
Rather than take this approach, we elected not to start this study by presenting 
to the participants the frequency with which outcomes were measured in 
clinical trials. Instead, we focussed on identifying which outcomes are 
important for making shared decisions in clinic consultations. During these 
consultations, clinicians, parents, and some young people themselves, 
develop an overall assessment of whether the current therapy regime is 
satisfactory, or whether it should be modified, and we felt that these 
outcomes should be reflected in clinical trials. To our knowledge, this 
approach, of using the Delphi process to identify outcomes, for clinical trials, 
by asking participants to focus only on how they assess treatments in clinical 
practice, has not been utilised before.    
We also acknowledged that the opinions of young people, parents and 
clinicians may differ, and so we felt that their results should be ascertained 
and analysed separately. This avoids bias occurring when groups with 
conflicting views are analysed together, if one group contains more people, or 
certain groups of participants tailor their answers to agree with the views of 
others whom they perceive to be more authoritative. 
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School-age and pre-school children 
We considered outcomes for pre-school (less than 5 years) and school-aged 
(5 to 18 years) children separately, because we anticipated that differences 
between the two age groups may lead to variation in the relevance of certain 
outcomes. Asthma in these two age groups differs phenotypically  (Bush 
2009), and in terms of the natural history (Kovesi et al 2010), and this may 
lead to different goals of therapies. Other important age-related differences 
may relate to the measurement of outcomes. Physiological tests of lung 
function are rarely measured in pre-school children, because of difficulties 
they may have with performing the procedure. Functional status may also be 
measured in different ways, because when children start attending school, the 
pattern of their normal daily activities changes.  
 
5.4 Participants and methods  
5.4.1 Structure of the study 
This study was conducted, using questionnaires, in two phases (1 and 2). The 
purpose of Phase 1 was to identify a long list of potential outcomes, and 
Phase 2 was designed to identify which of these was most important. 
Participants were asked to consider outcomes for evaluating therapies taken 
regularly, rather than for acute exacerbations.  
To ascertain the views of clinicians, a two-round, web-based, anonymised 
Delphi survey was conducted amongst members of the British Paediatric 
130 
 
Respiratory Society (BPRS), and a network of asthma nurses. The BPRS 
comprises medical and non-medical professionals, within the UK, who care 
for children with respiratory problems. To be eligible for the study, clinicians 
and nurses needed to have ongoing experience of managing children with 
asthma, but they did not require experience of designing or conducting 
clinical trials.  
Parents were invited to complete paper-based surveys in asthma clinics in 
Alder Hey Children’s Hospital (AHCH), a large paediatric hospital in the 
North of England, which takes referrals from primary and secondary care. 
Parents of all children younger than 18 years, who were prescribed regular 
preventer therapy for asthma, and did not have respiratory co-morbidities, 
were eligible. Young people aged 13 to 18, who attended these clinics, were 
also invited, because we anticipated that they might have different goals for 
their asthma treatment. The lower age limit was based on clinical experience 
that teenagers are generally more able to discuss their asthma than younger 
children.  
 
5.4.2 Phase 1 
Phase 1 comprised the first round of the Delphi survey of clinicians, and a 
survey of parents and young people. Open questions were asked, in order to 
identify a long list of outcomes that could be relevant in clinic consultations.  
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Phase 1 clinician questionnaire  
The questionnaire distributed to clinicians in Phase 1, including the initial 
invitation email sent through the BPRS, is included in Appendix 6. To avoid 
introducing researcher bias, by prompting responses based on our own ideas, 
we asked open questions to identify which outcomes clinicians use in clinic 
consultations. We asked the following question once in relation to pre-school 
children, and once for school-aged children:  
“When you see children with asthma in clinic, you make an assessment as to 
whether their treatment is working. Please list up to five beneficial or harmful 
outcomes of treatment that you find clinically most important in school 
aged/pre-school children. These factors should be things that you consider, 
when deciding whether to recommend continuing on current treatment or 
altering a child’s regular asthma therapy regime.” 
 
Phase 1 parent and young peoples’ questionnaires 
The questions on the initial drafts of the parents’ and young peoples’ 
questionnaires were initially devised after discussion amongst IS, PRW and 
RLS. General comments on the layout and wording of the first draft of the 
questionnaire for young people were sought from the MCRN Young Peoples’ 
group, who regularly assess clinical trial information leaflets designed for his 
age group.  
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Four versions of the parent and young people’s questionnaires were piloted 
before the study. This was done in asthma clinics, where parents and young 
people were asked their opinions about the wording of the questions. The 
main comment about terminology was that parents felt that the phrase “are 
you happy with your child’s asthma control” referred to their satisfaction with 
health care professionals and health service provision, so this was amended. 
The Phase 1 questionnaire for parents is included in Appendix 7. Parents of 
pre-school and school-aged children were asked four exploratory questions. 
The first two questions aimed to identify which outcomes were used to assess 
whether a treatment regime was satisfactory or not: 
1) “Over the last twelve months, have you generally felt that the regular 
preventer treatment that your child takes has kept their asthma under control? 
Yes/No. If you ticked YES, please tell us what aspects of your child’s 
asthma, or their daily life, have made you feel happy that they are on the 
correct regular medication. If you ticked NO, please leave this question 
blank.” 
2) “Over the last twelve months, have there been times when you felt that 
your child’s regular preventer treatment should be increased or changed, 
because their asthma was not under control? Yes/No. If you ticked YES, 
please tell us the reasons why you were not satisfied with the regular 
preventer treatment that they were taking? If you ticked NO, please leave this 
space blank”. 
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The other questions aimed to identify other outcomes of potential importance, 
such as long term beneficial and harmful effects of treatment:  
3) “Does anything worry you about the fact that your child has asthma? 
Yes/No. If you ticked YES, please tell us the worries you have about the fact 
your child has asthma. If you ticked NO, please leave this space blank”  
4) “Does anything worry you about the regular preventer treatment that your 
child takes for their asthma? Yes/No. If you ticked YES, please tell us what 
worries you have about the treatment your child takes for their asthma. Please 
be as specific as you can. If you ticked NO, please leave this question blank.” 
 
Analysis of the Phase 1 questionnaires 
IS interpreted each response from clinicians, parents and young people, and 
decided which outcome of treatment was being described. The broad 
framework for classifying responses as outcomes was based on the domains, 
subdomains and outcomes identified in Chapter 3. This comprised the 
following six categories: 
Short-term disease activity: Symptoms; relief inhaler use; exacerbations; lung 
function; overall asthma control 
Physical consequences of disease: death; progression of asthma into later 
childhood or adulthood  
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Functional status: ability to exercise or play sport; activities of daily living; 
school attendance 
QoL/family: overall QoL; emotional well-being; family outcomes  
Adverse effects of therapy: short term adverse effects; long term adverse 
effects 
Health resource utilisation 
 
The reviewers (IS, RG, RLS, PRW) discussed whether each of the responses 
that did not fit into this classification should constitute a ‘new’ outcome. 
To ensure that the views of each group were taken into account, we pre-
specified that outcomes suggested by at least 10% of children and/or parents 
and/or clinicians would be carried forward and listed on the Phase 2 
questionnaire. It was felt that a lower cut-off lower would have meant that too 
many outcomes would be carried forward, placing extra burden on 
participants. Outcomes were also considered for inclusion in the Phase 2 
questionnaire, after discussion amongst reviewers, if they were measured in 
at least 10% of RCTs identified in Chapter 3, even if they had not been 
suggested by at least 10% of participants.  
In order to identify responses that were open to interpretation, and to make 
categorisation of responses more accurate, Reviewer 2 (RG) independently 
analysed the first 36 (72%) questionnaires received from parents and young 
people, and Reviewer 3 (PRW) independently analysed a randomly selected 
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sample of 9/46 (20%) of the questionnaires completed by clinicians. Further 
review was not deemed necessary because interpretation of responses became 
easier as the study progressed. All disagreements were discussed, initially, 
with Reviewer 3 (PRW), and, if agreement was not reached, Reviewer 4 
(RLS). In addition, RLS was shown all responses felt to be atypical or 
difficult to interpret. 
 
Phase 1 participants 
The study flowchart is shown in Figure 5. 
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 Figure 5 Flowchart showing participants in Phases 1 and 2 
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The email invitation was sent to 260 members of the BPRS, and 21 specialist 
asthma nurses. Of these 281 invitees, 46 participated in Stage 1 of the study. 
This group comprised 38 hospital-base paediatricians and 8 nurses. Of the 
doctors, 14/38 stated that they were consultant respiratory paediatricians, 
13/38 were consultant general paediatricians, 3/38 were consultant 
paediatricians with a specialist interest in respiratory paediatrics, 6/38 were 
clinical academics (4 professors and 2 senior lecturers), 1/38 was a clinical 
research fellow and 1/38 was a specialist registrar in a national training post 
in respiratory paediatrics. One nurse was a specialist health visitor, and the 
others were based in hospitals. The institutions at which the participants 
worked encompassed a mixture of district general hospitals and tertiary 
paediatric centres, distributed throughout the United Kingdom.    
Of 44 asthmatic children identified in clinics, three were not eligible. In all 
three cases, this was because the child had concomitant respiratory diagnoses 
(two had immunodeficiencies predisposing to recurrent lower respiratory 
tract infection and one had bronchiolitis obliterans). In total, 52 people (41 
parents and 11 young people) were approached to participate in the study. Of 
the parents, three declined (one mother did not have time, and one 
grandmother and one father did not live with the children they had brought to 
clinic, so did not feel as if they could complete the questionnaire). All 11 
young people who were approached agreed to participate, including the 
young person whose grandmother declined. 
Of the participants, 27/49 (55%) were parents of school-aged children (of 
whom 17 were aged at least five years but not older than 12 years, and 10 
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were older than 12 years but younger than eighteen years), 11/49 (22%) were 
parents of pre-school children (all of whom were older than one year of age, 
but younger than five years), and 11/49 (22%) were young people (ranging 
from 13 to 15 years). The ages of the children ranged from one year to fifteen 
years. 
 
5.4.3 Phase 2  
Only the clinicians who participated in Phase 1 were invited to complete the 
Phase 2 questionnaire. Parents attending asthma clinics at AHCH were 
invited to participate, employing the same eligibility criteria as those used in 
Phase 1. To increase numbers, parents of pre-school children were recruited 
at a local district general hospital, whose paediatric respiratory department 
treats children with asthma with broadly similar characteristics to those seen 
at AHCH. As it was unclear whether young people would be able to answer 
the questionnaire in Phase 2, they were not included. In another attempt to 
increase the size of the sample, the Phase 2 questionnaire was distributed by 
Asthma UK, the largest UK-based asthma charity, to parents of children with 
asthma, who had previously expressed an interest to be involved in clinical 
research.  
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Phase 2 questionnaires 
The questionnaire used in Phase 2 were designed by IS, RLS and PRW, and 
shown to clinicians within the department for their comments. The clinician 
and parent questionnaires are shown in Appendix 8. 
In the clinician questionnaire, outcomes carried forward for school-aged and 
pre-school children were listed separately, and the questions were repeated 
for both age groups. Parents received a questionnaire in which outcomes for 
both age groups were listed, and they were instructed only to score those 
relevant to their own child. 
Participants were asked the following three questions: 
1) “Regular treatments for children can have a variety of beneficial effects, 
each of which could be measured as an outcome in clinical trials. Please score 
how important each of the following outcomes are on a scale of 0-4.” This 
question aimed to identify the relative importance of each outcome. 
2) “You have just scored the outcomes listed below. Please tick the three 
most important”. 
3) “Are there any other outcomes which are not listed that would have made 
it into your top three?” 
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Analysis of the Phase 2 questionnaires 
The scores from clinicians and parents were analysed separately. Scores from 
parents of pre-school children were analysed separately from those of school-
aged children. For each outcome, we calculated the following: 
Median score and IQR; the proportion of participants selecting the outcome 
in the top 3 
The median score was used as an overall measure of whether the outcome 
was important to the group. The main parameter for ranking the outcomes, by 
age-group, was the proportion of participants who selected the outcome in 
their top 3. 
 
Participants in Phase 2 
Of the 46 clinicians who participated in Phase 1, 45 agreed to participate in 
Phase 2. 43/45 (96%) participants who were sent the link to the Phase 2 
questionnaire responded. One of the non-responders was a clinical research 
fellow, and the other was a consultant respiratory paediatrician. The answers 
they provided in Phase 1 were similar to those of the overall group.  
Of a possible 53 parents whose child’s case notes were reviewed, two were 
not eligible. In both cases, this was because the child had concomitant 
respiratory diagnoses (one had immunodeficiency predisposing to lower 
respiratory tract infection, and one had bronchiolitis obliterans). Of the 51 
parents who were invited to participate, nobody declined. One parent, 
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however, took the questionnaire away but did not return it. In total, therefore, 
50 parent questionnaires were analysed. 
Of parents who completed the Phase 2 questionnaire, 27/50 had attended 
clinic with a school-aged child (of whom 18 were aged at least 5 years but 
not older than 12 years, and 9 were aged at least 12 years but not older than 
18 years), and 23/50 attended with a pre-school child (of whom 2 were 
younger than one year and 21 were at least one year but not older than five 
years). Eight of these were recruited at APH.  The children ranged from less 
than one to 16 years of age.  
In spite of several reminders, we received only 13/118 (11%) responses from 
Asthma UK. For this reason, these data have not been included in our 
analyses. They are, however, summarised in Appendix 9. 
 
5.4.4 Ethical considerations 
Details of the study were emailed to the National Research Ethics Service 
(NRES), who categorised it as “service evaluation and development”, which 
did not require ethical review by an NHS Research Ethics Committee. A 
copy of this correspondence is included in Appendix 10. The main ethical 
considerations are described below. 
The study was conducted according to the General Medical Council’s 
guidance about consent  (GMC 2008). Young people, parents and clinicians 
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were clearly told that, although it would be helpful if they participated in the 
study, they were not obliged to.  
 
Data protection for clinicians 
Clinician questionnaires were handled according to the eight principles 
described in the Data Protection Act (1998) 
(http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_9#sch1-pt1 – 
accessed 20th June 2010).  
Clinicians were told that their participation would be acknowledged in the 
final study report. Their email addresses were held securely and not 
distributed to any third party. Of several online survey websites evaluated 
before Phase 2, Survey Gizmo appeared to be one of the most established and 
reputable (http://www.surveygizmo.com/ - accessed 16th November 2009). A 
password is required to retrieve the information provided by participants. 
Furthermore, the administrators do not ‘harvest’ email addresses, or access 
data provided by participants.  
 
Confidentiality for patients and parents 
We did not ask for any details by which patients could be identified. 
Completed questionnaires were placed in an opaque box in the out-patient 
department. In order to avoid discussing the child’s diagnosis of asthma in 
the waiting room, patients were approached discretely.  
143 
 
5.5 Results 
5.5.1 Outcomes suggested in Phase 1 
Clinicians suggested 21 separate outcomes for pre-school children, and 21 for 
school-aged children. Parents of pre-school children suggested 15 outcomes, 
parents of school-aged children suggested 19, and young people suggested 
13. Outcomes for pre-school and school-aged children were broadly similar. 
In total, participants suggested 29 different outcomes, of which symptoms, 
effects of asthma on the ability to exercise and function as the child would 
like, and adverse effects of therapy, were the most frequently suggested. The 
frequency with which outcomes were suggested, and the domains into which 
they were categorised, are shown for clinicians considering pre-school 
children and school-aged children, parents of pre-school children, parents of 
school-aged children, and young people, in Tables 9, 10, 11, 12 and 13 
respectively. 
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Table 9 Outcomes suggested in Phase 1 by clinicians, for pre-school 
children 
Domain Outcome Number (%) of 
clinicians 
suggesting the 
outcome (n=46) 
Disease Activity Daytime symptoms 43 (93) 
 Nocturnal symptoms 28 (61) 
 Symptoms affecting physical activity 17 (37) 
 Need for bronchodilator 23 (50) 
 Exacerbations 29 (63) 
 Patient/parent overall view  4 (8) 
 Ability to feed 2 (4) 
 Wheezing in response to allergens 3  (7) 
 Normal chest examination 3 (7) 
Disease Damage Death 1 (2) 
Functional 
status 
Activities of daily living 9 (20) 
 School/nursery 5 (11) 
Quality of 
Life/family 
Overall Quality of Life  4 (9) 
 Family outcomes 8 (17) 
Adverse effects 
of therapy 
Short term adverse effects 10 (22) 
 Growth 8  (17) 
 Other long term adverse effects 1 (2) 
Health resource 
utilisation 
Unscheduled visit 9 (18) 
 Hospital admission 20 (45) 
 Admission to intensive care unit 1 (2) 
Other Developmental milestones 1 (2) 
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Table 10 Outcomes suggested in Phase 1 by clinicians for school-aged 
children 
Domain Outcome Number (%) of 
clinicians 
suggesting the 
outcome (n=46) 
Disease Activity Daytime symptoms 43 (92) 
 Nocturnal symptoms 30 (63) 
 Symptoms affecting physical 
activity 
29 (63) 
 Need for bronchodilator 27 (58) 
 Exacerbations 31 (67) 
 Patient/parent overall view 4 (8) 
 Lung function  14 (30) 
 Inflammatory markers a 2 (4) 
 Normal chest exam 2 (4) 
 Change in FEV1 in response to 
Salbutamol 
2 (4) 
Disease Damage --No outcomes suggested--  
Functional status Activities of daily living 14 (30) 
 School attendance 27  (59) 
Quality of 
Life/family 
Overall Quality of Life 7 (15) 
 Family outcomes 1 (2) 
Adverse effects of 
therapy 
Short term adverse effects 6 (13) 
 Growth 11 (24) 
 Other long term adverse effects 15 (30) 
Health resource 
utilisation 
Unscheduled visit 7 (15) 
 Hospital admission 13 (28) 
Other Achieving parent/ patient-defined 
goal 
1  (2) 
 
Footnotes:  
a: both clinicians suggested Exhaled Nitric Oxide (ENO) 
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Table 11 Frequency with which outcomes were suggested by parents of 
pre-school children (n=11) 
 
Domain Outcome Number (%) 
of parents of 
preschool 
children 
suggesting 
outcome 
(n=11) 
Disease activity Daytime symptoms 8 (73) 
 Nocturnal symptoms 1 (9) 
 Symptoms affecting  activity (eg 
exercise) 
3 (27) 
 Need for reliever medication (eg 
bronchodilator) 
2 (18) 
 Exacerbations 4 (36) 
 Patient/parent overall view on asthma 
control 
1 (9) 
 Ability to feed 1 (9) 
Disease damage --No responses categorised into this 
domain-- 
 
Functional status ADL 2 (18) 
 DOMAIN:   
Quality of 
life/family 
Overall QoL 1 (9) 
 Emotional well being 1 (9) 
Adverse effects of 
therapy 
Short term AE 5 (45) 
 Growth 1 (9) 
 Other long term AE 4 (36) 
 Dependence 1 (9) 
Health resource 
utilisation 
--No responses categorised into this 
domain-- 
 
Other Health-related problems when child 
is older 
2 (18) 
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Table 12 Frequency with which outcomes were suggested by parents of 
school-aged children (n=27) 
Domain Outcome Number (%) 
of parents of 
school-age 
children 
suggesting 
outcome 
(n=27) 
Disease activity Daytime symptoms 9 (33) 
 Nocturnal symptoms 20 (74) 
 Symptoms affecting 
physical activity 
11 (41) 
 Need for reliever medication 
(eg bronchodilator) 
3 (11) 
 Exacerbations 13 (48) 
 Patient/parent overall view  5 (19) 
 Ability to feed 1 (4) 
Disease damage Death 3 (11) 
Functional status Activities of daily living 13 (48) 
 School/nursery attendance 2 (7) 
Quality of life/family Overall Quality of Life 4 (15) 
 Emotional well being 1 (4) 
Adverse effects of therapy Short term adverse effects 16 (60) 
 Growth 2 (7) 
 Other long term adverse 
effects 
14 (52) 
 Development of dependence 
on medication 
2 (7) 
Health resource utilisation A+E/GP visit 2 (7) 
 Hospital admission 2 (7) 
Other Health-related problems 
when child is older 
5 (19) 
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Table 13 Frequency with which outcomes were suggested by young 
people (n=11) 
Domain Outcome Number (%) 
of parents of 
young people 
suggesting 
outcome 
(n=11) 
Disease activity Daytime symptoms 5 (45) 
 Nocturnal symptoms 2 (18) 
 Symptoms affecting physical activity 4 (36) 
 Exacerbations 1 (9) 
Disease damage Death 1 (9) 
Functional 
status 
Activities of daily living 3 (27) 
Quality of 
life/family 
Overall quality of life 1 (9) 
 Emotional well being 1 (9) 
Adverse effects 
of therapy 
Short term adverse effects 2 (18) 
 Growth 1 (9) 
 Other long term adverse effects 3 (27) 
Health resource 
utilisation 
Hospital admission 1 (9) 
Other Health-related problems when child is 
older 
1 (9) 
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5.5.2 Agreement between reviewers assessing the Phase 1 
questionnaires 
Interpretation of answers from parents and young people: independent 
analysis by IS and reviewer 2 (RG) 
Reviewer 2 was shown a sample of 36 completed questionnaires, from 27 
parents and 9 young people. Reviewer 1 felt that, from the responses in these 
36 questionnaires, participants had suggested a total of 124 items that could 
be interpreted as representing an outcome, and Reviewer 2 felt they had 
suggested 102. Of the 124 items that Reviewer 1 had extracted, Reviewer 2 
agreed with 100 (81%). In total, there were 26 disagreements, of which 24/26 
occurred when Reviewer 1 had categorised a response as an outcome but 
Reviewer 2 had not, and 2/26 had occurred when Reviewer 2 had categorised 
a response as an outcome but reviewer 1 had not.  
 
Interpretation of answers from clinicians: independent analysis by IS 
and reviewer 3 (PRW) 
Reviewer 3, who was not aware of IS’s interpretation of the individual 
questionnaires, was shown a randomly selected sample of 9/46 clinician 
questionnaires (20%), and found complete agreement with this evaluation. 
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Arbitration of the disagreements between IS and Reviewer 2: Discussion 
with Reviewers 3 (PRW) and 4(RLS) 
Reviewer 3 assessed all 26 of these disagreements. With regard to 20/26 
(77%), she agreed with IS. On the 6/26 occasions (23%) that she agreed with 
Reviewer 2, IS had classified a response as an outcome but Reviewer 2 did 
not. IS discussed each of these six responses with Reviewer 3.  
After discussion about one response, IS agreed with Reviewer 3. This related 
to a parent’s description that their child “saw [the] asthma nurse who 
confirmed that his results through breathing tests are much better”. IS initially 
thought this meant that the parents felt lung function was an important 
outcome. After discussion with Reviewer 3, IS agreed that the parents were 
simply reporting what the nurse did, rather than saying lung function is an 
important outcome.  
The other five disagreements were arbitrated by Reviewer 4, who agreed with 
IS’s assessment about four of these. IS had thought the outcome “overall 
asthma control” was most appropriate for the following responses from 
parents: “[she] has her asthma well controlled through the medication she 
takes”; “we do not feel it controls [his] asthma”; “her asthma is more under 
control”; “well controlled”. Reviewer 3 had suggested that the comments 
were not detailed enough to interpret in this way. Reviewer 4 suggested IS’s 
classification was appropriate, because “overall asthma control” is a concept 
that parents often discuss in out-patient consultations.  
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One disagreement related to whether outcomes relating to exercise should be 
categorised in the functional status domain (ie ability to exercise) or the 
disease activity domain (ie exercise-related symptoms). After discussion with 
Reviewer 4, IS agreed that this outcome is more appropriately placed in the 
disease activity domain.  
 
Discussion of atypical comments between IS and Reviewer 4 (RLS) 
Reviewer 4 was asked to check 18 responses, which IS felt may be open to 
interpretation. IS and Reviewer 2 had agreed on the classification of these 
responses. Reviewer 4 deemed the classification to be correct on 16/18 
occasions. After discussion, IS agreed with Reviewer 4 that the classification 
should be changed for the other two responses.  
For one of these, Reviewer 2 and IS had interpreted the response “the way 
my child can be normal and then fighting for breath” as relating to an 
exacerbation of asthma, but Reviewer 4 suggested this was just a description 
of acute shortness of breath, a frequent interval symptom which does not, in 
itself, constitute an exacerbation. For the other, Reviewer 2 and IS had 
classified “staying on medication for a long period” as representing a worry 
about having asthma later in life. Reviewer 4 disagreed with this 
classification, and suggested that this is more likely to represent a concern 
about long-term complications of asthma therapy. 
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Interpretation of responses which did not fit exactly into the initial 
outcomes framework: discussion amongst IS, Reviewer 3 and Reviewer 4 
Symptoms 
Symptoms were described in a variety of ways. Some parents responses 
described cough, wheeze, and shortness of breath. These were all classified as 
“symptoms”, rather than listing them separately on the Phase 2 questionnaire. 
Where parents specified that these were nocturnal problems, they were 
classed as such. Therefore, symptoms were classed as either nocturnal or 
daytime. Some parents discussed symptoms as part of a response to upper 
respiratory tract infections. It was felt that these could represent exacerbations 
of asthma, and were classed as such.  
 
Risk of problems in the future 
Responses relating to long-term respiratory or overall health, and future 
impact of asthma on children’s lives, were felt to be related. It was difficult to 
determine whether participants were referring to future risk of asthma, other 
respiratory illness, general health problems, or problems with functional 
status. It was also difficult to discern whether ‘future risk’ referred to later 
childhood or adulthood, so we felt it would be inappropriate to divide these 
into separate outcomes based on our interpretation of responses. These were, 
therefore, combined into the outcome ‘health related problems when older’. 
This outcome was not classed into any of the pre-defined domains, as it was 
felt to span several of them, but rather in a separate ‘other’ category.  
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Adverse effects of medication 
Adverse effects of medications were grouped together into three outcomes, 
namely short-term problems, growth, and other long-term problems. Short-
term problems included non-systemic adverse effects, and other comments 
about side-effects, unless they were specified by participants as relating to 
growth or other long-term problems. Long-term problems included systemic 
side effects, and responses from participants that described a future risk from 
medications because of long-term use.  
 
Quality of life 
Certain responses from parents were interpreted as referring to overall quality 
of life, because they either alluded to parents describing a child’s overall well 
being, or discussed a combination of functional and emotional problems from 
having asthma. IS and Reviewer 2 had complete agreement that these should 
be categorised as quality of life. Reviewer 4 had seen all these responses, and 
also agreed that they described overall quality of life. These responses are 
shown below: 
(1) “[She] is able to live her day-to-day life (school and home) as a normal 
child”;  
(2) “I worry that as she gets older her asthma gets worse and will prevent her 
from leading a normal life”;  
(3) “His general day-to-day quality of life”;  
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(4) “Difficulties in controlling symptoms, problematic breathing having 
impact on aspects of daily living, sports, socialising with friends and sleep. I 
am concerned my son has had anxiety due to worrying about asthma”  
(5) “I feel happy because I can do more”;  
(6) “Not as tired during the day and not as bad tempered. Eating habits have 
greatly improved – generally more engaged in life” 
 
Responses that were not classed as outcomes 
Some suggestions were not categorised as outcomes of treatment, because 
they did not relate to whether a treatment works, or does more good than 
harm.  
Four clinicians and one set of parents suggested that the ease which parents 
can administer the asthma therapy, and whether they have the correct 
technique for using inhalers, are important outcomes. We felt that, although 
these may affect the decision about whether to change a treatment modality, 
they do not reflect the efficacy or safety of therapy.  
Five clinicians suggested compliance with treatment to be an important 
outcome. We felt this not to be an outcome of treatment, as a variety of 
factors determine whether parents and young people comply with a therapy 
regime, not just whether it is felt to be efficacious and safe. 
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One young person said she was worried about whether, in the future, her 
children will be at risk of having asthma. We did not consider this to be an 
outcome associated with asthma treatments. 
One clinician suggested that, in clinic appointments with pre-school children, 
it is important to use licensed medications.  
 
Final list of outcomes included in the questionnaire in Phase 2  
The final list of outcomes carried forward to Phase 2, and those which were 
not, is shown in Table 14.  
156 
 
Table 14 Whether outcomes were carried forward to Phase 2: determined by the frequencies with which outcomes were suggested by 
participants at the end of Phase 1, and with which they were measured in RCTs of inhaled corticosteroids for children with asthma. 
Outcome Clinicians 
School age 
children 
(n=46) 
Clinicians  
Pre school 
children 
(n=46) 
Parents of 
school age 
children 
(n=27) 
Young 
people 
(n=11) 
Parents of 
preschool 
children 
(n=11) 
RCTs 
including 
school age 
children 
(n=95)  
RCTs 
including 
pre-school 
children 
(n=47) 
Is outcome 
carried 
forward for 
school age 
children 
Is outcome 
carried 
forward for 
pre-school 
age 
children 
Notes 
DISEASE ACTIVITY           
Daytime symptoms 43 (92) 43 (93) 9 (33) 5 (45) 8 (73) Yes Yes 
Nocturnal symptoms 30 (63) 28 (61) 20 (74) 2 (18) 1 (9) Yes Yes 
Symptoms affecting 
activity (eg exercise) 
29 (63) 17 (37) 11 (41) 4 (36) 3 (27) 
84 (88) 43 (91) 
Yes Yes 
84/95 and 43/47 RCTs measured 
symptoms. Daytime, nocturnal and 
exercise-induced symptoms were included 
in these scores. Because of the frequency 
with which this outcome was measured in 
RCTs in pre-school children, it was 
carried forward to the Phase 2 
questionnaire for pre-school parents 
Need for bronchodilator 27 (58) 23 (50) 3 (11) 0 2 (18) 71 (75) 39 (83) Yes Yes  
Exacerbations 31 (67) 29 (63) 13 (48) 1 (9) 4 (36) 31 (33) 17 (36) Yes Yes This outcome includes suggestions by 
clinicians, that exacerbations, specifically 
in response to URTIs, are an important 
outcome 
Patient/parent overall view 
on asthma control 
3 (6) 3 (6) 5 (19) 0 1 (9) 9 (9) 6 (13) Yes Yes Although parents did not specifically 
describe this outcome, 5 parents did 
describe terms relating to overall asthma 
control 
Lung function  14 (30) 0 1 (4) 0 0 89 (94) 36 (77) Yes  No Not carried forward for pre-school 
children because it was suggested by no 
parents or clinicians 
Bronchoconstriction 
induced by challenge  
0 0 0 0 0 28 (30) 1 (2) No No Not carried forward for school-age 
children because it was suggested by no 
parents or clinicians 
Inflammatory markers 2 (4) 0 0 0 0 16 (17) 3 (6) No No Not carried forward (said by 2/46 
clinicians; no parents) 
Ability to feed 0 2 (4) 1 (4) 0 1 (9) * * No No *May have been measured as part of 
symptom score in RCTs, but not as an 
outcome in itself 
Occurrence of wheeze in 
response to allergens 
0 3  (7) 0 0 0 * * No No *May have been measured as part of 
symptom score in RCTs, but not as an 
outcome in itself 
Normal chest exam 2 (4) 3 (7) 0 0 0 0 0 No No  
Change in FEV1 in 
response to B2+ 
 
 
2 (4) 3 (7) 0 0 0 0 0 No No  
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Outcome Clinicians 
School age 
children 
(n=46) 
Clinicians  
Pre school 
children 
(n=46) 
Parents of 
school age 
children 
(n=27) 
Young 
people 
(n=11) 
Parents of 
preschool 
children 
(n=11) 
RCTs 
including 
school age 
children 
RCTs 
including 
pre-school 
children  
Included 
for school 
age 
children 
Included 
for pre-
school age 
children 
Notes 
DISEASE DAMAGE           
Death 0 1 (2) 3 (11) 1 (9) 0 * * Yes Yes *Measured implicitly but not reported 
Lung growth 0 0 0 0 0 1 (1) 0 No No  
Development milestones 1 (2) 0 0 0 0 0 0 No No  
FUNCTIONAL STATUS           
ADL 14 (30) 9 (20) 13 (48) 3 (27) 2 (18) 6 (6) 5 (10) Yes Yes  
School/nursery 27  (59) 5 (11) 2 (7) 0 0 13 (14) 4 (4) Yes Yes  
QoL/ FAMILY 
OUTCOMES 
          
Overall QoL 7 (15) 4 (9) 4 (15) 1 (9) 1 (9) 7 (7) 5 (11) Yes Yes  
Emotional well being 0 0 1 (4) 1 (9) 1 (9) * * No No Incorporated in QoL scores, but not 
measured as an outcome itself 
Family outcomes 
 
1 (2) 8 (17) 0 0 0 7 (7) 10 (21) No Yes 
 
 
 
ADVERSE EFFECTS OF 
THERAPY 
          
Short term AE 6 (13) 10 (22) 16 (60) 2 (18) 5 (45) 78 (82)*  43 (96) * Yes Yes * Did not distinguish between short and 
long term AEs 
Growth 11 (24) 8  (17) 2 (7) 1 (9) 1 (9) 30 (32) 16 (34) Yes Yes  
Other long term AE 15 (30) 1 (2) 14 (52) 3 (27) 4 (36) * * Yes Yes * Did not distinguish between short and 
long term AEs 
Dependence 0 0 2 (7) 0 1 (9) 0 0 No No  
HEALTH RESOURCE 
UTILISATION 
          
A+E/GP visit 7 (15) 9 (18) 2 (7) 0 0 8 (8) 7 (15) Yes Yes * Either included in exacerbations or 
unscheduled HRU 
Hospital admission 13 (28) 20 (45) 2 (7) 1 (9) 0 * * Yes Yes * Either included in exacerbations or 
unscheduled HRU 
OTHER            
Health-related problems 
when child is older 
0 0 7 (26) 1 (9) 2 (18) 0 0 Yes Yes Includes disease damage (ie progression of 
respiratory illness into older childhood or 
adulthood) and long term functional status 
(eg career, lifestyle when older) 
Achieving parent/ patient-
defined goal 
1  (2) 0 0 0 0 0 0 No No  
*: Issues relating to the reporting of outcomes in RCTs are described in the column entitled ‘notes’  
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Abbreviations: ADL=Activities of Daily Living; AE=Adverse effect; A+E=Accident and Emergency; B2+= Beta agonist; FEV1= Forced 
Expiratory volume in 1 second; ICS= Inhaled corticosteroids; PEFR=Peak Expiratory Flow Rate; QoL=Quality of life; URTI=upper respiratory 
tract infection
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5.5.3 Phase 2: Ranking of outcomes in Phase 2 
 
Almost all outcomes received a median score of 4 from either parents or 
clinicians. Generally, clinicians and parents agreed on which outcomes 
were important. Both groups rated symptoms, exacerbations, QoL, and 
mortality as the most important outcomes, for both age groups. Parents 
rated health-related problems when their child is older as a more important 
outcome than clinicians did.  
The results for each outcome listed in the Phase 2 questionnaire, for pre-
school children, are shown in Table 15, and for school-aged children, are 
shown in Table 16. 
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Table 15 Preschool children: the importance of each outcome listed 
in the Phase 2 questionnaire, as scored by clinicians and parents.  
 Clinicians (n=43) Parents (n=23)  
Outcome Clinician 
Rank  
Median 
(IQR) 
Number (%) 
scoring outcome 
in Top 3  
Parent 
rank  
Median 
(IQR) 
Number (%) 
scoring outcome 
in Top 3  
Nocturnal 
symptoms 
1 4 (3,4) 19 (44) 1= 4 (4,4) 10 (43)  
Exacerbations 2 4 (3,4) 15 (35) 3 4 (4,4) 7 (30)  
Quality of Life 3 3 (3,4) 13 (30) 4 4 (3,4) 5 (22)  
Daytime symptoms 4 4 (3,4) 11 (26) 10 4 (3,4) 3 (13) 
Death 5 4 (2,4) 10 (23) 1= 4 (4,4) 10 (43)  
Hospital admission 6 4 (3,4) 9 (21) 7 4 (4,4) 4 (17) 
Parent/child global 
assessment of 
control 
7 4 (3,4) 9 (21) 11 4 (3,4) 3 (13) 
Impact of asthma on 
the family 
8 4 (3,4) 8 (19) 16 4 (3,4) 1 (4) 
Use of reliever  9 3 (3,4) 8 (19) 8 4 (3,4) 4 (17) 
Normal activities 10 4 (3,4) 5 (12) 14 4 (3,4) 2 (9) 
Long term AE 11 4 (3,4) 7 (16) 13 4 (4,4) 2 (9) 
School attendance 12 3 (3,4) 5 (12) 6 4 (3,4) 5 (22)  
Activity or exercise 13 3 (3,4) 4 (9) 12 3 (2,4) 3 (13) 
GP/A+E attendance 14 4 (3,4) 4 (9) 15 4 (3,4) 2 (9) 
Growth 15 3 (3,4) 3 (7) 9 4 (3,4) 3 (13) 
Health related 
problems when 
older 
16 3 (2,4) 0 5 4 (4,4) 5 (22)  
Short term AE 17 3 (2,3) 0 17 3 (3,4) 0 
 
Footnote: Young people were not involved in Phase 2 
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Table 16 School-age children: The importance of each outcome listed 
in the Phase 2 questionnaire, as scored by clinicians and parents.  
 Clinicians (n=43) Parents (n=27) 
Outcome Rank 
(n/17) 
Median 
(IQR) 
Number (%) 
scoring 
outcome in 
Top 3 
Rank Median 
(IQR) 
Number (%) 
scoring 
outcome in 
Top 3 
Quality of Life 1 4 (3,4) 20 (47) 2 4 (4,4) 9 (33)  
Exacerbations 2 4 (4,4) 18 (42) 3 4 (4,4) 9 (33)  
Nocturnal 
symptoms 
3 4 (4,4) 16 (37) 4 4 (4,4) 8 (30)  
Normal activities 4 4 (4,4) 12 (28) 8= 4 (4,4) 4 (15)  
Daytime symptoms 5 4 (4,4) 11 (26) 6 4 (4,4) 6 (22)  
Death 6 4 (2,4) 11 (26) 1 4 (4,4) 14 (52)  
Use of reliever 
inhaler 
7 4 (3,4) 9 (21) 10 4 (3,4) 3 (11) 
Hospital admission 8 4 (3,4) 8 (19) 12 4 (4,4) 2 (7) 
Activity or exercise 9 4 (3,4) 7 (16) 5 4 (3,4) 7 (26)  
Long term adverse 
effect 
10 4 (4,4) 7 (16) 8= 4 (4,4) 4 (15) 
School attendance 11 4 (3,4) 7 (16) 11 4 (4,4) 2 (7) 
Parent/child global 
assessment of 
control 
12 4 (3,4) 7 (16) 14 4 (3,4) 2 (7) 
Lung function tests 13 3 (2,3) 5 (12) 15 4 (3,4) 1 (4) 
GP/A+E attendance 14 4 (3,4) 3 (7) 16 4 (3,4) 0 
Growth 15 4 (3,4) 2 (5) 13 4 (3,4) 2 (7) 
Health related 
problems when 
older 
16 3 (2,4) 0 7 4 (4,4) 5 (19) 
Short term adverse 
effect 
17 3 (2,3) 0 17 4 (3,4) 0 
 
Footnote: Young people were not involved in Phase 2 
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5.6 Discussion 
5.6.1 Main findings 
We found that the most important outcomes in childhood asthma are 
symptoms, exacerbations, quality of life, and mortality. We identified these 
by asking clinicians, parents, and young people, how they evaluate benefits 
and harms of therapies when making shared decisions in clinic 
consultations. This differs from the usual approach, when developing core 
outcome sets, of focussing on outcomes measured in clinical trials. 
The frequency and severity of symptoms and exacerbations are universally 
accepted factors for deciding whether a patient’s asthma is well controlled  
(Kroegel, & Wirtz 2009), and it is not surprising that we found them to be 
very important to parents and clinicians, when evaluating beneficial effects 
of interventions. These clinical measures of disease activity appear more 
important, when making clinical decisions, than physiological measures of 
lung function. Although lung function is frequently assessed in clinical 
trials, because it is an objective evaluation of efficacy, we found that 
parents and clinicians are guided far more by clinical measures of asthma 
control, which reflect effectiveness of therapy. 
The effects of interventions on the ability to perform normal activities, play 
sport and not miss school were considered very important outcomes, as 
was overall quality of life. Unless an intervention improves these aspects of 
a child’s life, it is likely to be regarded, by parents and clinicians, as 
unhelpful. Studies which have examined the correlation between clinical 
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markers of asthma severity and quality of life have shown that an overall 
assessment of well-being “cannot be imputed from clinical outcomes, and 
that it must be measured and interpreted independently”  (Juniper et al 
2004), because clinical markers of disease do not help evaluate 
psychosocial and functional effects of having asthma, which are important 
determinants of a child’s overall QoL  (Reichenberg, & Broberg 2000; 
Mattsson 1972; Collins et al 2008; van den Bemt et al 2010). Outcomes 
reflecting QoL are rarely assessed in clinical trials, but we would 
recommend that they should be measured, either individually, or as part of 
a validated composite outcome.  
We found that parents place more emphasis on long-term beneficial effects 
of therapy than clinicians do. Previous qualitative research has identified 
that many parents of children with asthma worry about long-term effects 
on health (Schulz et al 1994), and long-term cohort studies show that 
asthma often persists into later childhood and adulthood  (Morgan et al 
2005; Oswald et al 1994). Long-term harmful effects of therapies were 
important to clinicians and parents in our study. These have also previously 
been shown to be a major concern for parents and children (Townsend et al 
1991), and have been identified as a research priority in asthma (James 
Lind Alliance, 2007). We feel that, despite difficulties of measuring long-
term effects of therapies, they should be regarded as important outcomes in 
clinical trials in children with asthma. Further work should be conducted to 
identify the most appropriate ways to measure and report these outcomes.  
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Another complication of asthma, which we found to be of particular 
importance for parents, was mortality. Around half of the parents who 
participated in Phase 2 selected ‘prevention of death’ as one of their top 3 
outcomes, compared with a quarter of clinicians. One reason for this 
discrepancy may be that some clinicians think that because mortality from 
childhood asthma is rare, it is not particularly relevant when considering 
beneficial effects of therapies. We recommend, however, that death should 
be measured, as a secondary outcome, in both treatment and control groups 
in clinical trials in children with asthma. 
 
5.6.2 Comparison with the ATS/ERS outcomes taskforce 
A recent collaboration, led by the ATS and ERS, suggested standardized 
definitions of asthma control, severity and exacerbations, and 
recommended outcomes that could be used to measure these in clinical 
trials in asthma  (Reddel et al 2009). The study was mainly focused on 
outcomes for trials in adolescents and adults, but the authors suggest that 
their outcomes are relevant for children older than six years of age, with 
some special considerations. 
The authors conducted literature reviews, to identify outcomes measured in 
clinical trials in asthma. Seven working groups, composed of clinicians, 
researchers, personnel from drug regulatory authorities, and representatives 
from the pharmaceutical industry, discussed the suitability of these 
outcomes for evaluating, in clinical trials, current asthma control and future 
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asthma-related problems. Three working groups focussed on the 
measurement and reporting of exacerbations, physiological outcomes and 
indirect measures of asthma control (ie unscheduled use of health care, loss 
of work and school productivity, and need for additional medication), and 
four discussed the use of composite scores, biomarkers, asthma control 
diaries and quality-of-life questionnaires. Two paediatricians were 
involved, with the task of assessing whether the group’s recommendations 
were applicable to clinical trials in children. Consensus was reached after 
round-table open discussions. 
The outcomes suggested by the group were considered in two broad 
domains, namely “current control” and “future risk”. The recommended 
outcomes are listed in Table 17. In Table 18, the top 6 six outcomes from 
our study are compared with the recommendations of the ATS/ERS group. 
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Table 17 Outcomes recommended by the ATS/ERS, categorised by 
whether they should be considered essential, desirable or optional 
 
 
 Essential Desirable Optional 
For assessing 
current 
control 
1. Symptom-free 
days   
2. Reliever use  
3. Composite scores  
4. Exacerbation 
(within last month) 
5. Quality of life 
1. FEV1 
2. Symptom/ reliever/ 
lung function diary 
3. Corticosteroid use  
4. Health care 
utilization 
 
For assessing 
future risk 
1. Exacerbations 
2. Post- 
bronchodilator 
FEV1x (for 
assessment of lung 
function decline)       
3. Composite scores 
which assess 
functional status and 
symptoms (eg 
Asthma Control 
Questionnaire) 
4. Treatment side-
effects  
5. Pre- 
bronchodilator 
FEV1 (as predictor 
for 
exacerbations) 
1. Symptom/reliever/ 
lung function diary 
2. Health care 
utilization  
3. Mortality 
due to asthma  
4. Airway 
hyperresponsiveness  
5. Biomarkers (sputum 
eosinophil, exhaled 
Nitric Oxide) 
1. Biomarkers 
2. Airway 
hyperresponsiveness 
 
Adapted from Reddel et al 2009 
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Table 18 Comparison between the top 6 outcomes for school-aged 
children, identified after Phase 2 of our study, and the 
recommendations of the ATS/ERS taskforce 
 Our study: 
Top 6 outcomes 
suggested by 
parents/clinicians 
Reddel et al 
(essential) 
(Reddel et al 
optional) 
Symptoms ! !  
Exacerbations ! !  
QoL ! !  
Death !  ! 
Normal activities ! As part of 
composite asthma 
score 
 
Exercise ability !   
Reliever use  !  
Lung function  !  
Treatment side effects  !  
Healthcare utilisation   ! 
Biomarkers   ! 
Bronchial 
hyperresponsiveness 
  ! 
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As can be seen in Table 18, the recommendations of the ATS/ERS 
taskforce are comparable with our results, especially with regard to 
symptoms, exacerbations, effects of asthma on daily life, and adverse 
effects of therapy. We would recommend that because these outcomes 
were noted to be of particular importance in both studies, they should 
strongly be considered for inclusion in a core outcome set for childhood 
asthma. Methodological research, to identify the most appropriate tools to 
measure these important outcomes, should be conducted. This should be 
used to inform consensus about how, and when, these outcomes should be 
measured and reported in all clinical trials of regular therapies for children 
with asthma. 
One difference between the studies was that physiological measures of 
lung function, though  ‘essential’ outcomes in the ATS/ERS core set, were 
found to be one of the least important outcomes in our study. This may be 
because our study focussed on clinical trials in children, in whom the 
problems with measuring and interpreting lung function have already been 
discussed, whereas the ATS/ERS study primarily focussed on outcomes for 
trials in adults. Similar problems, relating to whether or not outcomes 
measured in clinical trials in adults are applicable to children, have been 
highlighted by other groups involved in designing core outcome sets  
(Griffiths et al 2005). The discrepancy between our recommendations and 
those of the ATS may also reflect our empirical approach of considering 
the importance of outcomes in the context of a clinic consultation, 
compared to the other group’s approach of considering outcomes primarily 
from the perspective of clinical trials.   
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5.6.3 Robustness of the study 
Strengths of the study 
Our methodological approach was based on the idea that outcomes 
measured in clinical research studies should reflect those that are important 
and relevant in clinic consultations. In particular, two methodological 
choices enabled us to take this approach. Firstly, we involved parents, 
young people, and paediatricians, regardless of whether they had been 
involved in the design or conduct of clinical trials. Secondly, in Phase 1, 
we elected to ask participants open questions to identify they outcomes 
they felt were clinically important, rather than presenting them with a list 
of outcomes that are already measured in clinical trials. We are confident 
that these choices enabled us to identify outcomes of particular relevance 
when making shared decisions in routine practice, even if they are not 
routinely measured in clinical trials. In addition, this approach helped us 
avoid participants rating outcomes as important simply because they are 
traditionally measured in clinical trials. We would recommend that this 
approach is used when developing core outcome sets in other conditions.  
When designing this study, we were aware of sources of bias, and we 
addressed these accordingly. If participants had scored outcomes on the 
basis of how frequently they were measured in previous clinical trials, 
certain outcomes, namely death and long-term problems, would not have 
been included in the Phase 2 questionnaire. We avoided this bias by asking 
open questions, without prompting responses, in Phase 1. By revealing 
neither the identities of participants, nor their answers, to the group, 
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individuals did not tailor their answers to agree with those of others, which 
was especially important given the mix of experience and professional 
backgrounds in the group. By keeping the clinician questionnaires as brief 
as possible, and by sending reminders to complete the Phase 2 
questionnaire, we observed minimal attrition of participants. This is 
especially important when using the Delphi technique because if 
participants with opinions that do not match those of the rest of the group 
drop out, the overall results can be a biased representation of the original 
group’s opinion. 
Much of the validity of the study rested on the results of Phase 1, which 
determined the outcomes listed in Phase 2. We felt these results were valid 
and reliable for four reasons. Firstly, parents and young people offered 
extensive input when designing the questionnaires, and so we were 
confident that our questions, and the aim of the study, would be clearly 
understood.  Secondly, the agreement between the four reviewers was 
good, which suggests that our interpretation of participants’ responses was 
correct. Thirdly, all the outcomes we carried forward to Phase 2 received a 
median score of at least 3, and most scored 4, from both parents and 
clinicians, which suggests that the outcomes we identified in Phase 1 were 
all of some importance. Fourthly, we felt that the list of outcomes 
presented to participants in Phase 2 was comprehensive, because 
participants, when asked, did not suggest other outcomes that were not 
listed. This was particularly reassuring, given that we elected to collect data 
using questionnaires, rather than interviews or focus groups. Although 
these other qualitative research techniques can generate ‘rich’ data, they are 
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more time and labour intensive, for researchers and participants, and 
require specialist training.  
Another strength of our study was that we ensured that the views of each 
group, regardless of the number of participant, were considered equally. 
We carried outcomes forward from Phase 1 to Phase 2 if they had been 
suggested by 10% of either clinicians, parents, or young people, and so 
each group had equal opportunity to influence the composition of the Phase 
2 questionnaire. In Phase 2, we analysed the responses of parents and 
clinicians separately, rather than as one homogenous panel of participants, 
so that we could identify outcomes of importance to both groups, and also 
so that we could note relevant discrepancies. 
 
Weaknesses of the study 
One weakness of the study is that the sample is focussed on children whose 
asthma is managed by hospital paediatricians, although much asthma is 
treated in primary care and the community. Phase 2 of the study could be 
replicated amongst GPs, practice nurses, and parents with children whose 
asthma is managed in primary care. We feel, however, that our results are 
generalisable with regard to the types of children included in clinical trials, 
which are frequently conducted in the hospital setting. 
Despite good agreement between reviewers, certain responses from parents 
in Phase 1 were open to interpretation. One example related to the 
description of symptoms. Although some parents specified whether they 
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were referring to daytime or nocturnal symptoms, others did not. A 
pragmatic decision was taken that a description of cough, wheeze, or 
shortness of breath should be classified as referring to nocturnal symptoms 
only if the response was this specific. There were two potential errors that 
could have occurred, if our assumption had been false. Firstly the number 
of participants suggesting ‘daytime symptoms’ could have been 
overestimated, and this outcome could have erroneously been included in 
the Phase 2 questionnaire. Secondly the number of participants suggesting 
‘night-time symptoms’ could have been underestimated, and it could have 
been erroneously missed from the Phase 2 questionnaire. Ultimately, our 
results appear to be robust to this decision, because nocturnal symptoms 
were included in the Phase 2 questionnaire, and daytime symptoms scored 
highly. 
Responses from parents completing the Phase 1 questionnaire, which were 
classified as representing quality of life, were also open to interpretation. 
Although there are a variety of different schemes for describing quality of 
life, and its constituent components, we decided to keep a broad definition 
that reflects a patient’s overall sense of well being, including psychosocial 
status. Even if we had misinterpreted these responses in Phase 1, the 
composition of the Phase 2 questionnaire would not have been affected, as 
the term ‘quality of life’ was suggested by a sufficient number of clinicians 
for school-aged children, and was measured in a sufficient proportion of 
clinical trials of pre-school children, to warrant its inclusion for both age 
groups. A detailed examination of what participants meant by quality of 
life was outside the scope of this study. 
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A final weakness is that the response rate of clinicians initially was poor at 
the start of the study. This was in contrast with our experiences with 
parents and young people, almost all of whom agreed to participate. If this 
study were to be repeated, it would be essential to involve more young 
people in Phase 1, and to attempt to involve them in Phase 2 also. 
 
5.7 Summary 
When making shared clinical decisions, parents and clinicians wish to 
know whether an intervention is effective, and can confer benefits on a 
child’s ability to live a normal life. Outcomes in clinical trials, which 
generally measure short-term clinical and physiological efficacy, may not 
be sufficient to fully evaluate the effects of interventions in ways that are 
meaningful in clinical practice.  
A core set of outcomes for childhood asthma, that not only suits the needs 
of researchers, but also improves the usefulness of clinical trials from the 
perspective of clinicians, parents, and policy-makers, can be based on our 
findings, in conjunction with the recommendations of the recent ATS/ERS 
taskforce. Agreement amongst a wider group of people involved in such 
trials should focus on identifying the best ways to measure symptoms, 
exacerbations, effects of asthma on daily life and adverse effects of 
therapies. Further discussion should also address the particular questions of 
whether outcomes reflecting long-term beneficial and harmful effects of 
treatments should be measured in all trials and, if so, how this should be 
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done, and which lung function tests, if any, should be included in the core 
set.  
The main implication for the design of core outcome sets is that patients 
and practising clinicians should be asked which outcomes they feel are 
important in routine clinical practice, rather than focussing primarily on 
discussing outcomes which are traditionally measured in clinical trials.  
With regard to how this study can be taken forward, there is still much 
methodological research around the best way to design and implement core 
outcome sets, and further work to help identify the most appropriate 
outcomes, and the best way to measure them, for clinical trials in children 
with asthma. These future directions are discussed in Chapter 6. 
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C h a p t e r  6   
Conclusions and Future directions 
 
6.1 Main conclusions 
Several important conclusions can be drawn from the work contained within 
this thesis. In Chapter 2, in which we describe a systematic review of studies 
that aim to determine which outcomes to measure in clinical trials in 
children, we found few relevant paediatric initiatives, and we found that no 
core outcome set had been agreed for clinical trials in childhood asthma. 
Most of the existing studies did not use structured consensus techniques to 
agree on which outcomes to measure in clinical trials. Parents and children 
were rarely involved in identifying outcomes of importance to them.  
In the systematic review to determine which outcomes are measured in 
clinical trials of regular therapies for childhood asthma, described in Chapter 
3, we found that authors frequently evaluate the effects of interventions on 
short-tem disease activity, especially symptoms and physiological markers 
of lung function, but quality of life, functional status, and long-term 
beneficial and harmful effects of treatments are rarely assessed.  
The main recommendation from this systematic review was that a core 
outcome set, incorporating outcomes that are important in childhood asthma, 
should be developed. The Delphi technique was selected as the most 
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appropriate structured method of reaching consensus, because it enables the 
involvement of a large number of participants. We conducted a critique of 
studies that used the Delphi technique for developing core outcome sets, as 
there was little guidance for researchers who wished to utilise it for this 
purpose. Between the 15 included studies, we found that the methodology 
differed considerably, and the quality of reporting of key aspects was 
variable. Researchers dominated participation in such studies, and patients 
and families were seldom involved. This review was described in Chapter 4. 
Taking into consideration our recommendations from this critique of the 
Delphi process, as a method of developing core outcome sets, we designed a 
study that aimed to identify the most important outcomes in childhood 
asthma. This study was described in Chapter 5. The main methodological 
approach to this study was to focus on identifying outcomes of particular 
importance when shared decisions about asthma therapies are made in clinic 
consultations. In order to do this, we avoided aspects of methodology that 
are prone to bias, identified in the critique described in Chapter 4. We 
therefore involved clinicians, parents and young people, rather than 
researchers or trialists. We also asked open questions to identify potentially 
important outcomes, rather than presenting participants with a list of 
outcomes that had been measured in previous clinical trials. We found that 
the most important outcomes, in clinical practice, were daytime symptoms, 
nocturnal symptoms, QoL, and mortality. We recommend that these 
outcomes should be measured, and reported, in all clinical trials of regular, 
preventative therapies for children with asthma. 
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The systematic reviews described in Chapters 2 and 4 have raised important 
questions about core outcome sets in general, which should be addressed 
before a final core outcome set for childhood asthma is agreed and 
implemented by those people involved in designing and conducting clinical 
trials in this condition. These questions relating to how core outcome sets 
should be developed, disseminated, and implemented, are discussed in 
Sections 6.2 and 6.3. 
 
6.2 Identifying the best methods for designing core 
outcome sets 
People who wish to develop core outcome sets must make important 
methodological choices that can affect the validity of their 
recommendations. As we identified in Chapters 2 and 4, groups have 
approached the problem of agreeing which outcomes to measure in clinical 
trials using different methodological techniques. In Chapter 4, we offered 
guidance that should help inform some of these decisions, but further 
research should be conducted to improve the quality of core outcome sets.  
Such work is important in order to identify attributes of core outcome sets 
that make them more likely to be acceptable to trialists. If a core outcome 
set is to be implemented in all relevant studies, it should be accepted and 
endorsed by all groups of people involved in designing, and reporting, 
clinical trials. Currently, there is no definition of a minimum set of standards 
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that helps determine whether a core outcome set has been designed in a 
rigorous, robust fashion, and should hence be measured, and reported, in all 
clinical trials in a given condition. In order to identify these attributes, the 
views of several groups of individuals should be ascertained. 
Firstly, there should be discussions and interviews with trialists, to see what 
would make a core outcome set acceptable from their perspective. Research 
such as this could be conducted by interviewing trialists who are currently, 
or recently have been, involved in designing or conducting trials. Open 
questions could identify whether or not these trialists would consider using a 
core outcome set, if one were available. Similarly, if a core outcome set has 
been developed, it would be informative to know, if it were not used, the 
reasons behind this decision. These interviews would also be helpful in 
identifying barriers to the implementation of core outcome sets by trialists, 
such as whether or not core outcome sets are perceived to be too 
prescriptive.  
Organisations who fund clinical trials also have an important role in the 
promotion and endorsement of core outcome sets. In clinical trials that they 
fund, they could require that a core outcome set is measured, and may be 
able to influence trialists towards this. Another group who could be key to 
aiding the development and utilisation of core outcome sets are drug 
regulatory agencies, because they directly influence the methodology of 
clinical trials.  In order for these groups to be confident that a core outcome 
set should be endorsed, they may require that certain criteria are met when it 
was developed. It would be useful to identify these criteria, so that people 
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can be given guidance on how to design a core outcome set that will be 
more likely to be implemented.  
As well as interviewing the key personnel outlined above, there may be a 
different approach to determining the best way to develop core outcome 
sets. A retrospective audit of clinical trials in which a core outcome set has 
been developed could be conducted. This should include trials conducted 
after the core outcome set was published, in order to identify whether or not 
it was implemented in subsequent research studies. Analysis of the 
characteristics of these core outcome sets may provide useful information if 
those which appear to have been implemented are compared against others 
which have not. For example, there may be differences in the composition 
of the groups, the methodological techniques, the types of outcomes 
recommended, or even the journal in which the core outcome set was 
published.   
 
Methodological questions relating to the design of core outcome sets 
One relevant problem is whether or not a core outcome set can claim to 
include all appropriate outcomes, if patients have not been asked which 
outcomes they feel are important. Further research is required to identify the 
most appropriate method of involving parents and children in developing 
core outcome sets, and how their views should influence the final decision 
about which outcomes to measure in clinical trials. Although we used 
questionnaires, distributed in out-patient clinics, other groups have 
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conducted focus groups in patients with fibromyalgia (Mease et al 2008) and 
degenerative ataxia (Serrano-Aguilar et al 2009). In these conditions, our 
methodology could be replicated, and the results compared with those of the 
previous studies. Advantages and disadvantages of these approaches could 
then be evaluated and compared.  
Another methodological problem relates to whether recommendations of a 
group who reached agreement after open group discussion, rather than using 
structured consensus techniques, should be considered valid or not. 
Although we have advocated the use of structured consensus techniques for 
developing core outcome sets, there have been no studies that empirically 
compare open group discussion with more structured consensus techniques, 
for the purpose of developing core outcome sets. Important outcomes 
identified using these techniques could also be directly compared, and the 
relative strengths and weaknesses of the methods evaluated. 
 
6.3 Dissemination and implementation of core 
outcome sets: The COMET initiative 
One problem that we encountered throughout the work conducted in this 
thesis was identifying studies that aimed to determine which outcomes to 
measure in clinical trials. This is an important barrier to the implementation 
of core outcome sets. If trialists are not aware of core outcome sets, or do 
not have access to the study report in which they are described, their 
usefulness is very much impaired. The recently formed COMET initiative 
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(Core Outcome Measures in Effectiveness Trials) will hopefully improve 
the development and implementation of core outcome sets in clinical 
research studies (http://www.liv.ac.uk/nwhtmr/comet/comet.htm - accessed 
July 2010). This group advocates the use of core outcome sets, and aims to 
bring together individuals who are interested in the standardisation of 
outcomes, to collate relevant resources, and foster research in this area, and 
help disseminate core outcome sets that have been developed. 
One step in the identification of all relevant studies is to repeat the 
systematic review, of studies in which outcomes were selected for paediatric 
clinical trials, including conditions in all age groups. All relevant studies, 
from both systematic reviews, should be compiled, in a searchable database. 
This would mean that someone searching for a core outcome set, in a given 
condition, would be able to find it, if it existed. This makes it more likely 
that existing core outcome sets will be used, and that conditions in which 
core outcome sets do not exist could be identified.  
Such a database would need to be regularly updated. People involved in the 
design of core outcome sets can help the dissemination of their work by 
using standardised terminology and keywords in the abstract of the final 
publication, so it can be identified easily. These words should be determined 
using experts in literature searching and MeSH keyword assignment, such 
as librarians. One approach would be that the abstract should mention the 
terms “core set” or “standardised outcome set”, and a variety of synonyms 
for these terms. The abstract should also clearly define the methodology 
used to develop the core outcome set. Journal editors can also play a crucial 
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role by publishing studies that develop core outcome sets in open-access 
format. 
 
6.4 A core outcome set for paediatric asthma 
In this thesis, we have discussed difficulties associated with the selection 
and measurement of outcomes for clinical trials of regular therapies for 
children with asthma, and we recommended that a core outcome set should 
be agreed for this condition. In Chapter 5 we identified that the most 
important outcomes in clinical practice are symptoms, exacerbations, 
mortality, and the effects of asthma on the ability to live a normal daily life.  
There is still, however, some work to be done before a final core outcome 
set is agreed for clinical trials in childhood asthma. The next step is to 
formally reach as universal a consensus as possible amongst key personnel 
involved in clinical trials in children with asthma. As childhood asthma a 
global health problem, this should be an international collaboration. This 
should be agreed amongst people who design and conduct clinical trials in 
asthma, and also people who use the results to make decisions about 
treatments for asthma. This formalisation and universal acceptance of a core 
outcome set should substantially improve the likelihood that it will be 
implemented in all relevant trials. An outline for the possible future 
direction of this work is discussed below. 
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Who should be involved in agreeing a final core outcome set for clinical 
trials in children with asthma 
It is crucial that the group involved in the final consensus should include 
clinical trialists, as they will be expected to use the core outcome set in their 
studies. They would be able to offer useful insights into problems that may 
arise when measuring and reporting these outcomes. The core outcome set 
needs to be comprehensive enough to include all of the most relevant 
outcomes, but it should not be overly prescriptive, to the extent that trialists 
are discouraged from conducting trials in the first place. Their perspective 
on an appropriate balance between these two requirements would be very 
informative.  
It may also be appropriate to involve scientific representatives from 
pharmaceutical companies who are likely to conduct trials of therapies for 
children with asthma, as it may be more likely that the core outcome set 
would be properly implemented if these companies agreed that the core set 
was acceptable. It could also be appropriate to involve representatives from 
drug regulatory authorities, because their guidance with regard to the 
evidence required for licensing and marketing purposes largely determines 
the outcomes measured in trials conducted by the pharmaceutical industry. 
Regardless of whether representatives from the pharmaceutical industry are 
included in all discussions about which outcomes to measure, and given 
equal opportunities as other groups to determine the core outcome set, or 
whether they observe the process, but do not necessarily have much 
opportunity to help determine the core outcome set, it is important that their 
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potential conflicts of interest are recognised, and that any disagreements 
they may have with the views of other groups are justified. 
We have strongly advocated the involvement of those people who use the 
results of clinical research studies, to make shared decisions about treatment, 
when developing core outcome sets. In the case of paediatric asthma, we 
have involved clinicians, parents, and young people. Representatives from 
these groups should also be involved in the final agreement of the core 
outcome set. It is not necessary to involve large numbers of these groups, 
because we have already ascertained the views of several clinicians and 
young people. It would be appropriate, however, to have representatives 
from these groups, to ensure that the results from our study are considered 
when the consensus about the final core outcome set is reached. Although 
we would hope that people considering our results would agree that the 
important outcomes should be included in the core set, it is possible that, 
unless the views of parents and clinicians are strongly advocated, they may 
be overlooked.  
Another group who would benefit from the development of core outcome 
sets for clinical trials are systematic reviewers, such as those working within 
the Airways Group of the Cochrane Collaboration. The standardised 
selection of outcomes across clinical trials would improve the quality of 
recommendations from Cochrane reviews, and representatives from the 
Airways group may be interested in helping to develop and agree a final 
core outcome set in asthma. Their experiences of attempting to meta-analyse 
the results of clinical trials in asthma may highlight problems that we have 
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not identified in our work so far. Their involvement may also help to agree 
the core outcomes that should be considered in Cochrane reviews of 
interventions for childhood asthma, and included in the Summary of 
Findings tables.  
 
How these groups should reach consensus about a core outcome set for 
childhood asthma 
One way of reaching consensus amongst these individuals is to conduct a 
Delphi process, via email, and then convene the participants, at a meeting, to 
discuss issues that have arisen, and to formally agree on the final core 
outcome set.   
In the first round of the Delphi process, participants could be shown the list 
of outcomes included in the Phase 2 questionnaire we compiled in Chapter 
5. They would be asked, for each of these outcomes, whether or not they 
feel it should be included in the final core set. To help participants, we 
would distribute the results of the work we described in Chapter 5, and a 
copy of the ATS/ERS core outcome set. Participants would also be asked to 
justify their choices, especially for those whose inclusion, or exclusion, from 
the core outcome set was a matter they felt strongly about. In the second 
round of the Delphi process we could remove outcomes that the group 
clearly felt should not be included in the core outcome set, present the 
overall opinion for the remainder, and a summary of comments from 
participants, and ask participants whether they would wish to reconsider 
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their answers. The purpose of this round would be to enable the participants 
to reiterate their answer, or change their mind. It would also enable us to 
identify any discrepancies between the various groups of individuals. The 
third round of the Delphi process could be conducted at a meeting. Any 
contentious outcomes could be discussed at this meeting, before the core 
outcome set is agreed at the final vote. 
Although we have highlighted certain outcomes as being particularly 
important, there are others that may also be appropriate for a core outcome 
set. Whether or not measures of lung function should be measured and 
reported, in all clinical trials in children with asthma, warrants further 
discussion by the group agreeing the final core outcome set. Although we 
have identified that it is not particularly relevant when making decisions in 
clinical practice, the ATS/ERS taskforce have recommended that it should 
be measured, and these tests have been established, for several decades, as 
the most objective measurement of airway obstruction in clinical trials in 
asthma. Long-term beneficial and harmful effects of interventions also 
warrant further discussion when the final core set is agreed. We have 
suggested that these outcomes, which are very infrequently measured in 
clinical trials, are important to clinicians and parents. Although the 
difficulties of measuring these outcomes may preclude their measurement in 
all clinical trials, it may still be appropriate to suggest that, where possible, 
trialists consider them. It would be important to ascertain the views of 
clinicians and researchers about this recommendation. 
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Determining how the outcomes should be measured 
In this thesis, we have mainly focussed on identifying which outcomes to 
measure in clinical trials in asthma. There is also need for a consensus, 
around how to measure them. In order for this consensus to be evidence-
based, research should address which tools are most appropriate for 
measuring important outcomes. Such work should begin with a systematic 
review of other studies that have assessed the validity, reliability, or 
responsiveness of tools for measuring the relevant outcomes, in childhood 
asthma. If necessary, a prospective comparison of the attributes of these 
tools should be conducted, amongst large groups of patients in clinical 
practice, or ongoing clinical trials, to identify which is most appropriate. 
This work could be conducted between the second and third rounds of the 
Delphi process described above, and could inform consensus about how the 
important outcomes should be measured.  
Important questions relate to the most appropriate ways of measuring 
symptoms and QoL. The validity, reliability, responsiveness, and 
discriminative abilities of these tools should be assessed. There is also a 
need to determine the most appropriate way to analyse and report these 
outcomes. For example, they could be reported as mean daily scores, weekly 
scores, as the proportion of days in which the outcome was worse than a 
pre-determined cut-off.  
Another important issue would be to identify the most acceptable and useful 
definition for what constitutes an exacerbation. We demonstrated in Chapter 
3 that a variety of definitions were used in clinical trials. Exacerbations may 
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be considered in various ways, such as physiological terms (eg reduced 
FEV1 with increased respiratory rate), health resource utilisation (eg 
hospital attendance), need for treatment (eg oral prednisolone), or patient 
reported events (eg: “I felt like I had an exacerbation”). There are various 
ways in which endpoints such as exacerbation can be defined. One is to 
write various ‘paper patient’ profiles based on the different dimensions of 
the definition described above. These could be showed to clinicians, and 
parents, who could be asked whether they would classify the patient as 
having had an exacerbation. Analysis of the factors that were associated 
with the most popular definitions of exacerbation could help determine the 
most useful way of classifying this endpoint. 
 
Dissemination of the final core set 
Once the final core outcome set has been agreed, it should be disseminated 
in an easily accessible, open access format. This should be in an open-access 
journal, and the work should be deposited in the aforementioned registry 
held by the COMET group. The final core set should also be presented at 
large international meetings, such as the annual scientific meetings held by 
the ATS and ERS.  
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6.5 Final summary 
It is crucial that trialists measure the right outcomes. Core outcome sets 
make it more likely that the most appropriate outcomes are measured, in the 
right way, by all relevant studies. It is encouraging that important groups are 
now realising the potential advantages of standardising outcomes across 
clinical trials. There is still a long way to go before core outcome sets are 
widely accepted, however. A concerted effort is required, amongst all those 
involved in clinical research, to encourage the selection of the most 
appropriate outcomes in clinical trials, and to promote the use of core 
outcome sets. Better outcomes in trials leads to more useful evidence, which 
should in turn improve patient care. 
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Appendix 1 – Search strategies used in the 
systematic review of studies that aimed to 
determine which outcomes to measure in clinical 
trials in children (Chapter 2) 
MEDLINE (1950-2006) and CINAHL (1982-2006) were searched in 
January 2007 using the following search strategy: 
1 (clinical trials or clinical trials).mp. 
2 Clinical trials, phase III.mp. 
3 Clinical trials, phase IV/ 
4 multicentre studies.mp. or multicenter studies/ 
5 controlled clinical trials.mp. or controlled clinical trials/ 
6 randomized controlled trial.mp. or randomized controlled trial/ 
7 randomised controlled trial.mp. or randomised controlled trial/ 
8 randomized controlled trials.mp. or randomized controlled trials/ 
9 randomised controlled trials.mp. or randomised controlled trials/ 
10 controlled clinical trials.mp. or controlled clinical trials/ 
11 (Clinical adj3 trial$).tw. 
12 (controlled adj3 trial$).tw. 
13 rcts.mp. 
14 trial$.mp. 
15 therapeutic human experimentation.mp. or therapeutic human experimentation/ 
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17 methodology, research.mp. 
18 research methodology.mp. 
19 methodology.mp. 
20 research techniques.mp. 
21 research technics.mp. 
22 research design.mp. [mp=ti, hw, ab, it, ot, nm] 
23 experimental design.mp. [mp=ti, hw, ab, it, ot, nm] 
24 methodological stud$.mp. [mp=ti, hw, ab, it, ot, nm] 
25 design, experimental.mp. [mp=ti, hw, ab, it, ot, nm] 
26 study, methodological.mp. [mp=ti, hw, ab, it, ot, nm] 
27 studies, methodological.mp. 
28 group processes.mp. or group processes/ 
29 consensus.mp. or consensus/ 
30 consensus development conferences, NIH/ or "consensus development conference, NIH".mp. [mp=ti, hw, ab, it, ot, nm] 
31 consensus development conferences/ or "consensus development conference".mp. [mp=ti, hw, ab, it, ot, nm] 
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32 focus group$.mp. or focus groups/ 
33 group structure.mp. or group structure/ 
34 delphi technique.mp. or delphi technique/ 
35 nominal group$.mp. or nominal group/ 
36 "congresses [publication type]"/ or congresses/ or congresses.mp. 
37 consumer participation.mp. or consumer participation/ 
38 patient participation.mp. or patient participation/ 
39 literature review.mp. or "Review Literature"/ 
40 systematic review.mp. 
41 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
42 "outcome assessment (health care)".mp. or "Outcome Assessment (Health Care)"/ 
43 treatment outcome.mp. or treatment outcome/ 
44 patient outcome assessment.mp. 
45 outcome measures.mp. 
46 outcome studies.mp. 
47 outcomes assessment.mp. 
48 assessment, outcomes.mp. 
49 treatment failure.mp. or treatment failure/ 
50 outcome$.mp. 
51 outcome determination/ or outcome.mp. 
52 endpoint$.mp. 
53 end point$.mp. 
54 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 
55 child$.mp. or child$/ 
56 paediatric$.mp. 
57 pediatric$.mp. 
58 infant/ or infan$.mp. 
59 young$.mp. 
60 Toddler.mp. 
61 bab$.mp. 
62 child, preschool/ or preschool$.mp. 
63 Pre-school.mp. 
64 Adolesc$.mp. or adolescent/ 
65 Teenage$.mp. 
66 youth$.mp. 
67 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 
68 16 and 41 and 54 and 67 
69 remove duplicates from 68 
 
SCOPUS was searched in January 2007 using the following search strategy: 
((TITLE-ABS-KEY(clinical trial*)) OR (TITLE-ABS-KEY(controlled clinical 
trial*)) OR (TITLE-ABS-KEY(randomi?ed controlled trial*)) OR (TITLE-
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ABS-KEY(multicentre stud* OR multicenter stud*)) OR (TITLE-ABS-
KEY(rcts))) AND 
((TITLE-ABS-KEY(research methodology OR methodolog* stud*)) OR (TITLE-
ABS-KEY(research design OR experimental design)) OR (TITLE-ABS-
KEY(consensus OR consensus development)) OR (TITLE-ABS-KEY(focus 
group* OR group processes)) OR (TITLE-ABS-KEY(delphi technique OR 
congresses)) OR (TITLE-ABS-KEY(consumer participation OR consumer 
participation)) OR (TITLE-ABS-KEY(literature review OR systematic review))) 
AND 
((TITLE-ABS-KEY(outcome*)) OR (TITLE-ABS-KEY(endpoint*)) OR 
(TITLE-ABS-KEY(end point*)) OR (TITLE-ABS-KEY(outcome measure* 
OR outcome stud* OR outcome assessment)) OR (TITLE-ABS-KEY(patient 
outcome OR treatment outcome))) AND 
((TITLE-ABS-KEY(child*)) OR (TITLE-ABS-KEY(paediatric* OR 
pediatric*)) OR (TITLE-ABS-KEY(bab* OR toddler* OR infan*)) OR 
(TITLE-ABS-KEY(young OR pre-school OR preschool)) OR 26) 
 
 
 
 
 
 
 
Cochrane database of systematic reviews, Cochrane database of abstracts 
reviews of effects, Cochrane database of methodology reviews, Cochrane 
methodology register and Cochrane central register of controlled trials 
(CENTRAL) were searched in December 2006 using the following search 
strategy: 
 
#1 clinical trial*:ti,ab,kw OR controlled clinical trial:ti,ab,kw 
#2 randomi?ed controlled trial*:ti,ab,kw 
#3 multicentre stud* OR multicenter stud* 
#4 (#1 OR #2 OR #3) 
#5 research methodol*:ti,ab,kw OR methodol:ti,ab,kw 
#6 research design:ti,ab,kw OR experimental design:ti,ab,kw 
#7 methodolog* stud*:ti,ab,kw 
#8 consensus:ti,ab,kw OR consensus development:ti,ab,kw 
#9 focus group*:ti,ab,kw  
#10 group processes:ti,ab,kw 
#11 consumer participation:ti,ab,kw OR patient participation:ti,ab,kw 
#12 literature review:ti,ab,kw OR systematic review:ti,ab,kw 
#13 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12) 
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#14 outcome*:ti,ab,kw 
#15 outcome*:ti,ab,kw 
#16 outcome measure*:ti,ab,kw 
#17 outcome stud*:ti,ab,kw OR outcome assessment*:ti,ab,kw 
#18 patient outcome:ti,ab,kw OR treatment outcome:ti,ab,kw 
#19 (#14 OR #15 OR #16 OR #17 OR #18) 
#20 paediatric*:ti,ab,kw OR pediatric*:ti,ab,kw 
#21 child*:ti,ab,kw 
#22 bab*:ti,ab,kw 
#23 infan*:ti,ab,kw 
#24 toddler*:ti,ab,kw 
#25 preschool:ti,ab,kw OR pre-school:ti,ab,kw 
#26 adolescen*:ti,ab,kw 
#27 youth*:ti,ab,kw 
#28 teenage*ti,ab,kw 
#29 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28) 
#30 (#4 AND #13 AND #19 AND #29) 
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Appendix 2 – Studies excluded from the review 
described in Chapter 2  
 
Studies identified in our initial database search 
Study [ref  list 
at end of 
appendix] Reason for exclusion 
Adams 1998 
[1]          
This paper described the rationale behind the design of a 
clinical trial investigating stroke prevention in children with 
sickle cell anaemia. The paper did not, however, develop or 
use methodology for selecting the outcomes used in the trials. 
Allen 
1985[2] 
This review article discussing design issues in clinical trials 
of children with brain tumours is based on the author’s 
personal opinion. Although features of some outcomes are 
discussed, this does not qualify as methodology of selecting 
outcomes. 
Andrasik 
2005[3] 
This review article discussing design issues in clinical trials 
of children with headache is based on the author’s personal 
opinion. Although features of some outcomes are discussed, 
methodology of selecting outcomes is not used or developed. 
Arnold 
2003[4] 
This study validated the use of parent-reported outcomes in 
clinical trials of children with autism. The study was 
excluded, however, because it did not relate to the actual 
methodology of selecting an outcome, but the validation of 
an outcome which was already selected. 
Ball 2003[5] This study aimed to develop a definition of what constitutes a 
‘responder’ in clinical trials of children with abdominal pain. 
Therefore the authors used methodology to refine an existing 
outcome, rather than using methodology for selecting 
outcomes for use in clinical trials of children with abdominal 
pain. 
Beghi 
1993[6] 
This paper describes the rationale behind the design of a 
clinical trial, including the outcomes which were selected. 
The paper did not, however, describe methodology for 
selecting outcomes for use in clinical trials. 
Bower 
1994[7] 
The review article discussed in detail the potential ways of 
measuring outcomes, but did not describe the selection of 
outcomes for use in clinical trials of children with cerebral 
palsy. 
Children’s 
Amalgam 
Trial Study 
Group [8] 
This paper described the rationale behind various aspects of a 
clinical trial in children requiring dental restoration. The 
authors do not describe the methodology behind selecting the 
outcome. 
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Curley 
2005[9] 
This review article aims to review the performance 
characteristics of  outcomes used in clinical trials in children 
with sepsis. The study does not, however, use methodology 
for selecting outcomes for use in these trials. 
Curley 
2006[10] 
This paper describes the rationale behind the design of a 
clinical trial, including the outcomes which were selected. 
The paper did not, however, describe methodology for 
selecting outcomes for use in clinical trials. 
Furst 
2005[11] 
The review article does discuss scleroderma in paediatric 
trials, but discusses how to measure an outcome, rather than 
select one. 
Guilbert 
2004[12] 
This paper described the rationale behind the design of a 
clinical trial, but did not explain the methodology behind 
selecting the outcomes measured in the study. 
Hargrave 
2006[13] 
In this review article the authors appraised the consistency 
between different studies of children with brainstem glioma. 
The authors do not use methodology for selecting outcome 
measures for use in clinical trials, nor do they review the 
methodology that other authors use for this purpose. 
Hollander 
2004[14] 
This review article related to study design in clinical trials of 
children with autism. Because it was a commentary based on 
the personal opinion of the author it was excluded, as it did 
not describe methodology for selecting outcomes for use in 
clinical trials. 
Juniper 
2001[15]              
The study did not use methodology for selecting outcomes, 
and was not relevant specifically to children 
King 
2004[16] 
This systematic review did not use methodology for selecting 
outcomes in clinical trials, but did suggest outcomes for use 
in future bronchiolitis clinical trials. 
Kirkham 
2004[17] 
This article reviews clinical trial design issues in children 
with arterial stroke, and suggests strategies for future studies, 
but does not discuss selection of outcomes or use 
methodology for selecting outcomes. 
Law 
1989[18] 
This review article relates to several aspects of clinical trial 
design in the field of occupational therapy. Although 
characteristics of instruments for measuring outcomes are 
reviewed, the selection of outcomes or outcome domains is 
not. 
Mahoney 
2006[19] 
This article described the work of a research network for 
paediatric cardiology clinical trials, including work on 
validating outcomes for use in clinical trials. The article did 
not, however, describe studies which use methodology for 
selecting which outcomes should be measured in clinical 
trials of children with cardiology problems. 
Marshall 
2005[20] 
Although the article does quote some paediatric trials, it does 
not specifically state that the outcomes can be used in 
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paediatric research. 
Martin 
2006[21] 
This consensus statement relates to clinical trial design in 
adults with graft-versus-host disease (GVHD), but the 
authors do not specifically state that the outcomes suggested 
are for use in paediatric trials. 
McBride 
1990 [22] 
This review article is about outcomes in clinical trials of 
infants with bronchiolitis. The article does not describe or 
develop a methodology for selecting outcomes though. 
McDaid 
2005[23] 
At the end of this systematic review of treatments for 
retinoblastoma, the authors suggest outcomes for use in 
future clinical trials. These suggestions are a result of the 
methodological assessment of previously published studies, 
but not a result of methodology which the authors used to 
determine the most appropriate outcomes to use. 
Mehta 2003 
[24] 
This study reviews outcomes in trials of adults with renal 
failure, but not children. 
Meltzer 
2006[25] 
Paper mentioned several outcome measures as part of 
guidelines for clinical trials in rhinosinusitis, but did not 
discuss the process or methodology of selecting them. 
Mohanraj 
2003 [26] 
In this review article authors compare outcomes used to 
measure various outcome domains in clinical trials of 
children with epilepsy. The article does not, however, use 
methodology to select outcomes or outcome domains. 
Ozolins 2005 
[27] 
In the discussion section of this clinical trial of children with 
acne, the author assesses the performance characteristics of 
some of the outcomes which were used during the study, but 
he does not discuss outcome domains which should be 
selected in future trials, or use methodology to select 
outcomes.  
Pauwels 2001 
[28] 
This paper discusses aspects of the design of a clinical trial in 
children with asthma. The author does not describe the 
methodology used to select the outcome domains or 
outcomes. 
Ravelli 1997 
[29] 
This study assessed the collinearity between outcomes used 
in clinical trials of children with rheumatoid arthritis. 
Although the authors, therefore, assess performance 
characteristics of some outcomes, they do not use 
methodology for selecting outcomes for use in clinical trials. 
Romagnoli 
2001 [30] 
This clinical trial assessed the long-term effects of steroids on 
newborn infants. The authors, when discussing design issues 
relevant to possible future clinical trials, suggest outcomes 
for use in these trials. However, the authors do not use 
methodology to select these outcomes. 
Rosenfeld 
2001 [31] 
This study aimed to define ‘exacerbations’ as an outcome for 
use in clinical trials in children with cystic fibrosis. The study 
did not, however, aim to select outcomes for use in these 
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clinical trials. 
Rudorfer 
1993 [32] 
In this review article, the author reviews tools and 
instruments for measuring outcomes in clinical trials of 
children with psychiatric illness, but does not use 
methodology to select outcomes or outcomes that should be 
used in these studies. 
Ruperto 1996 
[33] 
This study assessed the redundancy of outcomes used in 
clinical trials of children with rheumatoid arthritis. Although 
the authors, therefore, assess performance characteristics of 
some outcomes, they do not use methodology for selecting 
outcomes for use in clinical trials. 
Schoenfeld 
2002 [34] 
The article discusses a study in which the participants were 
all adults. 
Schonbeck 
2005 [35] 
This paper describes the rationale behind several aspects of a 
clinical trial of influenza and pneumococcal vaccination, but 
the authors do not describe methodology used to select the 
outcomes measured in the trial. 
Shapiro 1999 
[36] 
The article describes several aspects of trial design in a 
clinical trial of children with asthma, but the authors do not 
describe the methodology used to select the outcomes. 
Sharek 2002 
[37] 
This study assesses the collinearity between five different 
measures of asthma status, but does not use methodology to 
actually select outcomes for clinical trials. 
Spahn 2003 
[38] 
This literature review assesses some of the performance 
characteristics of outcomes used in clinical research in 
asthma, but the author does not use methodology to identify 
which outcomes should be used in future clinical trials. 
Spencer 1997  
[39] 
The article does not use methodology for selecting outcome 
measures for use in trials. It relates to the change in 
distribution of the DMF index, an outcome used in clinical 
trials in dentistry. The author suggests outcomes for use in 
future clinical trials, but does not use methodology for 
selecting these outcomes. 
Thase 1999 
[40] 
This is a review article which does not use methodology for 
selecting outcomes for use in clinical trials. The article does 
not relate to clinical trials in children. 
Theander 
2005 [41] 
The study does not relate to clinical trials in children.  
Van Zanten 
2006 [42] 
The article discusses validation of an instrument to measure 
an outcome (dyspepsia), rather than using methodology to 
select one. It is a study in adults. 
Walsh 2003 
[43] 
In this study, the authors attempt to develop a physiological 
definition for bronchopulmonary dysplasia, a widely used 
outcome in neonatal trials. In other words, the authors are not 
using methodology for selecting outcomes, but improving the 
performance characteristics of an existing outcome. 
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Walsh 
2004[44] 
In this study, the authors assess the effect of a physiological 
definition on the incidence of bronchopulmonary dysplasia. 
The study does not select outcomes for use in future clinical 
trials. 
Zhang 2000 
[45]  
This study assesses the performance characteristics of 
outcomes used in neonatal clinical trials, but is not about 
selection of outcome domains or outcomes. 
Studies suggested by MCRN CSG members  
Study Reason for exclusion 
Aurora 
2005[46] 
In this study the correlation of various tests of lung function 
in children with CF was assessed. The study did not relate to 
the selection of which outcomes should be measured in 
clinical trials. 
Brody 
2004[47] 
In this study the authors assessed the correlation between 
high resolution CT scanning and pulmonary function tests in 
children with CF. The authors do not use methodology to 
determine which outcomes should actually be measured in 
clinical trials of children with CF however. 
Clayton 
2002[48] 
Consensus about management of children with 21-
hyroxylase deficiency, not relating to clinical trial design 
Clayton 
2005[49] 
Consensus about management of children treated with 
Growth Hormone, not relating to clinical trial design. 
Dunger 
2004[50] 
Consensus statement about management of children with 
Diabetic Ketoacidosis, not relating to clinical trial design 
Hughes 
2006[51] 
Consensus statement about children suffering from intersex 
disorders, not relating to clinical trial design. 
Lum 2007[52] In this study the authors assessed the extent at which 
multiple breath washout parameters are able to detect airway 
dysfunction in children with CF. The study did not relate to 
the selection of outcomes for use in clinical trials. 
Ordonez 
2003[53] 
This study assesses the performance characteristics of 
inflammatory and microbiological markers in clinical trials 
of children with cystic fibrosis. The authors do not use 
methodology to determine which outcomes should actually 
be measured in these clinical trials however. 
Ordonez 
2004[54] 
In this study the authors assess the reproducibility of 
inflammatory markers as an outcome measure in children 
with CF. The authors do not use methodology to determine 
which outcomes should actually be measured in clinical 
trials of children with CF however.  
Ratjen 
2006[55] 
In this review article the authors discuss some ways of 
measuring airway inflammation in children with CF. They 
do not use methodology however to determine which 
outcomes should be measured in clinical trials if children 
with this condition. 
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Suri 2003[56] In this study the authors assess the safety and usefulness of 
inducing sputum from children with CF in order to measure 
various inflammatory and microbiological markers that 
could be used as outcomes in clinical trials. The study does 
not use methodology to determine which outcomes should 
actually be measured in clinical trials of children with CF. 
Whitehouse 
2007[57] 
In this study consumers were involved in the design of a 
clinical trial of children with migraine. The consumers were 
not involved in the selection of which outcomes should be 
measured in the trial (personal communication from Dr 
Whitehouse) 
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Appendix 3 - Description of studies included in the 
systematic review described in Chapter 2 
Study Condition Type of Study People involved 
in selecting 
outcomes 
Patient 
involvement 
Methods used to 
select outcome 
Goldstein 
2005 
[1] 
Sepsis Consensus 
statement 
Paediatric critical 
care specialists; 
physicians and 
scientists with 
research 
experience in 
paediatric sepsis, 
members of past 
consensus 
conferences on 
adult sepsis 
No The group arrived 
at consensus by 
way of semi-
structured 
discussion. 
De Rouen   
2002 [2] 
Dental 
restoration 
Paper describes 
the design of 
specific trial– 
the authors of 
the trial 
consulted with a 
multidisciplinar
y team of 
experts to select 
the outcomes 
measured in the 
trial. 
(No of 
participants not 
reported) 
Physicians, 
epidemiologists, 
biostatisticians.  
Number of 
participants not 
stated 
No The consensus 
was reached by 
discussion within 
the group. 
Griffiths 
2005 [3] 
Crohn’s disease Consensus 
statement 
Clinicians with 
expertise in 
paediatric 
inflammatory 
bowel disease; 
clinical trial 
design specialists  
(Number of 
participants not 
reported) 
No Semi-structured 
discussion was 
used to select the 
most appropriate 
outcome domains  
and outcomes to 
measure 
Pavletic 
2006 [4] 
Graft Versus 
Host disease 
(GVHD) 
Consensus 
statement 
regarding trials 
of children with 
GVHD, 
including 
formulation of a 
preliminary core 
set of outcomes. 
Clinical experts in 
GVHD; Experts 
from other fields 
(gastroenterology 
and 
rheumatology) 
who were 
experienced in 
selecting 
outcomes for use 
in clinical trials 
within those 
fields. (Number of 
participants not 
stated) 
Yes – at the 
end of the 
report, the 
authors 
acknowledge 
“patients and 
patient and 
research 
advocacy 
groups”. The 
level of their 
involvement 
was not 
reported by 
the authors 
 
. 
 
The group arrived 
at consensus by 
way of semi-
structured 
discussion. 
Finer 2006 
[5] 
 
On behalf of 
NDDI 
Neonatal 
apnoea 
Consensus 
statement 
Physicians, 
research experts 
(Number of 
participants not 
reported) 
No The consensus 
was reached by 
semi-structured 
discussions by 
the group. 
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Study Condition Type of Study People involved 
in selecting 
outcomes 
Patient 
involvement 
Methods used to 
select outcome 
Short 2006 
[6] 
 
On behalf of 
NDDI 
Neonatal 
cardiovascular 
instability 
Consensus 
conference 
regarding trials 
of neonates with 
cardiovascular 
instability 
 
 
 
 
 
 
 
 
Physicians, 
research experts 
(Number of 
participants not 
reported) 
 
 
 
 
No The group arrived 
at consensus by 
using semi-
structured 
discussion. 
Anand 2005 
Anand 2006 
[7,8] 
 
on behalf of 
the NDDI 
Neonatal pain 1. Systematic 
review of 
literature 
relating to trial 
design in studies 
of neonatal pain 
2. Consensus 
statement 
regarding trial 
design 
considerations 
relevant to 
clinical trials of 
pain relief for 
neonates 
Experts on 
neonatal pain, 
clinical 
researchers  
(Number of 
participants not 
reported) 
No A systematic 
review of 
literature relating 
to trial design in 
studies of 
neonatal pain was 
performed, and 
specific articles 
relating to 
outcome 
measurement 
were reviewed. 
These findings 
were discussed 
amongst a group 
of experts, using 
a semi-structured 
discussion 
approach, and a 
consensus 
statement 
regarding the 
outcomes that 
should be 
measured was 
developed. 
Although a lot of 
the discussion 
centred around 
tools to measure 
outcomes, there 
was also 
discussion about 
composite 
outcomes, and 
also about 
outcome 
domains, such as 
long-term 
neurodevelopmen
tal outcome. 
 
 
 
Roth 2006[9] 
On behalf of 
NDDI 
Neonatal 
Postoperative 
Cardiac 
Dysfunction 
Consensus 
statement 
regarding trials 
of neonates with 
Postoperative 
Cardiac 
Dysfunction 
Physicians, 
research experts. 
(number of 
participants not 
reported) 
No The group arrived 
at consensus by 
using semi-
structured 
discussion. 
Clancy 2006 
[10] 
 
On behalf of 
NDDI 
 
Neonatal 
seizures 
Consensus 
statement 
Physicians, 
research experts 
(Number of 
participants not 
reported) 
No The consensus 
was reached by 
semi-structured 
discussions by 
the group. 
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Study Condition Type of Study People involved  Patient 
involvement 
Methods used to 
select outcome 
Lux 2004  
[11]Osborne 
2001 
[12]On 
behalf of the 
West Delphi 
collaboration 
Infantile spasms Consensus 
statement 
regarding trials 
of children with 
IS, including 
formulation of a 
preliminary core 
set of outcomes. 
Authors who had 
published articles 
on infantile 
spasms during the 
previous 10 years 
were invited to 
join the group, 
and were asked to 
invite others who 
may be interested 
in participating. 
(Questionnaires 
were sent to 133 
people, and there 
were eventually 
31 participants) 
No Delphi consensus 
performed over 6 
‘rounds’ of 
questions:1) 
Multiple Choice 
Questions (MCQ) 
covering various 
aspects of clinical 
trial design, 
including 
outcomes. 2) 
Qualitative 
comments and 
MCQ questions 
regarding the 
same questions, 
having fed the 
results of round 1 
back to the group 
3) Formulation of 
statements from 
rounds 1 and 2 
which 
represented 
majority opinion. 
Participants were 
invited to respond 
as to whether 
they agreed or 
disagreed with 
these. 4) These 
statements were 
modified, and 
participants 
commented on 
their suitability 
and content. 5) 
and 6) consisted 
of formulation of 
a draft and 
subsequently a 
final paper which 
were altered 
according to the 
group’s 
comments 
 
Carlson 
2003 [13] 
Bipolar 
affective 
disorder 
Consensus 
workshop 
regarding trial 
design 
considerations 
relevant to 
clinical trials of 
adolescents with 
bipolar disorder. 
Clinical 
researchers with 
expertise in 
bipolar illness, 
pharmaceutical 
industry sponsors, 
staff of the Food 
and Drug 
Administration, 
representatives of 
families with 
affected children.  
(Total number of 
participants: 53) 
Yes. The 
group 
included 
parents of 
children who 
were 
affected by 
bipolar 
affective 
disorder. 
Several separate 
groups used 
semi-structured 
discussion to 
come to 
consensus on 
several issues 
relating to clinical 
trial design, and 
one group was 
specifically given 
the remit of 
discussing 
outcomes. This 
included 
discussion on 
which primary 
and secondary 
outcomes should 
be measured, and 
which aspects of 
mania or 
depression best 
represent change 
in a child’s 
condition.  
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Study Condition Type of Study People involved 
in selecting 
outcomes 
Patient 
involvement 
Methods used to 
select outcome 
LaFrance 
(2006) [14] 
Non-Epileptic 
Seizures (NES) 
Consensus 
statement about 
clinical trials of 
patients 
suffering from 
NES 
Multidisciplinary 
group of 
neurologists, 
psychiatrists, 
neuropsychiatrists
, psychologists, 
statisticians, 
nurses and other 
researchers 
familiar with NES 
(44 participants) 
No Structured and 
focussed 
discussion. The 
group discussed 
the question 
“which variables 
or domains 
should be 
regarded as 
reflecting 
outcome?” The 
group identified 
areas of outcomes 
relevant to NES 
that could 
potentially be 
used as outcomes 
reflecting the 
effects of an 
intervention. 
These included 
psychosocial 
outcomes, 
clinical outcome, 
psychiatric status, 
health-related 
quality of life, 
medical resource 
utilisation, and 
psychophysiologi
cal markers.  
Smith 1996 
[15] 
Asthma Questionnaire-
based survey of 
health 
professionals 
and researchers. 
Researchers and 
clinical experts 
with experience in 
treating asthma. 
(14 participants) 
No Questionnaires to 
health 
professionals and 
researchers 
asking which 
outcomes they 
would use in 
various scenarios, 
including clinical 
trials, to assess 
whether a 
patient’s asthma 
had been 
improved by an 
intervention. The 
participants were 
also asked to 
provide an 
estimate of how 
valid they 
thought the 
indicators were. 
 
Ramsey 
1994 [16] 
Cystic Fibrosis Consensus 
statement 
regarding trials 
of children with 
Cystic Fibrosis, 
including 
formulation of a 
preliminary core 
set of outcomes. 
 
Clinicians with 
expertise in CF, 
laboratory and 
clinical 
researchers in the 
field of CF, 
representatives 
from the U.S. 
FDA (Number of 
participants not 
reported)   
 
 
 
 
 
 
 
No The group arrived 
at consensus by 
using semi-
structured 
discussion. 
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Study Condition Type of Study People involved 
in selecting 
outcomes 
Patient 
involvement 
Methods used to 
select outcome 
Miller 2001  
Rider 2002  
Rider 2003  
Rider 2004 
[17–20] 
On behalf of 
the IMACS 
collaboration 
 
Oddis 2005 
[21] 
Describing 
the work of 
the IMACS 
collaboration 
Juvenile 
idiopathic 
inflammatory 
myopathies 
(IIM) 
Development of 
core set of 
outcomes for 
use in trials of 
children with 
IIM, by 
formulation of a 
consensus 
statement 
Adult and 
paediatric 
specialists, patient 
support group 
leaders with 
expertise in IIM. 
This group was 
called The 
International 
Myositis 
Outcomes 
Assessment 
Collaborative 
Study Group 
(IMACS). 
(Number of 
participants not 
reported) 
Patient 
support 
group 
leaders were 
the parents 
of children 
with IIM.  
It was decided 
that in order to 
fully understand 
the totality of 
effects of 
interventions on 
patients with IIM, 
the outcomes 
should measure 
disease activity, 
disease damage 
and quality of 
life. A literature 
review was 
performed to 
review the 
performance 
characteristics of 
outcome 
measures used in 
IIM clinical trials, 
and Delphi 
technique was 
used to determine 
which outcomes 
best represented 
these domains. A 
definition of 
improvement was 
then developed, 
and this was 
subsequently 
validated. 
On behalf of 
the PRINTO 
collaboration 
Ruperto 
2003 
Ruperto 
2004 
Ruperto 
2006 [22–
24] 
Systemic lupus 
erythematosus 
(SLE) and 
dermatomyositis 
(DM) 
Development of 
a core set of 
outcomes for 
use in trials of 
children with 
SLE and DM 
Specialists in 
paediatric 
rheumatology 
267 people were 
initially involved, 
followed by a 
meeting of 40 
participants 
No 1) Development 
of a core set of 
outcomes 
Phase 1: (Delphi 
Technique) A 
questionnaire was 
sent to the group, 
and participants 
were asked to 
rank the 10 
variables they 
judged as 
clinically most 
important when 
determining 
whether a patient 
with SLE or DM 
has responded to 
therapy. 
Variables ranked 
by at least 10 
responders were 
then listed 
alphabetically 
and participants 
were asked again 
to rank their top 
10 choices. 
Phase 2: 
(Nominal group 
technique) A 
four-day 
international 
consensus 
conference was 
attended by 40 
participants. 
Using 5 
exercises, the 
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core set of 
outcomes was 
determined: 1) 
Classify all 
variables into one 
of 2 domains 
(disease activity 
and disease 
damage).The 
participants were 
invited to suggest 
any other 
domains. 2) 
Classify variables 
into ‘concepts’ of 
disease activity 
and damage 3) 
Select and rank 
the domains that 
should be 
included in the 
core set 4) Select 
the variables that 
should be used to 
measure these 
domains 
2) Validation of 
core outcomes  
This was done in 
clinical practice, 
on patients who 
were starting a 
new medication. 
Validation of the 
following 
characteristics 
was conducted: 
feasibility; face 
and content 
validity; 
responsiveness, 
discriminative 
ability; 
convergent 
construct validity; 
internal 
consistency 
3) Development 
of a definition of 
improvement 
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 Condition Type of Study People involved 
in selecting 
outcomes 
Patient 
involvement 
Methods used to 
select outcome 
Giannini 
1997 [25] 
Juvenile 
Arthritis 
Development 
and validation of 
a set of core 
outcomes using 
consensus 
formation 
techniques, and 
development of 
a definition of 
improvement for 
individual 
patients. 
Paediatric 
rheumatologists, 
OMERACT 
participants, and 
academic 
practitioners. (16 
participants in 
initial ‘Advisory 
Council’; 
dissemination of 
the results to 198 
paediatric 
rheumatologists 
for their opinions) 
No 1) 25 variables 
which had been 
used in juvenile 
arthritis (JIA) 
trials were listed 
in a 
questionnaire. 
2) This 
questionnaire was 
sent to a 16-
member 
‘advisory 
council’ who 
were asked to 
rank their top 6 
choices, and list 
other variables 
which were not 
included on the 
list. 16 variables 
received votes, 
and these became 
the ‘candidate 
variables’. 
3) The 
performance 
characteristics 
(validity, 
reliability, 
sensitivity to 
change, 
redundancy) of 
the candidate 
variables were 
reviewed using 
existing literature. 
4) Using nominal 
group technique, 
the group selected 
a preliminary 
core set of 6 
outcomes. These 
were physician 
global assessment 
of disease 
activity, parent or 
patient reported 
assessment of 
overall well 
being, functional 
ability, number of 
joints with active 
arthritis, number 
of joints with 
limited range of 
movement, and 
erythrocyte 
sedimentation 
rate. 
5) International 
consensus on the 
acceptability of 
this core set of 
variables was 
ascertained using 
a questionnaire. 
6) The 
multicollinearity 
of these outcomes 
was assessed 
using real 
patients. 
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7) A definition of 
improvement was 
developed 
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Appendix 4 – Outcomes selected in the studies included in the systematic review described in 
Chapter 2 
Studies selecting outcomes for use in clinical trials of interventions to treat specific illnesses or clinical features of underlying conditions 
Speciality 
 
Condition 
 
Study 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Critical care: 
 
Sepsis 
 
(Goldstein)  
Appropriate biomarkers (as 
secondary or pharmaco-
dynamic endpoints) 
Organ failure-free days;  
Mortality (not as the primary 
outcome) 
 Change in Pediatric 
Overall Performance 
Category score between 
admission and discharge; 
overall functioning at 3 or 
6 months 
  
Gastroenterology: 
 
Crohn’s disease 
 
(Griffiths)  
Acute:       
Primary    – CDAI 
Secondary- PCDAI 
Remission:CDAI 
Physician assessment; 
Parent/patient assessment; 
Height velocity 
 
 
 
 
 
 
Growth   HRQoL  
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continued 
 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Haematology: 
 
GVHD 
 
(Pavletic)  
 
 
Signs-organ specific 
measures 
Symptoms-clinican 
reported 
Symptoms – patient 
reported 
Global rating-physician  
Global rating-patient 
reported 
  Clinician assessed: 
Grip strength; 
2-minute walk 
time; 
Karnofsky/ 
Lansky scale 
Patient assessed: 
HAP; 
ASK; 
SF-36 
 
CHRIS 
 
Neonatology: 
 
Neonatal apnoea 
 
(Finer)  
Frequency/ 
duration/severity of apnoea 
 
Associated postnatal 
morbidity; 
 
 Neurodevelopment at 18 
months 
 Duration of 
hospital stay; 
Duration of 
assisted ventilation 
Number of days 
hospitalized  
Neonatology: 
 
Neonatal cardio-vascular 
instability 
(Short)  
Measures of organ 
perfusion 
Primary outcome: Combined 
endpoint of mortality or 
severe neurological outcome  
Secondary outcomes: 
NEC;ROP;BPD; 
Adverse effects of 
drugs- arrhythmia, 
hypertension, 
seizures, hormonal 
effects 
Development at 2 years   
Neonatology: 
 
Pain 
 
(Anand)  
 
 
Acute pain measurements: 
Behavioural/ 
Haemodynamic/ 
Metabolic/ 
Respiratory/ 
Renal; 
Need for supplemental 
opiates; 
Frequency of postnatal 
complications of 
prematurity  
Neurobehavioural assessment Global 
developmental 
delay 
 
Intervention-
specific adverse 
effects 
Sleeping pattern; 
Feeding/Growth; 
Mother-infant interaction; 
Cry characteristics; 
Pain response; 
Development of addiction; 
Substance abuse; 
Anxiety disorders;  
Neurological/ cognitive 
development at 18/36 
 Length of hospital 
stay/ ventilation/ 
NICU stay as 
represented by 
physiological 
definition of 
criteria to account 
for inter-centre 
variations in 
practice 
241 
 
 
continued 
 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Neonatology 
 
 
Neonatal post-operative 
cardiac dysfunction 
 
(Roth)  
Endpoint specific to 
underlying cardiac 
diagnosis. Secondary 
measures: blood 
lactate;oxygenation;creatini
ne clearance, BNP, Need 
for inotropes; cerebral 
perfusion 
 
 
 
 
 
 
Duration of delayed sternal 
closure; 
Mortality beyond 30th 
postoperative day;  
 
 Neurodevelopment at 1 to 
2 years 
 Duration of 
assisted ventilator; 
Duration of  NICU 
stay; 
Duration of 
hospital stay after 
cardiac surgery; 
 
Neonatology: 
 
Seizures 
 
(Clancy)  
 
Primary: Cessation of 
EEG-detected seizures 
 
  Neurodevelopment at 8 
years 
  
Neurology: 
 
Infantile spasms 
 
(West Delphi Group)  
 
 
Clinical outcome –spasm 
cessation  Electroclinical 
outcome- resolution of 
hypsarrhythmia 
Relapse-free response; 
Continued subtle spasm; 
Time to relapse;Presence 
of other seizures 
Development at 2 
years;Death and other serious 
adverse effects associated 
with the illness; 
Nonserious adverse events 
associated with the illness; 
Presence of and progression 
to other seizure types 
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continued 
 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Psychiatry: 
 
Bipolar affective disorder 
 
(Carlson)  
 
 
Primary: Mania (YMS); 
Depression 
(CDRS).Secondary:ADHD 
symptomology; 
Aggressive 
behaviour; 
Global improvement 
 
 
 
 
  Academic outcome and 
cognitive function 
Family outcome- 
CHQ; 
 
Other social effects 
 
Psychiatry: 
 
 
Non- epileptic seizures 
 
(LaFrance)  
Seizure frequency Depression; 
Personality characteristics; 
Arousal 
 
  HRQoL, including illness 
perceptions and individual 
concerns; 
Employment; 
Family functioning 
 
ER visits;  
Hospital 
admission 
Respiratory: 
 
CF 
 
(Ramsey)  
 
 
 
< 6 years of age 
Chest x-ray score; 
Oxygenation; 
Inflammatory markers; 
Illness severity; 
Bronchoscopy/ 
BAL/brushings 
>6 years of age 
As above, and  
Spirometry; 
Sputum: microbiology/ 
DNA 
 
 
Growth; 
 
Frequency of pulmonary 
exacerbations 
  QWB  
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continued 
 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Symptoms 
FEV1/FVC 
PEFR 
 
 
 
    Admission to 
hospital 
Respiratory: 
 
Asthma- 
 
(Smith)  
                    acute   
 
 
 
                 chronic 
Symptoms 
FEV1/FVC 
PEFR 
Frequency of medication 
use; 
Bronchial hyper-
responsiveness 
 
 
 
 
 
  Functional status HRQoL  
Rheumatology: 
 
IIM 
 
(IMACS)  
 
 
Global activity 
(physician/parent/ 
patient assessment); 
Muscle strenghth (Manual 
testing); 
Enzymes: 
CK, aldose, LD, AST, 
ALT; 
CMAS; 
Extra-skeletal muscle 
disease 
 
 
Core set: 
Global damage assessment; 
Assessment of different organ 
systems (VAS/SDI) 
Extended core set: 
MRI: muscle fibrosis/ 
scarring/ atrophy; serum 
creatinine; cutaneous 
assessment 
 
 
 HAQ/CHAQ 
 
 
 
HRQoL (SF36)  
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continued 
 
Disease Activity Physical consequences of 
disease – damage/ 
complications 
Adverse effects of 
therapy 
Functional status Social outcome/ family 
outcome, including 
Quality of Life 
Resource 
utilisation 
Global assessment-
physician; parent/ child; 
activity tool; 
AntiDNA antibody; 
24 hr proteinuria 
Serum creatinine 
Global damage tool-SDI; 
physician; 
Height and weight 
Pubertal stage: Tanners; 
menses 
 
    Rheumatology: 
 
 
SLE 
 
(PRINTO)  
 
 
 
 
 
DM 
 
(PRINTO) 
Global assessment-
physician; parent/ child; 
activity tool; 
Muscle strength; 
Laboratory: Muscle 
enzymes 
 
Global assessment-physician; 
MDI 
Height and weight; 
Pubertal stage: Tanners; 
menses 
Muscle strength-CMAS  
 CHAQ   
Rheumatology: 
 
Juvenile arthritis 
(Giannini)  
Physician global 
assessment; 
Number of active joints; 
ESR 
Number of joints with limited 
range of movement 
 
 Functional ability 
 
Overall well being (Parent/ 
child reported) 
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Appendix 5 – Search strategy used in the systematic 
review, described in Chapter 3, of RCTs of inhaled 
corticosteroids for children with asthma 
 
CENTRAL was searched in January 2008 (no language restrictions) using 
the following search strategy: 
 
#1  asthma:ti,ab,kw  
#2  (antiasthma OR anti-asthma):ti,ab,kw  
#3  wheez*:ti,ab,kw  
#4  (bronch?spas* OR bronchoconstric* OR bronchismus OR 
bronchiospas*):ti,ab,kw  
#5  cough:ti,ab,kw  
#6  (#1 OR #2 OR #3 OR #4 OR #5)  
#7  (child*):ti,ab,kw  
#8  (paediatric* OR pediatric):ti,ab,kw  
#9  (infan*):ti,ab,kw  
#10  (young*):ti,ab,kw  
#11  (toddler*):ti,ab,kw  
#12  bab*:ti,ab,kw  
#13  (preschool or pre-school):ti,ab,kw  
#14  (teenage*):ti,ab,kw  
#15  (adolesce*):ti,ab,kw  
#16  (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 
OR #15)  
#17  beclomet?asone:ti,ab,kw  
#18  betamet?asone:ti,ab,kw  
#19  fluticasone:ti,ab,kw  
#20  budesonide:ti,ab,kw  
#21  (corticosteroid* OR *corticoid*):ti,ab,kw  
#22  (inhaled *steroid*):ti,ab,kw  
#23  (pulmicort or azmacort or becoride or flixotide or flovent or 
aerobid or aerobec or qvar or vanceril or triamciclone):ti,ab,kw  
#24  (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23)  
#25  (#6 AND #16 AND #24)  
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Appendix 6 – Phase 1 questionnaire, and invitation, 
sent to clinicians 
 
Dear BPRS member 
My name is Ian Sinha, Specialist Registrar in paediatrics in the 
Mersey Deanery. I am a clinical research fellow in the Medicines for 
Children Research Network Clinical Trials Unit, at Alder Hey 
Childrens’ NHS Foundation Trust, and I am undertaking a PhD. My 
thesis (supervised by Professor Rosalind Smyth and Professor Paula 
Williamson) relates to outcomes in children with asthma. I hope to 
identify which outcomes should be measured in randomised 
controlled trials (RCTs) of chronic therapies for children with asthma. 
Your help in this project would be invaluable and I am very grateful to 
Professor Warren Lenney and the BPRS Executive Committee for 
contacting you on my behalf. 
How you can help 
In this study I hope to identify which outcomes are most important to 
clinicians who have experience of the outpatient management of 
children with asthma. I would be grateful if you would spare a few 
minutes to complete a very brief questionnaire, which can be found 
on the BPRS website (www.bprs.co.uk/asthmaquestionnaire.doc ). 
You will be asked to list up to 5 beneficial or harmful outcomes of 
treatment that you find clinically important in school aged children 
(aged 5 to 18) and preschool children (less than 5 years). These 
should be things that you consider, when deciding whether to 
continue a child on treatment or alter a child’s regular asthma regime. 
The deadline for completing this questionnaire is Friday 8 May 2009  
What happens then? 
If you complete this questionnaire, and are happy to be contacted 
again, you will be invited to complete a second questionnaire. On 
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this, you will be asked to score the importance of the outcomes 
suggested in the first questionnaire.  
In the final study report, I would like to acknowledge, by name, 
participants who complete both questionnaires. For this reason only, 
you will be asked to provide your name, job title, and the institution in 
which you work. Your details will not be passed on to any other party. 
The other participants will not know the answers which you, 
personally, provide. 
Rationale for this study 
Consensus guidelines on outcomes for children with asthma do not 
exist. In a systematic review of asthma RCTs, I found marked 
variations between studies in outcomes measured and the ways in 
which they were measured. I hope this study will contribute to the 
standardisation of selection and measurement of outcomes in RCTs 
in children with asthma. 
 
Funding 
I am funded by the NIHR Medicines for Children Research Network 
Clinical Trials Unit and Co-ordinating Centre.  
Ethics 
NRES have provided the following statement: “Based on the information 
you provided, our advice is that the project is not considered to be 
research. Therefore it does not require ethical review by a NHS Research 
Ethics Committee. We would deem this a service evaluation and 
development.” 
Thank you 
Thank you for taking the time to read this. I am very grateful and 
hope you will consider taking part. If you have any questions please 
do not hesitate to contact me. (iansinha@liv.ac.uk). The 
questionnaire is now ready for completion, and can be found on the 
BPRS website (www.bprs.co.uk/asthmaquestionnaire.doc).   
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Asthma Questionnaire for Dr Ian Sinha 
 
Please answer the following two questions: 
When you see children with asthma in clinic, you make an 
assessment as to whether their treatment is working. Please list UP 
TO FIVE beneficial or harmful outcomes of treatment that you find 
clinically most important in school aged children (aged 5 to 18). 
These factors should be things that you consider, when deciding 
whether to recommend continuing on current treatment or altering a 
child’s regular asthma therapy regime. 
 
Now please list UP TO FIVE beneficial or harmful outcomes of 
treatment that you find clinically most important in pre-school aged 
children (aged less than 5). These factors should be things that you 
may consider, when deciding whether to recommend continuing on 
current treatment or altering a child’s regular asthma therapy regime. 
 
 
 
Thank you for your time. From your answers, and those from a group 
of children with asthma and their parents, we will compile a list of 
outcomes suggested by a pre-defined minimum number of 
participants. This will form the basis for a second questionnaire, on 
which participants will be asked to score the importance of each 
outcome.  
Would you like the study facilitator (Ian Sinha, SpR in paediatrics) to 
contact you by email when this second questionnaire is ready? 
Yes [] No [] 
If you answered YES, please provide your email address here. 
 
Your email address will NOT be passed on to ANY other party under 
any circumstances. We will not use it to contact you about any other 
studies. You would receive one email to confirm that your 
questionnaire was received, and one to inform you that the second 
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questionnaire is ready for completion. After that, we would only 
contact you once, to inform you when the final study report is ready 
for publication. After this, your email address would be permanently 
deleted from our records. 
For acknowledgement purposes, we would like to know your name, 
job title and institution. These will not be passed to anyone else, and 
will be kept completely confidential, until the final study report is 
ready for publication. If you do not want to be acknowledged in this 
way, please leave the name and institution spaces blank, but for data 
analysis purposes, please let us know your job title. 
 
 
 
 
 
 
  
PLEASE SEND YOUR COMPLETED QUESTIONNAIRE TO IAN 
SINHA BY EMAIL: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAME 
JOB TITLE 
INSTITUTION 
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Appendix 7 - Phase 1 questionnaire distributed to 
parents 
                                  
 
 
 
 
 
 
 
 
This questionnaire is about the daily preventer treatment your 
child takes to control their asthma. 
In order to know whether medications for young people with asthma 
are helpful and safe, they must be tested by researchers. These 
researchers measure whether medications affect children in a 
number of ways. For example, they could test the following effects of 
a medication: 
1. Whether it improves how well a child’s asthma is controlled in the 
short term, eg by reducing coughing or wheezing  
2. Whether it improves the ability of children to do normal activities, 
eg playing sports or going to school  
3. Whether it prevents long term problems associated with having 
asthma as a child, eg by preventing a child having asthma when they 
are an adult 
Developing a core set of outcomes for clinical trials 
of regular therapies for children with asthma – 
Parent questionnaire 
Investigators: Dr Ian Sinha, Professor Paula 
Williamson, Professor Rosalind Smyth 
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4. Whether it reduces the number of times children are admitted to 
hospital with asthma 
5. Whether it generally improves life for children and their families 
6. Whether it has side effects.  
 
We believe the good and bad effects of medications that researchers 
measure should be things that are important to children with asthma, 
and their parents. We would be grateful if you could complete this 
quick questionnaire. If you do, your answers will be kept completely 
confidential.  
 
 
Question 1 
How old is your child? _______________ 
 
Question 2 
Over the last twelve months, have you generally felt that the regular 
preventer treatment that your child takes has kept their asthma under 
control?  
Tick ONE box:  Yes [ _ ]No [ _ ] 
 
If you ticked YES, please tell us what aspects of your child’s asthma, 
or their daily life, have made you feel happy that they are on the 
correct regular medication.  
If you ticked NO, please leave this question blank 
 
______________________________________________________
______________________________________________________
______________________________________________________
_______________________________________ 
______________________________________________________
_____________ 
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Question 3 
 
Over the last twelve months, have there been times when you felt 
that your child’s regular preventer treatment should be increased or 
changed, because their asthma was not under control? 
Tick ONE box:  Yes [ _ ]No [ _ ] 
 
If you ticked YES, please tell us the reasons why you were not 
satisfied with the regular preventer treatment that they were taking?  
If you ticked NO, please leave this space blank 
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
____________________________________________________ 
 
Question 4 
Does anything worry you about the fact that your child has asthma? 
 
Tick ONE box:   Yes [ _ ]No [ _ ] 
 
If you ticked YES, please tell us the worries you have about the fact 
your child has asthma 
If you ticked NO, please leave this space blank 
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
____________________________________________________ 
 
Question 5 
Does anything worry you about the regular preventer treatment that 
your child takes for their asthma? 
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Tick ONE box:  Yes [ _ ] No [ _ ] 
 
If you ticked YES, please tell us what worries you have about the 
treatment your child takes for their asthma. Please be as specific as 
you can. 
If you ticked NO, please leave this question blank 
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
____________________________________________________ 
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Appendix 8 – Questionnaires distributed to clinicians and parents in Phase 2 
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Appendix 9 – Summary of results from Asthma UK 
Outcomes for pre-school children as scored by Parents from Asthma UK 
(n=7) 
 Median 
(IQR) 
Number (%) of 
times outcome 
scored in Top 3 
Number (%) of 
times outcome 
scored as 4/4 
Daytime symptoms 4 (3,4) 3 4 
Nocturnal symptoms 4 (4,4) 6 6 
Activity or exercise 3 (2,4) 1 3 
Use of reliever inhaler 3 (3,4) 0 3 
Exacerbations 4 (3,4) 0 5 
Parent/child overall assessment 4 (3,4) 2 4 
Death 4 (3,4) 5 5 
Normal activities 4 (3,4) 1 5 
School 4 (3,4) 2 5 
Quality of Life 4 (3,4) 1 5 
Family outcomes 4 (3,4) 0 3 
GP/A+E attendance 4 (3,4) 1 3 
Hospital admission 4 (4,4) 0 6 
Health related problems when older 4 (3,4) 0 4 
Short term adverse effects 4 (3,4) 0 3 
Growth 4 (3,4) 0 3 
Long term adverse effects 4 (3,4) 1 3 
 
Outcomes for school-aged children as scored by Parents from Asthma UK 
(n=6) 
 Median 
(IQR) 
Number (%) of 
times outcome 
scored in Top 3 
Number (%) of 
times  outcome 
scored as 4/4 
Daytime symptoms 4 (3,4) 1 4 
Nocturnal symptoms 4 (3,4) 5 4 
Activity or exercise 2.5 1,3)  1 2 
Use of reliever inhaler 4 (3,4) 2 3 
Exacerbations 4 (4,4) 1 6 
Parent/child overall assessment 4 (4,4) 0 5 
Lung function tests 3 (3,4) 0 3 
Death 4 (4,4) 2 6 
Normal activities 4 (3,4) 2 4 
School 3 (3,4) 2 3 
Quality of Life 4 (4,4) 0 6 
GP/A+E attendance 3 (3,3) 0 1 
Hospital admission 4 (3,3) 0 3 
Health related problems when older 4 (3,3) 1 3 
Short term adverse effects 3 (2,4) 0 2 
Growth 4 (3,4) 1 3 
Long term adverse effects 4 (4,4) 1 4 
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Appendix 10 – Correspondence with National 
Research Ethics Service 
 
From: Sinha, Ian [mailto:I.Sinha@liverpool.ac.uk]  
Sent: 26 November 2008 15:23 
To: NRES Queries Line 
Cc: Williamson, Paula; Smyth, Rosalind 
 
Subject: Advice regarding ethical review for survey of asthma outcomes 
 
 Dear COREC 
I am a clinical research fellow at the Medicines for Children Research 
Network Clinical Trials Unit, Liverpool. We are currently planning a piece 
of work to standardise, and improve, the outcomes which are measured in 
clinical trials of children with asthma. The work will be entitled 
“Development of a core set of outcomes for use in clinical trials in children 
with asthma”.  Ultimately we aim to conduct a Delphi survey of clinicians 
who are involved in clinical research, to come to a consensus regarding what 
should be measured in clinical trials in asthma. In the first phase of our 
study we wish to survey parents of children with asthma, and children 
themselves (where appropriate), regarding their views on which outcomes 
should be measured in clinical trials. An outline of this project is listed 
below: 
 
Format: Anonymous questionnaire 
Participants:  
(a) Parents of children attending asthma clinics at Alder Hey Childrens’ 
NHS Foundation Trust 
(b) Children, aged at least 10 years old, attending asthma clinics at Alder 
Hey Childrens’ NHS Foundation Trust 
(c) Parents of children with asthma who are involved in the Asthma UK 
research and policy groups. We will not be contacting children through 
Asthma UK.  
Confidentiality and anonymity of all participants will be maintained. 
We need to consider the potential timeframe of this study, and therefore we 
need to know whether or not we require ethical review. Having seen the 
COREC ethics e-group guideline “Differentiating audit, service evaluation 
and research” (November 2006), it would seem that our survey is not 
designated as research. We would, however, appreciate your advice 
regarding our interpretation of the guidance, with particular reference to the 
following question: 
 
As this is an anonymised survey of attitudes towards clinical trials, we 
would anticipate that ethical review would not be required. Is this correct? 
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I look forward to hearing from you  
Kind regards 
Yours sincerely 
Ian Sinha  
 
RE: Advice regarding ethical review for survey of asthma outcomes  
NRES Queries Line [queries@nres.npsa.nhs.uk]  
 
Sent: 28 November 2008 10:56  
To: Sinha, Ian 
Your query was reviewed by our Queries Line Advisers.  
Our leaflet “Defining Research”, which explains how we differentiate 
research from other activities, is published at:  
http://www.nres.npsa.nhs.uk/rec-community/guidance/#researchoraudit  
   
Based on the information you provided, our advice is that the project is not 
considered to be research according to this guidance. Therefore it does not 
require ethical review by a NHS Research Ethics Committee.  
I would deem this a service evaluation and development 
If you are undertaking the project within the NHS, you should check with 
the relevant NHS care organisation(s) what other review arrangements or 
sources of advice apply to projects of this type.  Guidance may be available 
from the clinical governance office.  
Although ethical review by a NHS REC is not necessary in this case, all 
types of study involving human participants should be conducted in 
accordance with basic ethical principles such as informed consent and 
respect for the confidentiality of participants.  When processing identifiable 
data there are also legal requirements under the Data Protection Act 2000.  
When undertaking an audit or service/therapy evaluation, the investigator 
and his/her team are responsible for considering the ethics of their project 
with advice from within their organisation.  University projects may require 
approval by the university ethics committee.   
This response should not be interpreted as giving a form of ethical approval 
or any endorsement of the project, but it may be provided to a journal or 
other body as evidence that ethical approval is not required under NHS 
research governance arrangements. 
However, if you, your sponsor/funder or any NHS organisation feel that the 
project should be managed as research and/or that ethical review by a NHS 
REC is essential, please write setting out your reasons and we will be 
pleased to consider further.   
Where NHS organisations have clarified that a project is not to be managed 
as research, the Research Governance Framework states that it should not be 
presented as research within the NHS. 
Regards  
Queries Line 
National Research Ethics Service 
National Patient Safety Agency 
4-8 Maple Steet, London, W1T 5HD , Ref:  04/02 , **This reply may have 
been sourced in consultation with other members of the NRES team. 
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A B S T R A C T
Background
In clinical trials the selection of appropriate outcomes is crucial to the assessment of whether
one intervention is better than another. Selection of inappropriate outcomes can compromise
the utility of a trial. However, the process of selecting the most suitable outcomes to include
can be complex. Our aim was to systematically review studies that address the process of
selecting outcomes or outcome domains to measure in clinical trials in children.
Methods and Findings
We searched Cochrane databases (no date restrictions) in December 2006; and MEDLINE
(1950 to 2006), CINAHL (1982 to 2006), and SCOPUS (1966 to 2006) in January 2007 for studies
of the selection of outcomes for use in clinical trials in children. We also asked a group of
experts in paediatric clinical research to refer us to any other relevant studies. From these
articles we extracted data on the clinical condition of interest, description of the method used
to select outcomes, the people involved in the selection process, the outcomes selected, and
limitations of the method as defined by the authors. The literature search identified 8,889
potentially relevant abstracts. Of these, 70 were retrieved, and 25 were included in the review.
These studies described the work of 13 collaborations representing various paediatric
specialties including critical care, gastroenterology, haematology, psychiatry, neurology,
respiratory paediatrics, rheumatology, neonatal medicine, and dentistry. Two groups utilised
the Delphi technique, one used the nominal group technique, and one used both methods to
reach a consensus about which outcomes should be measured in clinical trials. Other groups
used semistructured discussion, and one group used a questionnaire-based survey. The
collaborations involved clinical experts, research experts, and industry representatives. Three
groups involved parents of children affected by the particular condition.
Conclusions
Very few studies address the appropriate choice of outcomes for clinical research with
children, and in most paediatric specialties no research has been undertaken. Among the
studies we did assess, very few involved parents or children in selecting outcomes that should
be measured, and none directly involved children. Research should be undertaken to identify
the best way to involve parents and children in assessing which outcomes should be measured
in clinical trials.
The Editors’ Summary of this article follows the references.
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Introduction
The purpose of a clinical trial is to determine the benefits
and harms of an intervention. This determination is made by
measuring the effects of different treatments on outcomes.
The selection of appropriate outcomes, therefore, is crucial
to the assessment of whether one intervention is better than
another. This review relates to studies that explain how
outcomes have been selected for use in clinical trials in
children younger than 16 years of age. For the purposes of
this review we define children by age rather than by the literal
meaning of offspring.
What Outcomes Measure—The Impact of Illness on a
Patient’s Life
Models have been developed that describe the effects of a
disease on a patient, for example the biopsychosocial model
and the World Health Organisation framework of impair-
ment, disability, and handicap [1,2]. Although these models
differ in many ways, an underlying theme is that illnesses
affect more than one aspect of a patient’s life. For example,
asthma may affect a child’s life by way of troublesome daily
symptoms even when the child is ‘‘well,’’ exacerbations,
disrupted school attendance, and abnormal lung function.
Each of these effects of asthma on the child’s life is potentially
amenable to improvement after starting an intervention. In
clinical trials, the extent to which an intervention affects the
impact of an illness on a patient’s life is reflected by
measuring change in outcomes.
For the purpose of this review, we clarify our terminology
in Table 1.
Outcomes can reflect various effects of an intervention.
They may directly measure a definitive clinical change, such
as death or hospital admission. Surrogate outcomes, which
are sometimes used in lieu of a definitive clinical outcome,
aim to capture the effects of an intervention without having
to wait for the clinical change to actually occur. In other
words, they are proximal to the clinical outcome on the
disease pathway, so a change can be detected sooner. They
may be a measure of intermediate health status, which may be
used to predict future health status; for example, glycosylated
haemoglobin is used as a measure of current disease control
in patients with diabetes mellitus, and has been shown to be a
useful predictor of future control [3]. A surrogate outcome
may even be an assumed or established risk factor that
actually impacts on disease progression; for example, neo-
natal intraventricular haemorrhage, which is a recognised
complication of prematurity, is thought to alter brain
development in the early stages of life and predispose babies
to developmental problems in childhood. There are valida-
tion criteria that should be fulfilled before a surrogate
outcome can be confidently used in place of a definitive
clinical outcome in clinical trials [4].
An outcome domain may be represented by a variety of
outcomes. The domain of health care utilisation, for example,
may be reflected by number of visits to a general practitioner,
number of hospital admissions, or days spent in hospital.
Conversely, outcomes may be relevant to more than one
domain. For example, in clinical trials of children with
asthma, the outcome ‘‘number of courses of rescue predni-
solone therapy’’ may be a measure of health care utilisation,
or could alternatively represent change in the domain
‘‘exacerbations.’’ These various ‘‘levels’’ of outcome measure-
ment are illustrated schematically in Figure 1.
Selecting Outcomes for Use in Clinical Trials
Clinical trials are ‘‘only as credible as their outcomes’’ [5],
so when designing a clinical trial, the decision as to which
outcomes should be measured is crucial. The selection of
inappropriate outcomes can lead to wasted resources or
misleading information that overestimates, underestimates,
or completely misses the potential benefits of an interven-
Table 1. Definitions Used in Review
Terminology Description Examples
Outcome domain A relatively broad aspect of the effect of illness on a child,
within which an improvement may occur in response to
an intervention. In general these domains may not be directly
measurable themselves, so outcomes are selected to assess
change within them.
(1) In clinical trials of children with diabetes,
outcome domains may include acute metabolic
complications, long-term glucose control, renal
damage, or effects on schooling.
(2) In clinical trials of children with asthma, outcome
domains may include lung function, health care
utilisation, and symptom control
Outcome/endpoint A measurable variable within an outcome domain. The outcome
can be measured at a variety of time points, which must be clearly
stated by authors of clinical trials.
(1) Absolute FEV1 expressed as change from baseline
(2) Number of admissions to hospital within a six month period
(3) Time to first seizure after starting an antiepileptic intervention
Composite outcome An outcome that encompasses more than one domain. A
composite outcome may span more than one outcome domain.
These are sometimes referred to as global outcomes, because they
theoretically measure several aspects of the impact of illness on a patient.
In the NIMH Collaborative Multisite Multimodal Treatment Study
of Children with Attention Deficit/Hyperactivity Disorder, response
to treatment was measured by a composite outcome comprising
outcomes that reflect clinical outcome, academic functioning,
effects on family life, and other domains [37]
Outcome measure A scale, scoring system, questionnaire, or other tool used for
measuring an outcome. They may be an amalgamation of more than
one outcome within an outcome domain, such as a score based on
a variety of symptoms. More than one outcome measure may be
possible to use to represent change in an outcome.
(1) The Paediatric Asthma Quality of Life Questionnaire [38]
(2) Childhood Health Assessment Questionnaire [39]
(3) Gastro-esophageal Reflux Disease Symptom Questionnaire [40]
doi:10.1371/journal.pmed.0050096.t001
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tion. Examples of these problems are well documented [6,7].
Investigators can select from a range of several potential
outcomes spanning different domains when they are design-
ing a clinical trial, however, and the process of determining
which outcome to use can be complex. The difficulty of
selecting the most appropriate outcomes for use in a clinical
trial is reflected in the fact that in several fields of clinical
research there is much heterogeneity between clinical trials
of specific diseases regarding exactly which outcomes to
select [8,9]. Some of the factors underlying this uncertainty
may be that for these conditions there is uncertainty about
which outcome domains are most relevant to patients, that
the performance characteristics of potential outcomes have
not been established, or that as the general care of patients
has improved, previously used outcomes are no longer
relevant.
Since the late 1980s there have been attempts, notably in the
field of rheumatology (Outcome Measures in Rheumatology,
http://www.omeract.org/), to develop ‘‘core sets’’ of outcomes
that should be measured in all clinical trials of specific
conditions. These studies generally use techniques to ascertain
a consensus opinion from clinical experts as to which
outcomes are most suitable for use in clinical trials. The three
commonly used consensus techniques are nominal group
technique (NGT), which entails structured face-to-face dis-
cussion with the aim of developing a solution to a specific
problem, followed by a vote on the issue; Delphi technique, in
which opinions are sought from individuals and the collated
results are fed back to the group as a whole, to generate further
discussion and finally reach an agreement; and semistructured
discussion based around broader discussion points.
The objective of this project was to systematically review
studies that address the process of selecting which outcome
domains or outcomes to measure in clinical trials in children
under 16 years of age. We have restricted this review to
studies in children for the following reasons. In clinical
research there is increasing recognition that children are not
merely ‘‘small adults,’’ and the methodology of conducting
research in a paediatric population should be tailored
accordingly. We anticipate that one way of determining
which outcomes to use, in addition to the consensus
techniques described above, may be to ascertain the opinions
of both children and their parents regarding what they think
are important aspects of their disease. This process poses
unique challenges that may not be relevant when conducting
similar research in adults with a particular condition, so it is
appropriate to specifically review studies pertaining to
outcome domain and outcome selection in clinical trials in
children.
Methods
Study Selection
Included studies. We decided that the following types of
studies would be eligible for inclusion in the review: (1)
Studies that develop or apply methodology for selecting
outcome domains or outcomes to be used in clinical trials in
children younger than 16 years of age, and (2) systematic
reviews of these articles.
Excluded studies. We excluded the following types of
studies. (1) Studies that do not specifically state that the
outcomes are appropriate for use in a paediatric population.
(2) Studies that discuss how to measure, rather than how to
select, an outcome domain or outcome for use in clinical
trials. This category includes studies discussing performance
characteristics of outcomes or instruments for measuring
them. (3) Studies relating to clinical trials that assess
interventions given to adults by measuring outcomes in
children, for example the selection of neonatal outcomes to
assess care given to their mothers.
Identification of Studies
In December 2006 we searched Cochrane databases (no
date restrictions), and in January 2007 we searched MEDLINE
(1950 to 2006; http://www.ovid.com/site/catalog/DataBase/901.
jsp?top¼2&mid¼3&bottom¼7&subsection¼10), CINAHL (1982
to 2006; http://www.cinahl.com/), and SCOPUS (1966 to 2006;
http://www.scopus.com/). SCOPUS is a platform that enables
the searching of several databases, including EMBASE,
simultaneously. We used the following abbreviated search
strategy: ‘‘Clinical trials’’ AND ‘‘Outcomes’’ AND ‘‘Children’’
AND ‘‘methodology’’. Details of the full search strategy are
included in Table S1.
The abstracts produced by the searches were initially
screened twice by one reviewer. The full texts of all
potentially relevant articles were obtained, and these were
assessed with regard to the eligibility criteria. Data were
extracted from the studies that met all the eligibility criteria.
A second reviewer, who was blinded to the first reviewer’s
assessment of the abstracts, independently screened a data-
base of abstracts that comprised all the abstracts for which the
first reviewer obtained full text, plus a selection of abstracts
rejected at the initial screening stage by the first reviewer. The
purpose of this approach was to check the sensitivity of the
initial screening process that had been performed in full by
the first reviewer. A sample, rather than the complete set, was
selected due to resource constraints. Any disagreements
between the reviewers were resolved by discussion.
This process led to a list of studies for which full text were
obtained. Both reviewers then scrutinised these articles for
the predetermined inclusion and exclusion criteria in order
to determine which studies should be included in the
systematic review.
We then emailed a list of the studies we had identified to
the Clinical Study Group (CSG) members of the Medicines for
Children Research Network (MCRN) and asked if they knew
of any other relevant studies, published or unpublished, that
should be included. The CSG constitutes a multidisciplinary
group of clinical experts with a strong interest in the
planning of clinical trials within their specialities.
Data Extraction
The following data were extracted by one reviewer (IS) and
checked independently by the second reviewer (LJ): (1)
Figure 1. Levels of Outcome Measurement
doi:10.1371/journal.pmed.0050096.g001
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Condition for which the outcome domains or outcomes are
discussed; (2) Description of the method; (3) People involved
in selecting outcome domains or outcomes; (4) Outcome
domains or outcomes selected; (5) The geographical setting of
the collaborations, ascertained either by reading the text or,
where listed, the names and institutions of people involved in
the collaborations; (6) Limitations of the method as defined
by the authors
Assessment of Methodological Quality
The methodological quality of the studies was assessed by
one author (IS). If a study developed or used methodology to
select an outcome domain or an outcome, the article was
assessed in terms of whether the method was described in
sufficient detail to allow a reader to utilise it.
If a study described a consensus procedure, the following
points were noted: (1) Is the selection process and areas of
expertise of the participants described?; (2) Is the process of
coming to consensus described in detail?
We searched for a validated assessment tool for critically
appraising consensus statements but we could not identify
one. We therefore asked two experts, one with experience of
qualitative research and the other with experience of
participating in a consensus statement exercise to advise on
this methodological assessment checklist.
For systematic reviews of studies which used methodology
for selecting outcomes it was agreed that we would use the
Critical Appraisal Skills Programme Systematic Review
Appraisal tool for assessing their methodological quality
(http://www.phru.nhs.uk/Pages/PHD/resources.htm).
Data Analysis and Presentation of Results
For synthesis of data we described the studies narratively
and tabulated their characteristics. Consistent with the
nature of the data, the results are presented in textual format.
Results
Description of Studies
The initial database search identified 8,889 potentially
relevant abstracts, of which 70 articles were retrieved in full
and, finally, 25 included in the full review, as depicted by the
flowchart in Figure 2.
In total, 57 full-text articles were reviewed and subse-
quently excluded. Of the 57 studies 19 were excluded because
the authors did not use methodology for selecting outcomes
(e.g., a review article based on personal opinion), 18 because
the study related to how to measure outcomes rather than
which ones to select, ten because the study made no mention
of outcome selection, six because the study did not
specifically state that the outcomes which were selected were
relevant to children, and four that described consensus
statements relating to clinical practice rather than clinical
trial design. The reasons for exclusion of each individual
study are presented in Table S2.
In addition, 13 specific articles were suggested by the
members of the MCRN CSGs in response to our email query.
One of these articles summarised the work of a collaboration
that had been identified by the literature search but did not
describe the methodology used by the group in sufficient
detail to warrant inclusion in the full review, so is added as an
additional reference [10]. The other studies identified were
not deemed to be eligible for the full review.
Agreement between Reviewers
The second reviewer was provided with a database of 100
abstracts. These included 70 for which the first reviewer
thought full text should be retrieved, and a randomly selected
sample of 30 abstracts that had been excluded by the first
reviewer at the abstract screening stage.
The second reviewer agreed that all 30 abstracts rejected at
the abstract screening stage were appropriately excluded by
the first reviewer.
Of the 70 abstracts for which full text was obtained by the
first reviewer, the second reviewer agreed with 61, and
disagreed with nine. After discussion it was agreed that all
nine should be retrieved in full based on the abstract. Of
these, eight were excluded after reading the full text and one
was included.
Following full text review there was complete agreement
between the second and first reviewer about the 25 included
and 45 excluded abstracts. The second reviewer also checked
all the data that had been extracted by the first reviewer, and
agreed completely with the tabulated characteristics of the
studies.
Included Studies
The 25 articles included in the full review represented the
work of 13 collaborative groups. The characteristics of each
study are included in Table S3, and summarised in Table 2.
Six of these groups (Griffiths et al. [11], Ramsey et al. [12],
Pavletic et al. [13], Giannini et al. [14], International Myositis
Assessment and Clinical Studies group (IMACS) [15], and
Paediatric Rheumatology International Trials Organisation
(PRINTO) [16]) aimed to develop a consensus statement
specifically about outcome measures that should be used in
clinical trials of certain medical conditions. Five groups
(Carlson et al. [17], Goldstein et al. [18], LaFrance et al. [19],
Neonatal Drug Development Initiative (NDDI) [20–24], and
West Delphi group [25]) discussed which outcomes to
measure as part of workshops which addressed wider clinical
trial design issues. One group (Smith et al. [26]) aimed to
ascertain the opinions of clinical experts about which
Figure 2. Study Flowchart
doi:10.1371/journal.pmed.0050096.g002
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outcomes to measure in clinical trials in children with
asthma. One group (DeRouen et al. [27]) ascertained the
opinions of experts about which outcome to measure in a
specific safety trial of two interventions used in paediatric
dental restoration. Our search identified no systematic
reviews of studies that had selected outcome measures for
use in clinical trials.
Most groups appeared to comprise an international
collaboration of participants. Eight groups were based in
the US (Ramsey et al. [12], Goldstein et al. [18], La France et al.
[19], the NDDI [20–24], Carlson et al. [17], Griffiths et al. [11],
DeRouen et al. [27], and Pavletic et al. [13]). One group was
based in Europe (West Delphi group [25]). One group was
based in Australasia (Smith et al. [26]). The three rheumatol-
ogy collaborations [14–16] seem to have been based mainly in
the US, but it appears that many of the leaders of these
groups were based in Europe.
Methodological Quality of Studies
General observations regarding the methodological quality
of the studies are provided in this section. Methodological
features of each specific study are provided in Table S4.
Reporting of methodology. Of the 13 collaborations four
used structured techniques to formulate a consensus (Gian-
nini et al. [14], West Delphi group [25], PRINTO [16], and
IMACS [15]); these were NGT and/or Delphi technique. Of
these groups, three described the process very clearly. Eight
collaborations came to a consensus by structured discussion,
but without using structured consensus formulation techni-
ques mentioned above (Goldstein et al. [18], Ramsey et al. [12],
LaFrance et al. [19], NDDI [20–24], Carlson et al. [17], Griffiths
et al. [11], De Rouen et al. [27], and Pavletic et al. [13]). All of
these groups described the discussions in some detail. One
group sought opinions in a questionnaire-based survey, and
the methodology used for this study was described in
sufficient detail to be able to repeat the study (Smith et al.
[26]).
Selection of participants. All groups described the back-
ground of their participants. Only two of these groups
described in detail the process by which it was decided
specifically which individuals would be involved (West Delphi
group [25] and Smith et al. [26]).
Methods Used to Select Outcomes
The following techniques were used to ascertain expert
opinion concerning which outcomes ought to be measured in
clinical trials of children with specific conditions.
Delphi technique. As described earlier, Delphi technique is
one method of reaching a consensus opinion that relies on
one person collating the views of each individual in a group,
collating the results, and feeding these back to the whole
group [28]. Statements made by participants at each stage of
the process can be used to formulate the next round of
questions. This technique has been used since the 1950s.
Three groups utilised this method as follows.
The West Delphi group [25] used this technique to develop
a core set of outcomes for use in clinical trials of children
suffering from infantile spasms. The whole process was
conducted by email over six rounds. In round one a group
of 133 invited participants, of which 42 responded, were
asked multiple-choice questions covering various aspects of
clinical trial design, including outcomes. In round two a
separate set of multiple-choice questions was provided,
having fed the results of round one back to the group. At
this stage the participants were also invited to comment and
provide their personal opinions regarding outcomes. In
round three statements were formulated from those re-
sponses in rounds one and two that had represented majority
opinion. Participants were invited to respond as to whether
they agreed or disagreed with these statements. For round
four the statements were modified, and participants com-
Table 2. Summary of Included Studies
Speciality Condition Authors
Critical care Sepsis Goldstein 2005 [18]
Dentistry Dental restoration DeRouen 2002 [27]a
Gastroenterology Crohn disease Griffiths 2005 [11]
Haematology/bone transplant medicine GVHD Pavletic 2006 [13]
Neonatology Apnoea Finer 2006 [22]b,c
Cardiac instability Short 2006 [24]b,c
Pain Anand 2005 [41], Anand 2006 [20]b,c
Postoperative cardiac dysfunction Roth 2006 [23]b,c
Seizures Clancy 2006 [21]b,c
Neurology Infantile spasms Lux 2004 [25], Osborne (on behalf of the West Delphi group) 2001 [42]
Psychiatry Bipolar affective disorder Carlson 2003 [17]
Nonepileptic seizures La France 2006 [19]b
Respiratory medicine Asthma Smith 1996 [26]
Cystic fibrosis Ramsey 1994 [12]
Rheumatology IIM Miller 2001 [15], Rider 2002 [43], Rider 2003 [33], Rider (on behalf of IMACS) 2004
[44], Oddis 2005 (describing the work of IMACS) [45]
SLE Ruperto 2003 [16], Ruperto 2004 [30], Ruperto (on behalf of PRINTO) 2006 [46]
Rheumatoid arthritis Giannini 1997 [14]
aConcerned the selection of outcomes for use in a specific clinical trial.
bConcerned the selection of outcomes which could be used in clinical trials of children with clinical features of an underlying condition.
cCollaboration working on behalf of the Neonatal Drug Development Initiative (NDDI).
doi:10.1371/journal.pmed.0050096.t002
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mented on their suitability and content. Rounds five and six
consisted of formulation of a draft and, subsequently, a final
paper that were altered following comments from the group.
The IMACS [15] group used a Delphi technique to develop
a core set of outcome domains and outcomes for use in
clinical trials in children with inflammatory myopathy. The
actual process itself is not described in detail in the article,
but authors stated that the group consisted of ‘‘more than
100’’ members.
The PRINTO [16] group used a Delphi technique over two
sequential questionnaire-based surveys to identify which
variables should be measured in clinical trials of children
with SLE. In the first questionnaire they asked 267 partic-
ipants to indicate up to ten variables they judged as clinically
most important. In the second questionnaire, the facilitators
listed those indicators that had been suggested by at least ten
responders, and asked the participants to rank in order their
top ten choices.
Nominal group technique. NGT is a technique based on
structured face-to-face discussion developed in the early
1970s. Having discussed a problem, with a view to providing
potential solutions, the participants vote on the options
presented, and ultimately a consensus is reached [29]. Two
groups utilised this technique.
PRINTO [16] used NGT to discuss specific issues regarding
the potential outcomes identified by the initial Delphi
technique discussions described earlier. The NGT exercise
had five objectives, which were tackled by a group of 40
participants: (1) to classify the proposed outcomes into
‘‘domains’’; (2) to classify the outcomes into ‘‘concepts of
disease activity’’; (3) to select the outcome domains that
should be measured in clinical trials; (4) to select the
outcomes that should be used to measure these domains;
and (5) to discuss specific design issues of the prospective
validation phase of the study.
Giannini et al. [14] used NGT to select from a set of
potential outcomes a preliminary core set of six. The process
used is not described in further detail in the study. The initial
list of potential outcomes had been identified by sending a
questionnaire to a 16-member advisory council.
Semistructured discussion. Most groups did not use
structured techniques of consensus development such as
Delphi or NGT, but rather came to consensus by discussion at
meetings or workshops. As mentioned earlier, some collab-
orations—for example those groups discussing methodology
issues in studies of neonates—discussed outcome selection
broadly, as part of wider discussions about neonatal clinical
trial designs. Other groups—for example, the group selecting
outcome measures for use in an individual clinical trial of
dental restoration—conducted very focussed discussions
about very specific problems.
Questionnaires. Smith et al. [26] sent questionnaires to 39
health care professionals and researchers with expertise in
asthma to ask which outcomes they would use for a variety of
clinical, research, and public health scenarios, including
questions about which outcome they would use in clinical
trials of acute and preventative asthma medication. Three
groups (Giannini et al. [14], West Delphi [25], and PRINTO
[16]) used questionnaires as part of the process of ascertain-
ing the opinions of experts, mainly in the preliminary phases
of the consensus process.
People Involved in Selecting Outcomes
Clinical experts. All 13 groups included people with clinical
expertise in the fields for which they were selecting outcomes.
Eight groups specifically mention the involvement of clini-
cians in both paediatric and adult health care.
Research experts. All groups appeared to include members
who were experienced in research in the clinical condition
for which outcomes were being selected. In addition to these
clinical research experts, some groups also included bio-
statisticians and epidemiologists. Three groups involved
experts from other clinical research areas who had experi-
ence in collaborations that had selected outcomes for clinical
trials of other medical conditions. More collaborations may
have used experts from this category, but may have referred
to them generically as ‘‘research experts,’’ so it is difficult to
quantify exactly how many groups used this approach.
Patients or parents. Three groups ascertained the opinions
of parents of children with medical conditions as to which
outcomes they thought should be measured, but no group
involved children directly. IMACS [15] involved two patient
support group leaders who had a child who suffered from
inflammatory myopathy. Although this was not explicitly
stated in the text, we elicited this information by searching
for the names of the support group leaders on an internet
search engine. Carlson et al. [17] also involved ‘‘representa-
tives of families with affected children’’ in their discussions
about outcomes in clinical trials of children with bipolar
affective disorder. Pavletic et al. [13], at the end of their
report, acknowledge ‘‘patients and patient and research
advocacy groups.’’ The level of involvement of these people
was not described in detail in any of these articles.
Industry and drug regulatory authority representatives.
Three groups (Carlson et al. [17], Ramsey et al. [12], and the
NDDI [20–24]) specifically mention that representatives from
industry or the Food and Drug Administration (FDA) were
present. The NDDI is described as a collaboration between
the FDA and ‘‘neonatal experts and colleagues, representing
industry and academia’’ [10]. Carlson describes invited
participants in the group selecting outcomes for clinical
trials of children with bipolar disorder as including ‘‘phar-
maceutical industry sponsors with an interest in mood
stabilizer products, staff of the FDA and their counterparts
from regulatory agencies in Canada and the European
Union’’ [17]. The Cystic Fibrosis Foundation sponsored a
consensus conference that also included ‘‘representatives
from both the Cystic Fibrosis Foundation and the U.S. Food
and Drug Administration’’ [12].
Techniques Used to Validate Outcomes
Three groups made some attempt to validate the outcomes
they had selected.
Giannini et al. [14] assessed the multicollinearity and
redundancy of a core set of outcomes for use in clinical
trials of children with rheumatoid arthritis by measuring
them in a group of children in a clinical practice setting, and
using a database from a previous observational cohort study.
The acceptability of the core set of outcomes to a wider group
of clinicians was assessed by sending a questionnaire to an
international selection of rheumatologists seeking their
reactions to the outcomes.
The IMACS group retrospectively assessed the validity,
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reliability, and responsiveness of the outcomes they had
selected by reviewing available literature on the topic [15].
The PRINTO group prospectively validated the core set of
outcomes they had produced for clinical trials of children with
SLE [30]. This was done bymeasuring the outcomes in patients
in a clinical out patients setting who were being started on
new modalities of treatment for their condition. In this way
the authors aimed to ‘‘mirror’’ a clinical trial setting. The
feasibility, discriminative ability, validity, and internal con-
sistency of the core set of outcomes were assessed in this way.
All three of these groups also developed ‘‘definitions of
improvement,’’ based on the degree of change within each
outcome, which could be used as a dichotomous index in
clinical trials to determine whether patients had benefited
from the treatment they had received. This was done in all
cases by developing a set of ‘‘paper patient profiles,’’ and
asking a group of experts whether or not they thought the
patient had improved. A set of potential definitions of
improvement was then narrowed down to a final definition by
way of consensus formation techniques.
Which Outcomes Were Selected by the Groups?
In Table S5 we summarise the outcomes that were selected
by each group, categorised into the following outcome
domains: disease activity; disease complications; adverse
effects of therapy; functional status; social outcomes, family
outcomes and Quality of Life; resource utilisation.
Discussion
To our knowledge this is the first systematic review of
studies that addressed selection of outcomes for use in
clinical trials in children.
We identified 13 groups formed to address the issue of
selecting outcomes for use in paediatric clinical trials. Certain
groups—notably, those who have selected outcomes for
clinical trials of children with rheumatological conditions—
have specifically highlighted that it is inappropriate simply to
use the outcomes utilised in adult clinical trials in a
paediatric population.
We identified three methods used for reaching consensus,
namely NGT, Delphi technique, and semistructured discus-
sion. Many groups used a multidisciplinary approach to the
problem of outcome selection, including researchers with
experience of clinical trial design, statisticians, and clinicians.
Some groups also involved representatives from industry or
drug regulatory authorities, but the nature of their involve-
ment is not evident from reading the reports.
No group among the studies we reviewed directly involved
children in the process of selecting outcomes. As the aim of
clinical trials should be to determine whether patients
experience important benefits from an intervention, it was
notable that we did not identify any studies that had directly
asked children what they considered to be the most relevant
outcome domains or outcomes. In the United Kingdom steps
are being taken to involve consumers in medical research. A
major initiative is the James Lind Alliance (http://www.
lindalliance.org/), a collaboration with the aim of ascertaining
from patients what they think are the most pressing research
priorities for various conditions. Determining appropriate
outcomes for paediatric studies is thus another area in which
consumer involvement in clinical trial design should be
encouraged. The difficulties of undertaking this task, how-
ever, should not be underestimated [31].
Robustness and Limitations of the Review
Our review was conducted in a rigorous, systematic
manner. Two reviewers adhered to strict eligibility criteria
to determine which studies should be included. Although the
sample of excluded papers checked by the second reviewer
represented a small proportion of all the ineligible studies, we
concluded that agreement between the reviewers was
adequate. We determined that a smaller proportion of
excluded studies would be sufficient for quality assurance as
compared to a review in which we were meta-analysing the
results of clinical trials; possible missed studies were
considered an acceptable tradeoff.
There were recurring features of the methodology and
reporting quality of the consensus statements that may have
compromised the scientific validity of the studies we
identified. Most studies that described formation of a
consensus statement did not explain in sufficient detail two
key aspects of the process—namely, the method used to select
group participants, and the process by which consensus was
reached. Insufficient information was given to determine the
level of involvement of certain groups involved in the
research, particularly industry representatives, drug regula-
tory authority representatives, and parents of affected
children.
Although the 8,889 abstracts identified were screened
twice, it may be possible that some relevant studies were
missed. The types of studies that may not have been identified
at this stage include clinical trials that did not describe in the
abstract how the authors selected their outcomes, but
subsequently in the full text may have mentioned the process
used. It is also possible that some studies may have been
missed by not searching the ‘‘grey’’ literature such as
unpublished conference proceedings.
We excluded studies that did not state specifically that they
selected outcomes for use specifically in clinical trials in
children. Our reason for this exclusion was that such studies
should involve patients themselves, and the unique challenges
of doing this in children warrants the separation of adult and
paediatric studies. Another group of studies excluded were
those concerned with the development of assessment tools
for outcomes such as quality of life. Although this work is
crucial for designing valid assessment tools, and will to some
degree ascertain from children how illness affects their life,
these studies focussed on how to measure an outcome rather
than what outcome to measure.
Another set of studies outside the scope of this review were
those relating to the selection of outcomes that are measured
in newborns as a surrogate measure of maternity care given
to women. For example, one way of evaluating the efficacy of
antenatal care is to measure outcomes in babies such as rates
of neonatal infection [32]. Similarly, studies in which out-
comes were selected that evaluate the effect of interventions
given to children by measuring effects on the family were not
systematically sought. We did, however, identify two studies in
which such outcomes were selected [19,33].
Core Outcomes
If implemented, the studies we have identified should
reduce the impact of inappropriate outcome selection on the
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quality of the evidence provided by individual clinical trials.
The development of a universally agreed core set of outcomes
for a condition could, as well as improving the quality of
individual clinical trials, lead to less heterogeneity between
trials. One problem associated with nonuniform reporting of
outcomes is outcome reporting bias, a phenomenon that
results from the selective reporting of some outcomes but not
others, depending on the results [34,35].
One cause of outcome reporting bias may be that statisti-
cally insignificant results are more likely to be left out of the
report, so outcomes at the planning stage of a trial that might
otherwise have been deemed clinically relevant are deemed
‘‘irrelevant’’ after data analysis, rendering the published
literature a biased and selective representation of the
research [36]. Disease-specific, universally agreed core sets of
outcomes that should be measured and reported in all clinical
trials of a specific condition, regardless of statistical signifi-
cance, have been advocated as a solution to this common
problem [35]. Uniform selection of outcomes would also make
interpretation of results and comparison across trials simpler,
hence making meta-analyses easier and more powerful [9].
European Drug Regulation
It is increasingly recognised that there is a need for high-
quality paediatric clinical trials, and the development of
Paediatric Investigation Plans (PIPs) is one of the changes in
drug regulation in Europe that should facilitate this goal. The
PIP is a detailed outline of the research, submitted to the
European Medicines Agency (EMEA), that would be needed to
investigate the potential benefits and harms of medications for
use in children. If a drug company were to be involved in the
writing and implementation of a PIP, they would be eligible
for marketing rewards in the form of prolonged patent
protection and market exclusivity. When a PIP is submitted,
the endpoints selected for the trial must be clearly stated and
their appropriateness described (http://www.emea.europa.eu/
htms/human/paediatrics/pips.htm). The studies we have iden-
tified that suggest to trialists which outcomes to measure
should be of use to people designing a PIP, and it is possible
that the types of studies we have identified may become more
popular as drug companies seek to take advantage of the
benefits of conducting high-quality clinical trials.
The new standards for conducting clinical trials of
investigational medicinal products set by the EMEA aim to
improve the quality of paediatric research. In order to obtain
a license for a drug, it must be investigated according to these
guidelines http:/ /www.emea.europa.eu/htms/human/
humanguidelines/efficacy.htm). In July 2007, of the 13
paediatric conditions identified in this review the EMEA
Web site included guidelines for one (juvenile idiopathic
arthritis) and a concept paper discussing the need for
guidelines for another (cystic fibrosis).
The Selection of Outcomes for Use in Children
It is appropriate that some aspects of study design in
clinical trials in children differ from equivalent studies
performed in adults, and selection of outcomes is one such
issue that trialists should consider. In certain situations
outcome selection may be similar between the two groups,
and some outcomes could be appropriately transposed from
adult studies into trials in paediatric populations either in
their original state or with slight modification. The danger,
however, of not acknowledging the differences between
children and adults with the same disease is that the overall
validity of trial results could be compromised. Griffiths et al.
[11], when discussing which outcomes to measure in clinical
trials of children with Crohn disease, highlight that the
importance of linear growth is ‘‘unique to pediatric patients.’’
Another example of an outcome exclusive to children is the
assessment of neurodevelopment. Other differences between
adults and children that may preclude the use of the same
outcomes for both groups include distinct disease patho-
genesis, different clinical features and natural history,
variations in physiological and psychological outcomes, and
contrasting roles within the contexts of families and society
in general that may preclude the use of the same outcomes.
Unanswered Questions
The best strategy for selecting outcomes for clinical trials
in children is currently not known, and future research in this
area is warranted. One important question relates to the
involvement of children and parents in the formulation of
consensus statements. It seems logical that their involvement
would help determine the most appropriate outcomes to
measure, but there is no evidence to substantiate this
hypothesis, nor is there a framework that could recommend
the best strategy for involvement. Another area for research
is the investigation of the relative strengths and weaknesses of
the consensus formation techniques identified here when
applied to the problem of selecting outcomes for paediatric
studies.
In summary, we have reviewed studies that address the
process of selecting outcomes for clinical trials in children.
Although it is commendable that there are existing collabo-
rations in several clinical areas, future work in this area may
be improved by involving children and parents in the process.
The studies identified by this review will go some way to
improving the quality of paediatric research, but further
research is justified and urgently needed.
Conclusions
Implications for the practice of designing clinical trials. We
identified 13 paediatric conditions for which work has been
done to determine which outcomes should be measured in
clinical trials. When designing clinical trials in these
conditions, this work should make the selection of outcomes
easier and more uniform.
Implications for research. Although some work on how to
select outcomes in paediatric trials has been published in a
few clinical areas, there is a need for similar work to be
conducted in other areas. Very little work has been done that
involves parents or children in assessing which outcomes
should be measured in clinical trials; future research should
be undertaken to address this deficiency.
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Editors’ Summary
Background. When adult patients are given a drug for a disease by their
doctors, they can be sure that its benefits and harms will have been
carefully studied in clinical trials. Clinical researchers will have asked how
well the drug does when compared to other drugs by giving groups of
patients the various treatments and determining several ‘‘outcomes.’’
These are measurements carefully chosen in advance by clinical experts
that ensure that trials provide as much information as possible about
how effectively a drug deals with a specific disease and whether it has
any other effects on patients’ health and daily life. The situation is very
different, however, for pediatric (child) patients. About three-quarters of
the drugs given to children are ‘‘off-label’’—they have not been
specifically tested in children. The assumption used to be that children
are just small people who can safely take drugs tested in adults provided
the dose is scaled down. However, it is now known that children’s bodies
handle many drugs differently from adult bodies and that a safe dose for
an adult can sometimes kill a child even after scaling down for body size.
Consequently, regulatory bodies in the US, Europe, and elsewhere now
require clinical trials to be done in children and drugs for pediatric use to
be specifically licensed.
Why Was This Study Done? Because children are not small adults, the
methodology used to design trials involving children needs to be
adapted from that used to design trials in adult patients. In particular,
the process of selecting the outcomes to include in pediatric trials needs
to take into account the differences between adults and children. For
example, because children’s brains are still developing, it may be
important to include outcome measures that will detect any effect that
drugs have on intellectual development. In this study, therefore, the
researchers undertook a systematic review of the medical literature to
discover how much is known about the best way to select outcomes in
clinical trials in children.
What Did the Researchers Do and Find? The researchers used a
predefined search strategy to identify all the studies published since
1950 that examined the selection of outcomes in clinical trials in children.
They also asked experts in pediatric clinical research for details of
relevant studies. Only 25 studies, which covered several pediatric
specialties and were published by 13 collaborative groups, met the
strict eligibility criteria laid down by the researchers for their systematic
review. Several approaches previously used to choose outcomes in
clinical trials in adults were used in these studies to select outcomes. Two
groups used the ‘‘Delphi’’ technique, in which opinions are sought from
individuals, collated, and fed back to the individuals to generate
discussion and a final, consensus agreement. One group used the
‘‘nominal group technique,’’ which involves the use of structured face-
to-face discussions to develop a solution to a problem followed by a
vote. Another group used both methods. The remaining groups (except
one that used a questionnaire) used semistructured discussion meetings
or workshops to decide on outcomes. Although most of the groups
included clinical experts, people doing research on the specific clinical
condition under investigation, and industry representatives, only three
groups asked parents about which outcomes should be included in the
trials, and none asked children directly.
What Do These Findings Mean? These findings indicate that very few
studies have addressed the selection of appropriate outcomes for clinical
research in children. Indeed, in many pediatric specialties no research has
been done on this important topic. Importantly, some of the studies
included in this systematic review clearly show that it is inappropriate to
use the outcomes used in adult clinical trials in pediatric populations.
Overall, although the studies identified in this review provide some
useful information on the selection of outcomes in clinical trials in
children, further research is urgently needed to ensure that this process
is made easier and more uniform. In particular, much more research must
be done to determine the best way to involve children and their parents
in the selection of outcomes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050096.
! A related PLoS Medicine Perspective article is available
! The European Medicines Agency provides information about the
regulation of medicines for children in Europe
! The US Food and Drug Administration Office of Pediatric Therapeutics
provides similar information for the US
! The UK Medicines and Healthcare products Regulatory Agency also
provides information on why medicines need to be tested in children
! The UK Medicines for Children Research Network aims to facilitate the
conduct of clinical trials of medicines for children
! The James Lind Alliance has been established in the UK to increase
patient involvement in medical research issues such as outcome
selection in clinical trials
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e960578
Selecting Outcomes for Paediatric Trials
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Abstract
Background: Little work has been done to determine which outcomes should be measured in randomised controlled trials
(RCTs) in children with asthma. Drug regulatory authorities require that short term disease activity is measured, but other
outcome domains are not mandatory for licensing and marketing purposes. We aimed to identify whether any domains
were underrepresented in RCTs of regular therapies for children with asthma over a 20 year period, and to examine what
consistency there was between RCTs in the outcomes used to assess the domains.
Methodology/Principal Findings: By searching the Cochrane Central Register of Controlled Trials in January 2008, we
identified all parallel-group RCTs, published between January 1988 and December 2007, which assessed inhaled
corticosteroids (ICS) as regular therapy for children with asthma. We evaluated how frequently RCTs measured the following
pre-defined domains: disease activity; disease damage; functional status; quality of life; health resource utilisation; and
adverse effects of therapy. Our initial search identified 1668 abstracts, of which 412 were retrieved in full. 159 RCTs, of which
115 involved only children and 44 involved children and adults, were included in the review. Disease activity was measured
in 157 RCTs, adverse effects of ICS in 135, functional status in 25, quality of life in 21, and health resource utilisation in 17. No
RCT measured long term disease damage, although two used FEV1 as a measure of ‘lung growth’. RCTs were inconsistent in
the outcomes used to measure the domains.
Conclusions: Short term disease activity is the most frequently measured outcome domain in RCTs in children with asthma.
Effects of regular therapies on functional status, quality of life, and long term consequences of asthma are infrequently
assessed. A core set of outcomes, developed using consensus techniques, would standardise the measurement of
appropriate outcomes in these RCTs. Involving patients would identify outcomes which are most relevant from their
perspective.
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Introduction
Asthma in children is a major global health problem [1],
because it is an important cause of morbidity, mortality and
economic cost [2], it is the commonest chronic condition in
industrialised countries [3], its prevalence is increasing [4], and in
many children it is a progressive condition that continues into
adulthood [5].
The first line of regular therapy for the control of asthma in
children is inhaled corticosteroids (ICS), and recommended
additional treatments are long acting beta-2 agonists and
leukotriene receptor antagonists [6]. Randomised controlled trials
(RCTs) are the most scientifically rigorous method for evaluating
the efficacy and safety of these medications [7], but it can be
difficult to select the most appropriate outcomes to measure in
these studies, because asthma impacts on many aspects of the lives
of children. For example, the effects of treatment could include
improvement of daily symptoms, quality of life, or physiological
tests of lung function such as Forced Expiratory Volume in
1 second (FEV1) or Peak Expiratory Flow Rate (PEFR) [8].
We previously published a systematic review, of studies that
determined which outcomes should be measured in clinical trials
in children [9]. In this review, we proposed that outcomes
measured in RCTs that include children should be considered
under six domains: short term measures of disease activity,
physical consequence of disease, functional status, family outcomes
and quality of life, side effects of therapy and health resource
utilisation. We found one study that addressed the outcomes used
in clinical trials of regular therapies for childhood asthma, in which
the authors ascertained, by questionnaire, the opinions of 14
specialists and researchers about outcomes relating to disease
activity, functional status, and quality of life [10]. As this study
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consulted only a limited group of experts, and did not use
recognised consensus techniques, it does not provide a robust basis
for recommendations about which domains and outcomes are
most appropriate for RCTs of children with asthma.
There have been initiatives to standardise the outcomes which are
measured in clinical trials of other conditions. The most notable is the
OMERACT collaboration, an international network of clinicians
and patients, initially formed in response to the observation that
clinical trials of patients with rheumatoid arthritis conducted in the
USA measured different outcomes to those conducted in Europe.
OMERACT uses structured consensus techniques to determine
which outcomes should be measured in clinical trials in a variety of
rheumatological conditions [11–13]. Initiatives such as these increase
the likelihood that all important outcome domains are measured,
reduce the measurement of inappropriate outcomes [14], and aid
comparison and synthesis of findings between different clinical trials
[15,16]. It has also been suggested that arbitrary or inconsistent
outcome selection may lead to clinical trials with unnecessarily large
sample sizes [17] and reporting biases [17,18].
The aim of this systematic review was to assess which outcomes
had been measured in clinical trials of ICS in children with
chronic asthma between 1988 and 2007, in order to determine
whether all relevant domains were represented, and whether there
was consistent selection of outcomes within these domains.
Secondary objectives were to determine whether the selection of
outcome domains has changed between 1988 and 2007, whether
domains measured in RCTs exclusively involving children differ
from those in studies involving both children and adults, and
whether domains measured in publically funded trials differed
from those in trials funded by the pharmaceutical industry.
Methods
Included studies
In order to ensure that we assessed a group of similar studies, we
limited this review to include only RCTs with parallel group
design that assessed ICS as a therapy to prevent symptoms or long-
term effects of asthma in children. We excluded crossover trials
because they are generally of acute interventions, the length of
treatment in these studies is typically shorter, and the outcomes
they measure may differ from those measured in parallel trials
[19]. In order to only include RCTs assessing long term
preventative therapy for asthma, we excluded studies with a
treatment phase of less than one month. The review was restricted
to studies published between January 1988 and December 2007.
Identification of studies
Using the abbreviated search strategy ‘children AND inhaled
corticosteroids AND asthma’, the Cochrane Central Register of
Controlled Trials was searched in January 2008. This database
comprises RCTs from MEDLINE, and also from conference
proceedings and journals not indexed in MEDLINE. The
references of identified studies were also screened for other
potentially eligible studies. The full search strategy is included in
supplementary File S1. One reviewer (IS) assessed trial eligibility,
under the supervision of the senior authors (PRW and RLS).
Data extraction and quality assessment
The same reviewer extracted the following data, and any
problems were resolved by discussion with the other two authors:
1. All outcomes measured in the trial
2. If stated, the designated primary outcome, and whether this
was described in sufficient detail, including the methods used to
measure it, by whom, and when it was measured and analysed.
3. Masking of interventions was examined because the extent
to which interventions were masked may affect the choice of
outcomes, and whether they were measured objectively or
subjectively. The adequacy of masking was categorised as follows.
Adequately masked. Authors either clearly describe or
imply, in the methods, how the allocated treatment was masked
to the patient and family, medical caregiver, and relevant trial
personnel involved in measuring outcomes.
Inadequately masked. Authors specifically state that the
identity of the allocated treatment arm was not masked to at least
one of the following: patient and family, medical caregiver, or
relevant trial personnel involved in measuring outcomes.
Unclear. Unclear from study methods whether masking was
adequate or not.
4. Other study features: year of publication; interventions
compared; ages of children included; length of study treatment;
source of funding; single- or multi-centre
Data analysis and presentation
For each study that included exclusively children, the data were
tabulated and each outcome was grouped into one of the following
six outcome domains, some of which were further divided into
subdomains [9]: disease activity, physical consequence of disease,
functional status, social outcomes and quality of life, side effects of
therapy and health resource utilisation. Where it was unclear
which domain was appropriate, this was resolved by discussion
between the authors.
To assess how the selection of outcomes has changed over time,
we divided the period 1988 to 2007 into sixteen separate epochs,
each lasting five years. In each epoch we calculated the proportion
of studies measuring each outcome domain, and we presented the
results as a moving window.
Results
Flow of included studies
The search yielded 1668 potentially eligible reports. Of these,
1256 were excluded by reading the abstract. The remaining 412
were retrieved in full, and 203/412 were subsequently excluded.
In total, 209 eligible reports, of 159 RCTs, were included in the
review. The review flowchart is shown in Figure 1. Included
studies are listed in supplementary File S2.
Description of included studies
Of the 159 studies included in this review, 115 exclusively
included children, and 44 included children and adults.
The characteristics of included studies are summarised in
Table 1. Within the group of studies that included only children,
all paediatric age groups were represented, but only 25/115 (21%)
included children younger than four years of age. In the studies of
adults and children, 42/44 (95%) included children aged between
12 and 18 years of age, but not younger than 12, and 2/44 (5%)
included children between 5 and 18 years of age, but not younger
than 5.
83/159 (52%) included a comparison between ICS groups
(either different doses, modes of delivery, or different types of ICS
eg fluticasone vs beclomethasone), 63/159 (40%) included a
comparison with placebo, and 54/159 (34%) included a
comparison with another drug.
Masking of interventions was deemed adequate in 121/159
studies (76%), inadequate in 33/159 (21%), and unclear in 5/159
(3%). Of the 33 studies that were classed as inadequately masked,
18 compared ICS with another drug, 8 compared ICS
administered by different devices, 3 compared one ICS to another,
Childhood Asthma RCT Outcomes
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3 compared ICS administered using different dosing schedules,
and 1 compared ICS with no treatment. Subjective outcomes that
could have been affected by the lack of blinding were measured in
29/33 of these studies (29/33 measured symptoms, 8/33
measured quality of life and 6/33 measured functional status).
Outcome domains which were measured in the studies
Disease activity was measured in 157/159 (99%) studies,
adverse effects of therapy in 135/159 (85%), functional status in
25/159 (16%), quality of life in 21/159 (13%), and health resource
utilisation in 17/159 (11%). No studies measured the effects of ICS
on long-term physical consequences of asthma, although two
studies measured post-bronchodilator FEV1, as a percentage of
the predicted value, to assess ‘lung growth’. In one of these studies
children, aged between 5 and 12 years, were randomised to
receive inhaled budesonide, nedocromil sodium or placebo for a
period of four to six years, and FEV1was measured as the primary
outcome [20]. In the other study, patients aged between 5 and 66
years were randomised to treatment with inhaled budesonide or
placebo for three years, and FEV1 was measured as a secondary
outcome [21]. Similar outcome domains were represented in the
115 studies that included only children and the 44 that included
children and adults.
There was a wide variety of outcomes within individual
domains. This was greatest for the disease activity domain, which
was divided into five subdomains (clinical measures, physiological
tests of lung function, global measures, bronchial responsiveness to
a challenge agent or exercise and markers of inflammation), each
of which included outcomes measured in different ways. As can be
seen in Table 2, the selection of subdomains and outcomes was
inconsistent across the studies.
Primary outcomes
The primary outcomes measured in the RCTs that included
only children are listed in Table 2. It was possible to determine the
primary outcome in 84/115 (73%) studies. In 64 of these, the
primary outcome was clearly stated by the authors, and in the
remaining 20 it was inferred from the outcome used to calculate
the sample size. Five studies each selected two co-primary
outcomes. Of the 84 studies that specified a primary outcome,
74 (88%) selected primary outcomes that measured disease
activity. A total of 17 different primary outcomes were selected,
of which physiological measures of airway obstruction, including
PEFR (26 studies) and FEV1 (16 studies), were the most frequent.
None of the primary outcomes addressed the functional status or
quality of life domains
It was possible to determine the primary outcome in 39/44
(89%) studies that included children and adults. In 34 of these, the
primary outcome was clearly stated by the authors, and in the
remaining 5 it was inferred from the outcome used to calculate the
required sample size. In 38/39 (97%), was some measure of
disease activity. The most widely used primary outcome was FEV1
(28 studies).
Outcomes measured in studies funded by the
pharmaceutical industry
The frequency with which most domains were measured in the
127 studies sponsored by the pharmaceutical industry was similar
to the 32 publicly funded studies. The main difference we observed
was that adverse effects of therapy were measured in a higher
proportion of studies sponsored by the pharmaceutical industry
(118/127, 93%) compared to studies funded from other sources
(17/32, 53%).
How the selection of outcome domains has changed
over time
The trend over the period January 1988 to December 2007 in
the selection of outcome domains in RCTs including only children
is shown in Figure 2. Disease activity and adverse effects of therapy
have remained consistently frequently measured outcome do-
mains. Since the 1992–1996 epoch the proportion of studies
measuring functional status, for example by assessing school
absence due to asthma, has decreased from 40% to 10%, and
those measuring quality of life have increased from 10% to 25%.
Discussion
We found that RCTs in children with asthma almost always
assess the effects of therapies on short term disease activity, but
none consider the effects on long term progression of disease.
Quality of life and functional status are measured infrequently.
While there were similarities between studies, particularly in the
selection of primary outcomes that measure disease activity, other
outcomes showed wide variability.
The pharmaceutical industry funded 80% of the RCTS we
identified, and so it is not surprising that the frequency with which
outcomes in the disease activity domain have been measured as
primary or secondary outcomes reflects, to some extent, the
requirements of the FDA [22,23] and EMEA [24–27]. These
authorities recommend, for the purpose of drug licensing and
marketing authorisation, that risks and benefits of preventative
therapies for children with asthma are assessed in clinical trials that
measure, as primary outcomes, physiological tests of pulmonary
function and clinical measures such as symptom scores. Other
measures of short term disease activity, such as use of rescue
medication, rate of exacerbations, and bronchial hyper-respon-
Figure 1. Study flowchart. Flowchart shows the number of abstracts
identified by the search, the number of full texts retrieved, and the
number of studies included in the review.
doi:10.1371/journal.pone.0006276.g001
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siveness are suggested as important outcomes. Quality of life and
exercise tolerance are mentioned as additional outcomes that may
provide useful information, but no clear recommendations have
been made regarding the use of these outcomes [25].
It is disappointing that, despite the use of ICS in childhood
asthma for more than twenty years, their effects on functional
status, quality of life, and long term consequences of asthma
remain largely unknown. Markers of short-term disease activity,
despite their prominence in drug regulatory guidelines and
popularity amongst trialists, have been shown to correlate poorly
with quality of life [28–30], and are therefore not appropriate
surrogate markers for aspects of asthma that could be of more
relevance to patients.
Given that the aim of an RCT is to evaluate the safety and
efficacy of interventions, and provide some assessment of whether
the intervention does more good than harm, it is disappointing to
note that quality of life and family outcomes are only measured in
20% of RCTs, and that the impact of disease on functional status is
now measured in less than 10%. We identified no clinical trials in
which the primary outcome measured these domains. In studies that
have investigated which outcomes are clinically relevant to patients
with other conditions, such as chronic pain [31], fibromyalgia [32],
and rheumatoid arthritis [33], measures of functional status and
quality of life were identified as being of great importance, and it is
likely that this is the case in children with asthma.
Functional status overlaps with quality of life and disease
activity. However, we feel that measures of functional status are
important, distinct, markers of how asthma affects children. In
clinical trials in adults with chronic illnesses, absence from work is
an important outcome, and we feel that an appropriate childhood
equivalent would include measures of school attendance and other
activities of daily living.
It is particularly important in trials of children to assess the
impact of treatments in the long term. Very few studies have
Table 1. Characteristics of included studies.
Study characteristic Category
Number (%) of studies
which included only
children (n =115)
Number (%) of studies
which included
children and adults
(n =44)
Date of publication January 1988 to December 1992 10 (9) 1 (2)
January 1993 to December 1997 19 (17) 5 (11)
January 1998 to December 2002 48 (42) 22 (50)
January 2003 to December 2007 38 (32) 16 (37)
Length of treatment period 1 to 3 months 30 (26) 5 (11)
3 to ,6 months 46 (40) 30 (69)
6 to ,12 months 13 (11) 4 (9)
12 months or longer 24 (21) 5 (11)
Unclear 2 (2) 0
Age groups of children included ,4 years only 17 (15) 0
,4 and 4 to ,12 years 7 (6) 0
,4 and 4 to,12 and 12 to 18 years 1 (1) 0
4 to ,12 years only 36 (31) 0
4 to ,12 years and 12 to 18 years 53 (46) 2 (5)
12 to 18 years only 1 (1) 42 (95)
Number of centres Multicentre 75 (65) 42 (95)
Single centre 39 (34) 2 (5)
Unclear 1 (1) 0
Source of funding Industry 85 (74) 42 (95)
Public funding bodies 30 (26) 2 (5)
Comparisons ICS vs Other drug 26 (23) 12 (27)
ICS vs placebo 25 (22) 4 (9)
ICS 1 vs ICS 2 14 (12) 3 (7)
ICS vs same ICS (different delivery device) 12 (10) 2 (5)
ICS vs same ICS (different dose) 9 (8) 3 (7)
ICS vs no treatment 1 (1) 0
ICS 1 vs ICS 2 vs Placebo 16 (14) 10 (23)
ICS 1 vs ICS 2 vs Other drug 7 (6) 1 (2)
ICS vs Other drug vs placebo 4 (3) 4 (9)
ICS vs same ICS (different dose and mode) 1 (1) 0
ICS 1 vs ICS 1 (different dose) vs ICS 2 0 5 (11)
doi:10.1371/journal.pone.0006276.t001
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Table 2. Frequency with which outcome domains, and outcomes used to measure them, were selected in 115 trials involving only
children published between 1988 and 2008.
Domain Subdomain 1 Subdomain 2 Outcome
Number (%) of
studies in which
measured as
primary or
secondary
outcome
n=115
Number (%)
of studies
in which
measured as
primary
outcome
n=84a
Disease activity 114 (99) 74 (88)
Clinical measures n = 109 Symptoms Symptom severity 90 (77) 10 (12)
Symptom frequency 55 (47) 5 (6)
Use of rescue therapy 90 (77) 2 (2)
Exacerbations Exacerbation frequency 35 (30) 4 (5)
Time to exacerbation 10 (9) 0
Tests of lung function n = 103 Spirometry FEV1 80 (70) 16 (19)
FVC 31 (26) 0
Mid expiratory flow 23 (20) 0
FEV1:FVC 6 (5) 0
FEV1 reversibility 9 (8) 0
PEFR PEFR 85 (73) 26 (31)
Diurnal variability 13 (11) 0
Day-to-day variability 5 (4) 0
Lung volume Plethysmographic 4 (3) 0
Airway flow Resistance/conductance 5 (4) 2 (2)
Global measure of control n = 29 Physician-rated 8 (7) 1 (1)
Parent/patient – rated 14 (12) 0
‘Treatment failure’ 13 (11) 0
‘Treatment success’ 3 (3) 0
Bronchial responsiveness to a
challenge agent n = 29
Induced BHR Methacholine-induced 26 (22) 6 (7)
Exercise-induced 7 (6) 0
Markers of inflammation n = 20 Exhaled nitric oxide 5 (4) 1 (1)
Leukotrieneb/interleukinc 4 (3) 1 (1)
Eosinophilsd/IgEe 18 (15) 0
Physical consequence
of disease
0 0
HRU 15 (13) 1 (1)
Unscheduled HRU 15 (13) 1 (1)
Functional status 20 (17) 0
Effect of asthma on ADL 10 (9) 0
School attendance 15 (13) 0
QoL/family outcomes 19 (17) 0
Child’s QoL 9 (8) 0
Caregiver QoL 5 (4) 0
Caregiver functional status 8 (7) 0
Adverse Effects
of therapy
96 (83) 14 (16)
Routinely monitored AE n= 82 Patient/parent- reported 80 (70) 1 (1)
Routine laboratory AE 32 (27) 0
Orophayryngeal infection 28 (24) 0
Ophthalmological events 7 (6) 0
H-P-A axis n = 52 Urine/serum cortisol 52 (44) 0
ACTH stimulation 17 (15) 1 (1)
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attempted to study the impact of ICS on modifying or affecting the
physical consequences of asthma. Two studies, the Childhood
Asthma Management Program (CAMP) [20], and the Inhaled
Steroid Treatment as Regular Therapy in Early Asthma (START)
[21] indicated in their aims that they wished to investigate this
effect. Both measured primary outcomes which we have classified
as related to disease activity, although the CAMP study stated that
their primary outcome (FEV1, %predicted) was a measure of ‘lung
growth’. Investigators acknowledge the difficulties in assessing the
impact of disease, or therapy, on ‘lung growth’ in children with
asthma. It is unlikely that, in a clinical trial, a single measure will
provide the best primary outcome and more methodological
research is needed to identify whether longitudinal outcomes, such
as rate of change in lung function measures, would be a more
appropriate way of assessing lung growth. Although 24 of the
studies that exclusively included children had a treatment period
lasting longer than one year, only three measured outcomes after
the end of the treatment period [20,34,35]. The other 21 studies
represent missed opportunities to investigate the long term effects
of ICS on progression of asthma in children, and this question
should be addressed in future clinical trials.
The long term safety of treatments for asthma has recently been
identified as being of particular importance to patients and
clinicians [36]. Although 83% of studies that only included
children assessed the safety of ICS, the quality with which long
term systemic side effects of ICS were measured was variable. Of
the 24 studies that lasted longer than a year, 21 measured effects
on growth. None of the studies measured the final adult height
attained, despite the fact that this is of most interest to children and
parents. Only 14 studies measured the effect of ICS, when
administered for longer than one year, on hypothalamo-pituitary-
adrenal function, despite the serious and potentially fatal
consequences of this type of adverse reaction [37]. We suggest
that serious systemic side effects should be monitored in all clinical
trials of ICS in children with asthma, so that both the benefits and
risks of these drugs can be appropriately evaluated.
As well as the fact that measurement of long-term efficacy and
safety outcomes is not a requirement of drug regulatory
authorities, there are other reasons why they may not have been
measured in the studies we identified. Diagnostic and technical
problems associated with measurement of lung growth, financial
cost, and problems with patient attrition also hinder the conduct of
long-term studies in children with asthma. Agreement that long-
term outcomes are important, amongst clinicians, patients, and
researchers, could promote the conduct of such studies. There is
also a need for research to identify the most appropriate long-term
outcomes, and the ways in which they should be measured.
The studies we identified are comparable in terms of the
population they include and the interventions which they
compare, and so we feel that our finding of heterogeneity of
outcome selection between studies is valid. Even though we have
reviewed RCTs assessing one aspect of the treatment of childhood
asthma, it is likely that our findings would be similar if we were to
conduct a similar review of, for example, clinical trials of
leukotriene antagonists or long acting beta2 agonists.
We have reviewed outcomes which have been reported rather
than those which were actually measured. Outcome reporting bias
in published RCT reports is common [18,38], and in order to
have evaluated exactly which outcomes had been measured it may
have been more accurate to assess trial protocols. Although
outcome reporting bias may lead to an underestimation of the
frequency with which some outcomes were actually measured, it is
unlikely that it would affect heterogeneity between studies.
Non-uniform outcome selection can make it difficult to design,
interpret, and meta-analyse clinical trials [15,16,39,40], and so a
few collaborations have begun to address the problems of which
outcomes to measure in clinical trials of a variety of paediatric and
adult conditions [9,15]. One solution is a universally-agreed core
set of outcomes which should be measured, as a minimum, in all
clinical trials of a specific condition. Core sets were first designed
by the OMERACT group, which utilises structured consensus
techniques amongst a diverse group of stakeholders and
consumers. Our findings would suggest that a similar initiative
in childhood asthma, with separate consideration of pre-school
and older children, would make an important contribution to
improving clinical research in this very prevalent, chronic disease.
Domain Subdomain 1 Subdomain 2 Outcome
Number (%) of
studies in which
measured as
primary or
secondary
outcome
n=115
Number (%)
of studies
in which
measured as
primary
outcome
n=84a
Growth n = 41 Growth 41 (35) 9 (11)
Lower leg growth 1 (1) 1(1)
Effects of ICS on bone n = 15 Markers of bone turnover 11 (9) 0
Measures of bone density 8 (7) 2 (2)
Abbreviations used in Table 2: ACTH= adrenocorticotropic hormone; ADL =Activities of Daily Living; AE = adverse events; BHR =bronchial hyperresponsiveness;
FEV1 = forced expiratory flow in one second; FVC = forced vital capacity; H-P-A=Hypothalamic-pituitary-adrenal; HRU= health resource utilisation; ICS = inhaled
corticosteroids; IgE = Immunoglobulin E; PEFR =peak expiratory flow rate; QoL =Quality of life.
aOf 84 studies that specified primary outcomes, 5 specified co-primary outcomes, and hence the total number of primary outcomes measured is 89.
bLeukotriene LTC4 in serum and nasal secretions and leukotriene LTE4 in urine.
cInterleukins in serum and sputum.
dEosinophils in serum and sputum, and Eosinophil Cationic Protein in serum and urine.
eIgE in serum.
doi:10.1371/journal.pone.0006276.t002
Table 2. cont.
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Conclusions
We have shown that outcomes in RCTs in children with
asthma, mainly driven by the requirements of drug regulatory
authorities, are focussed on short term disease activity, and
those which may be more relevant to patients are largely
overlooked. Future research must be directed towards deter-
mining the most appropriate and important outcomes to
measure in these trials.
Supporting Information
File S1 Search strategy
Found at: doi:10.1371/journal.pone.0006276.s001 (0.04 MB
PDF)
File S2 List of included studies
Found at: doi:10.1371/journal.pone.0006276.s002 (0.32 MB
PDF)
Figure 2. Change in selection of outcomes between 1988 and 2007. The figure shows trends in the measurement of outcome domains in clinical
trials of inhaled corticosteroid for children with asthma published between 1988 and 2008. Data are presented as a moving window. Each point along the
horizontal axis represents the midpoint of a five year epoch. In each epoch the proportion of studies measuring each individual domain is shown.
doi:10.1371/journal.pone.0006276.g002
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What Are Core Outcome Sets and Why Are They
Useful?
Good clinical trial design requires researchers to specify in
advance, in the protocol, those outcomes to be measured. If
research has not been conducted to identify the most appropriate
clinical trial outcomes in a given condition, three problems may
impair the usefulness of the research in informing clinical practice.
Firstly, researchers can select outcomes that suit their needs, at the
expense of outcomes that are of most importance to patients or
clinicians [1–3]. Secondly, heterogenous selection and measure-
ment of outcomes in clinical trials can impair the ability to
synthesise results across studies in systematic reviews [4]. Thirdly,
in the absence of a set of outcomes that should be measured and
reported in all clinical trials in the same condition, it can be
difficult to ascertain, in the final publication, whether authors
report all results or only those that they find favourable [5,6].
As a result, the standardisation of outcomes for clinical trials has
been proposed as a solution to the problems of inappropriate and
non-uniform outcome selection [4,7] and reporting bias [5,8]. The
most notable work relating to outcome standardisation has been
conducted by the OMERACT (Outcome Measures in Rheuma-
tology) collaboration, which advocates the use of core outcome sets
designed using consensus techniques that are then measured and
reported in clinical trials in rheumatology [9]. However, such
initiatives are uncommon. In some specialties, such as paediatrics,
the number of conditions covered is low and the quality of existing
studies variable [10]. In addition, there is limited guidance in the
literature regarding the development of a core outcome set. This
paper aims to contribute to the methodology of determining which
outcomes to measure in clinical trials, or systematic reviews of
clinical trials.
The Delphi Technique as a Method of Developing
Core Outcome Sets
One method for reaching consensus around which outcomes to
measure is the Delphi technique, which comprises sequential
questionnaires answered anonymously by a panel of participants
with relevant expertise. After each questionnaire, the group
response is fed back to participants [11]. In terms of the overall
validity of the final consensus, this approach has advantages over
less structured methods of reaching consensus such as round-table
discussions. Participants in a Delphi study do not interact directly
with each other, so situations where the group is dominated by the
views of certain individuals can be avoided. When participants
consider whether to change their opinion or stick to their original
answers, after seeing the group response this decision is not
affected by the desire to be seen to agree with senior, overly vocal,
or domineering individuals. Improvements in global communica-
tion have made it feasible to use the Delphi technique to involve
geographically distant participants in larger numbers than are
traditionally used in studies employing face-to-face discussion, and
so it is also increasingly being used to reach consensus around
many topics in medicine, such as education, development of
clinical guidelines, and prioritisation of research topics.
There is little guidance for researchers who wish to use the
Delphi technique, even though aspects of its methodology can be
interpreted in a variety of ways. Most published work has provided
guidance based on authors’ experiences, rather than empirical
research or theoretical justification for the methodological
decisions made. One systematic review describes a variety of
consensus techniques used for designing clinical guidelines [12].
The authors highlighted important methodological decisions that
may affect the overall quality of the final consensus, such as the
types of participants involved, the questions they are asked, the
information they receive to inform their answers, the manner of
the interaction between them, and the way in which consensus is
agreed. These have also been variously highlighted as important
aspects of methodology in other commentaries about the Delphi
technique [13–15].
To our knowledge, there is no guidance related to methodo-
logical considerations or reporting for studies using the Delphi
technique to determine which outcomes or domains to measure in
clinical research studies. The objective of the systematic review
summarised below (and included in full in Text S1) was to
examine studies that used the Delphi technique for this purpose.
Our recommendations from this review are then summarised to
help inform the conduct and reporting of future initiatives.
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A Systematic Review of Studies That Have Used
the Delphi Technique to Identify Which Outcomes
to Measure in Clinical Trials
We searched Medline (no date restrictions) in January 2010 to
identify studies that used the Delphi technique to determine which
outcomes to measure in clinical trials or systematic reviews of
clinical trials. From each eligible study, the following methodo-
logical aspects were noted: the participants involved, the types of
questions asked, whether the study was completely anonymised,
whether non-responders in earlier rounds were included or
excluded from subsequent rounds, and the definition of consensus
used by the authors. We also evaluated the quality with which the
methods and results were reported. These assessments enabled us
to identify variations in the methods applied within these studies,
and areas of reporting quality that could be improved.
Of 656 abstracts, 20 full text articles were retrieved, of which
five were excluded because they aimed to identify outcomes for use
in clinical practice, and the authors did not state whether the
participants considered their use in clinical research studies. Many
of the 636 studies excluded on the basis of the abstract described
the use of the Delphi process to develop clinical guidelines and
educational curricula. Of 15 studies included in the review, eight
developed core outcome sets for rheumatological conditions.
Others identified outcomes for pain in children, degenerative
ataxia, gastro oesophageal reflux disease, infantile spasms,
maternity care, multiple sclerosis, and thyroid eye disease.
Studies varied in terms of group composition and the manner in
which the Delphi process was conducted. Participation in such
studies was dominated by researchers, with patients and families
seldom involved.
The reporting quality of studies also varied. Important
methodological aspects that were generally less well reported were
the information provided to participants at the start of the Delphi
process, the information fed back to participants after each round,
and the level of anonymity. A summary of the reporting quality of
the studies is shown in Table 1. Each of the items included in the
table had been highlighted, by one or more of the commentaries
mentioned earlier [13–15], as an important methodological
consideration when using the Delphi technique. We tailored the
Summary Points
N Studies that use the Delphi process for gaining
consensus around a core outcome set for clinical trials
should be of sufficiently high quality in order for their
recommendations to be considered valid.
N We report a systematic review of 15 studies that used
the Delphi technique for this purpose, in which we
identified variability in methodology and reporting.
N To improve the quality of studies that use the Delphi
process for developing core outcome sets, we recom-
mend that patients and clinicians be involved, research-
ers and facilitators avoid imposing their views on
participants, and attrition of participants be minimised.
N Methodological decisions should be clearly described in
the main publication in order to enable appraisal of the
study.
Table 1. Reporting quality of the 15 included studies.
Broad Aspect of Reporting
Specific Items for Which the Reporting
Quality Was Assessed
Studies in Which
Clearly Reported
Studies in Which Not
Clearly Reported N/A
Size and composition of the panel Number of participants 15 0 0
Types of participants (e.g., clinicians, patients) 15 0 0
Proportion of each type of participant 15 0 0
How participants were identified/sampled 14 1 0
Methodology of the Delphi process Administration of questionnaires (e.g., postal) 15 0 0
How items were generated for first questionnaire 14 1 0
What was asked in each round 15 0 0
Information provided to participants before
the first round
6 9 0
How the overall group response was fed
back to participants
8 7 0
Level of anonymity (total or quasi-anonymity) 4 11 0
A priori definition of ‘‘consensus’’ about
whether an outcome should be measured)
7 1 7a
Were non-responders invited to subsequent rounds 10 0 5b
Results Number of respondents to each round 14 1 0
Number who completed every round 11 4 0
Results for each outcome in each round 0 15 0
Group response for each outcome (final round) 8 7 0
Distribution of response for each outcome in
the final round
7 8 0
List of all outcomes that participants agreed
should be measured
8 0 7a
aReaching a final consensus was not the aim of the Delphi process, so a definition of consensus was not given.
bAll participants responded to each round, so no discussion was made regarding non-responders.
doi:10.1371/journal.pmed.1000393.t001
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statements so they were relevant for the Delphi process as a
method of developing consensus around a core outcome set.
Although an assessment of response rate to each round could be
made in 14/15 studies, it was only possible to accurately assess
attrition rates in 11/15 studies, which reported the proportion of
first round respondents who also completed the final round. Of
these, only six studies reported the proportion of participants who
completed every round in the Delphi process, from start to finish.
Only seven reports presented a measure and distribution of the
group opinion for each outcome listed in the final round. No study
reported the results, in each round, for every outcome that was
considered by the group.
Guidance about Using the Delphi Technique to
Determine Core Outcome Sets
Involve Clinicians and Patients
Informed clinical decisions can only be based on the results of
trials that have measured outcomes of importance to both
clinicians and patients. Initiatives to identify which outcomes to
measure in clinical trials, however, focus on the opinions of
researchers. This means that outcomes included in existing core
sets may be selected to serve the needs of researchers in academia
or industry, rather than considering how important they are to
patients.
Patients have a variety of perspectives about living with a
condition, which may differ from those of clinicians and
researchers. In one study, involvement of patients in the design
of a systematic review highlighted certain outcomes as being of
particular importance, but these had not been measured in any of
the included trials [16]. Research conducted within the OMER-
ACT group also suggests that clinicians and researchers may not
realise that certain outcomes are very important for patients [17].
The perspective of patients is now routinely incorporated into the
work conducted by OMERACT [18]. Another important
initiative, which actively promotes the involvement of patients
and families in identifying priorities in clinical research, is the
James Lind Alliance (http://www.lindalliance.org/). In a recent
systematic review, this group found a few examples of conditions
in which patients and clinicians have worked, together, to identify
important research questions [19], and we feel that similar
collaboration is necessary to develop core outcome sets. Deter-
mining which outcomes are important may be useful to groups
who aim to identify important research questions.
The opinions of different groups can be analysed either together
or separately. The use of multiple panels, each comprising a
different group [17], acknowledges that there may be differences
in opinion. If different groups with potentially conflicting views are
included in a single panel, they may not be equally represented in
the final consensus. This can happen either because the panel
includes more participants from a certain group, so the final
consensus is numerically dominated by their responses [20], or
because participants tailor their answers to agree with a group they
perceive to be more authoritative.
In studies that use a single panel, comprising a mixture of
participants, authors should report a measure of the distribution of
scores for each outcome considered in the final round. This is
because cut-off scores, used in most studies, do not describe how
strongly the minority feel, and so an apparent consensus could
actually be masking major disagreement within the group [13].
Begin by Asking Open Questions
So that researchers do not impose their views on participants
and thus introduce bias into the study, participants are
traditionally asked open questions in the first round of a Delphi
process. In the context of identifying which outcomes to measure
in clinical research studies, this means that participants should
suggest potential outcomes that they feel should be considered in
the Delphi process, without being prompted or guided by
facilitators, steering committees, or reviews of the literature. Most
studies we identified did not take this approach. It is not clear
whether providing a list to participants for initial consideration
may overstate the importance of outcomes that are favourable to
the researchers, rather than those which may be of more
importance to clinicians and patients. Outcomes measured in
previous clinical trials do not always reflect those deemed most
appropriate by all stakeholders [1,2,21].
Try to Minimise Attrition
People with minority opinions may be more likely to drop out of
studies that use the Delphi process, so attrition as rounds progress
can lead to overestimation of the degree of consensus in the final
results. Strategies to prevent attrition bias are to only invite people
who respond to a pre-Delphi invitation to participate in the first
round [22] or to list, in the publication, only those participants
who either completed the entire Delphi process, or agreed the final
consensus statement [23]. An example of a paragraph that could
be used to explain to participants the importance of completing
the whole Delphi process is shown in Box 1.
Report Certain Aspects of the Methodology and Results
In order to enable appraisal of the quality of studies that use the
Delphi process to identify outcomes that should be measured in
clinical research, which may in turn affect whether the
recommendations are implemented, authors should describe
certain important methodological features in the study report.
Criticisms of the Delphi technique are that ‘‘expertise’’ of the
panel is arbitrarily defined, and that the validity of the final
consensus is questionable because individual participants are not
accountable for their responses, and they may be led towards
conformity with the group, rather than consensus of true opinions
[24]. As described earlier, attrition of participants may mean the
degree of consensus reached in the final round is overestimated
[25]. A recommended checklist of study characteristics and results
that should be reported in all studies that use the Delphi technique
to determine which outcomes to measure in clinical research
studies is shown in Table 2. Given the variation across previous
studies, it would be helpful if authors explained their methodo-
logical choices, and discussed the effects these may have on the
results.
Box 1. Example Text to Emphasize to
Participants the Importance of Completing
the Whole Delphi Process
Thank you for agreeing to participate in our study. It is very
important that you complete the questionnaires in each
round. The reliability of the results could be compromised
if people drop out of the study before it is completed,
because they feel that the rest of the group does not share
their opinions. If people drop out because they feel their
opinions are in the minority, the final results will
overestimate how much the sample of participants agreed
on this topic.
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Determining How to Measure the Outcomes
Included in the Core Set
Following the determination of which outcomes to include in a
core set, guidance is then required as to how to measure them.
One established method for doing so is the OMERACT
approach. Once core outcomes are agreed upon, potential
instruments to measure them are identified. The psychometric
properties of these instruments are then reviewed in terms of
feasibility, validity, and responsiveness before the preferred
instruments are agreed [9]. A more detailed review of the possible
approaches to this question of how to measure the chosen
outcomes is beyond the scope of this paper.
Future Areas of Methodological Research
Given variations in methodology between studies, we feel there
is a need for research to determine how best to develop core
outcome sets. An agenda for this research could be designed
through the COMET Initiative (Core Outcome Measures for
Effectiveness Trials), which is an international network of
individuals and organisations with interest or experience in the
development, application, and promotion of core outcome sets
(http://www.liv.ac.uk/nwhtmr/comet/comet.htm). One such ar-
ea of ongoing research and discussion relates to whether core
outcome sets designed for clinical practice, such as those developed
in the five studies we excluded, should be the same as those
designed for research. Another priority is research to identify the
most effective ways to incorporate the views of different groups of
participants, especially patients, in the design of core outcome
sets.
Supporting Information
Text S1 Full report (and PRISMA checklist) of the systematic
review of studies that used the Delphi technique to determine
which outcomes to measure in clinical trials.
Found at: doi:10.1371/journal.pmed.1000393.s001 (0.87 MB
DOC)
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Table 2. Recommended checklist that should be reported in studies using the Delphi technique to determine which outcomes to
measure in clinical trials or systematic reviews.
Size and Composition of the Panel
The total number of participants invited, and the number who completed the first round
Whether the following types of participants were involved in the study: clinicians (and whether they were eligible on the basis of treating patients with the condition of
interest, or whether clinical trial involvement was an additional requirement), patients or their families, researchers, biostatisticians, representatives from the
pharmaceutical industry, representatives from drug regulatory authorities, or other types of participants.
The proportion of each type of participant described above
How participants were identified/sampled
Methodology of the Delphi Process
Administration of questionnaires: postal, email, Internet, in person (e.g., at a clinic), or at a meeting
Information about outcomes, known to the facilitators before the study, which was provided to participants before the first round: e.g., if the Delphi process followed a
review of outcomes measured in clinical trials, were the results of the review shared with participants? Alternatively, if some work had been conducted prior to the
Delphi (e.g., workshop meeting, or focus groups amongst patients), were the results presented to the participants?
How outcomes were considered in the first questionnaire: were participants asked an open question i.e., no outcomes were initially listed, or were they asked to
comment on a pre-specified list? If the latter, was the source of the list identified? Where possible, the questions asked to participants should be described in the
methods, or made available to the reader, as supplementary information.
What was asked in subsequent rounds: where possible, the questions asked to participants should be described in the methods, or made available to the reader, as
supplementary information
Feedback to participants after each round: if the results were not fed back, but only certain outcomes were carried forward to the next round (e.g., only those suggested
by at least 10% were carried forward), this should be clearly described
Level of anonymity should be described: In order to be ‘‘fully anonymised’’, participants should not know the identities of the other individuals in the group, nor should
they know the specific answers that any other individual gave. In studies that are ‘‘quasi-anonymised’’, the participants know the identities of some or all of the other
individuals, but do not know how they individually responded to any of the questions in any round. In studies that are not anonymised, participants know the identity
of some or all of the other individuals, and also know how some or all of them responded to any of the questions in any round.
If a pre-determined definition of consensus was used, this should be clearly described in the methods section of the study report
Were non-responders invited to subsequent rounds, or were they excluded from the rest of the study? Were additional people invited as the Delphi progressed?
Results
Number of participants invited to each round
Number who completed every round
Results for each outcome scored by participants in each round: a measure of group response, preferably with a measure of distribution. If these data cannot be included
in the publication, even as a supplementary file, it should be made available on request.
Measure of group response for each outcome scored by participants in the final round
Distribution of response for each outcome scored by participants in the final round
A comprehensive list of all the outcomes that participants agreed should be included in the core set
doi:10.1371/journal.pmed.1000393.t002
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